Document:

EX-10.1

 Exhibit 10.1 

VIGIL NEUROSCIENCE, INC. 

AMENDMENT NO. 2 TO THE 

2020 EQUITY INCENTIVE PLAN 

The Vigil Neuroscience, Inc. 2020 Stock Option and Grant Plan (the “Plan”), is hereby amended as follows: 

Section 3(a)(i) of the Plan is hereby amended by deleting it and replacing it with the following: 

Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant
to Stock Awards from and after the Effective Date will not exceed 9,389,281 shares (the “Share Reserve”). 
 ADOPTED BY BOARD OF
DIRECTORS:         August 12, 2021 
 ADOPTED BY STOCKHOLDERS:        
August 12, 2021 

  
 1. 

 VIGIL NEUROSCIENCE, INC. 

AMENDED & RESTATED 2020 EQUITY INCENTIVE PLAN 

ADOPTED BY THE BOARD OF DIRECTORS: June 4, 2021 

APPROVED BY THE STOCKHOLDERS: June 4, 2021 

TERMINATION DATE: September 17, 2030 

1. General. 
 (a)
Eligible Stock Award Recipients. Employees, Directors and Consultants are eligible to receive Stock Awards. 
 (b)
Available Stock Awards. The Plan provides for the grant of the following types of Stock Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock
Awards, (v) Restricted Stock Unit Awards and (vi) Other Stock Awards. 
 (c) Purpose. The Plan, through the grant of
Stock Awards, is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the
eligible recipients may benefit from increases in value of the Common Stock. 
 2. Administration. 

(a) Administration by the Board. The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee or
Committees, as provided in Section 2(c). 
 (b) Powers of the Board. The Board will have the power, subject to, and within the
limitations of, the express provisions of the Plan: 
 (i) To determine (A) who will be granted Stock Awards; (B) when and
how each Stock Award will be granted; (C) what type of Stock Award will be granted; (D) the provisions of each Stock Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or
Common Stock under the Stock Award; (E) the number of shares of Common Stock subject to, or the cash value of, a Stock Award; and (F) the Fair Market Value applicable to a Stock Award. 

(ii) To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for
administration of the Plan and Stock Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it will deem necessary or expedient
to make the Plan or Stock Award fully effective. 
 (iii) To settle all controversies regarding the Plan and Stock Awards granted
under it. 
 (iv) To accelerate, in whole or in part, the time at which a Stock Award may be exercised or vest (or the time at which
cash or shares of Common Stock may be issued in settlement thereof). 

  
 2. 

 (v) To suspend or terminate the Plan at any time. Except as otherwise provided in the
Plan or a Stock Award Agreement, suspension or termination of the Plan will not impair a Participant’s rights under the Participant’s then-outstanding Stock Award without the Participant’s written consent except as provided in
subsection (viii) below. 
 (vi) To amend the Plan in any respect the Board deems necessary or advisable, including, without
limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or bringing the Plan or Stock Awards granted under the Plan into compliance with the
requirements for Incentive Stock Options or ensuring that they are exempt from, or compliant with, the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law. If
required by applicable law or listing requirements, and except as provided in Section 9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A) materially increases the
number of shares of Common Stock available for issuance under the Plan, (B) materially expands the class of individuals eligible to receive Stock Awards under the Plan, (C) materially increases the benefits accruing to Participants under
the Plan, (D) materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (E) materially extends the term of the Plan, or (F) materially expands the types of Stock Awards available for
issuance under the Plan. Except as otherwise provided in the Plan or a Stock Award Agreement, no amendment of the Plan will materially impair a Participant’s rights under an outstanding Stock Award without the Participant’s written
consent. 
 (vii) To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan
intended to satisfy the requirements of Section 422 of the Code regarding Incentive Stock Options. 
 (viii) To approve forms of
Stock Award Agreements for use under the Plan and to amend the terms of any one or more Stock Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Stock Award Agreement,
subject to any specified limits in the Plan that are not subject to Board discretion; provided however, that a Participant’s rights under any Stock Award will not be impaired by any such amendment unless (A) the Company requests the
consent of the affected Participant, and (B) such Participant consents in writing. Notwithstanding the foregoing, (1) a Participant’s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole
discretion, determines that the amendment, taken as a whole, does not materially impair the Participant’s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Stock Awards
without the affected Participant’s consent (A) to maintain the qualified status of the Stock Award as an Incentive Stock Option under Section 422 of the Code; (B) to change the terms of an Incentive Stock Option, if such change
results in impairment of the Stock Award solely because it impairs the qualified status of the Stock Award as an Incentive Stock Option under Section 422 of the Code; (C) to clarify the manner of exemption from, or to bring the Stock Award
into compliance with, Section 409A of the Code; or (D) to comply with other applicable laws. 
 (ix) Generally, to exercise
such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Stock Awards. 

(x) To adopt such procedures and sub-plans as are necessary or appropriate to permit
participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Stock Award
Agreement that are required for compliance with the laws of the relevant foreign jurisdiction). 

  
 3. 

 (xi) To effect, with the consent of any adversely affected Participant, (A) the
reduction of the exercise, purchase or strike price of any outstanding Stock Award; (B) the cancellation of any outstanding Stock Award and the grant in substitution therefor of a new (1) Option or SAR, (2) Restricted Stock Award,
(3) Restricted Stock Unit Award, (4) Other Stock Award, (5) cash and/or (6) other valuable consideration determined by the Board, in its sole discretion, with any such substituted award (x) covering the same or a different
number of shares of Common Stock as the cancelled Stock Award and (y) granted under the Plan or another equity or compensatory plan of the Company; or (C) any other action that is treated as a repricing under generally accepted accounting
principles. 
 (c) Delegation to Committee. The Board may delegate some or all of the administration of the Plan to a Committee or
Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the
power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable). Any
delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Board may retain the authority to concurrently
administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. 
 (d)
Delegation to an Officer. The Board may delegate to one or more Officers the authority to do one or both of the following: (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent
permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such Stock Awards, and (ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such
Employees; provided, however, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a
Stock Award to himself or herself. Any such Stock Awards will be granted on the form of Stock Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation
authority. The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section 13(t) below.  

(e) Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board in
good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. 
 3. Shares Subject to the Plan.

 (a) Share Reserve. 

(i) Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be
issued pursuant to Stock Awards from and after the Effective Date will not exceed 5,889,281 shares (the “Share Reserve”). 

  
 4. 

 (ii) For clarity, the Share Reserve in this Section 3(a) is a limitation on the
number of shares of Common Stock that may be issued pursuant to the Plan. Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a). 

(b) Reversion of Shares to the Share Reserve. If a Stock Award or any portion thereof (i) expires or otherwise terminates
without all of the shares covered by such Stock Award having been issued or (ii) is settled in cash (i.e., the Participant receives cash rather than stock), such expiration, termination or settlement will not reduce (or otherwise offset)
the number of shares of Common Stock that may be available for issuance under the Plan. If any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency
or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased will revert to and again become available for issuance under the Plan. Any shares reacquired by the Company in satisfaction of tax
withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will again become available for issuance under the Plan. 

(c) Incentive Stock Option Limit. Subject to the Share Reserve and Section 9(a) relating to Capitalization
Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 17,667,843. 

(d) Source of Shares. The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including
shares repurchased by the Company on the open market or otherwise. 
 4. Eligibility. 

(a) Eligibility for Specific Stock Awards. Incentive Stock Options may be granted only to employees of the Company or a “parent
corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants;
provided, however, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any “parent” of the Company, as such term is defined in Rule 405, unless (i) the
stock underlying such Stock Awards is treated as “service recipient stock” under Section 409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction), (ii) the
Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from Section 409A of the Code, or (iii) the Company, in consultation with its legal counsel, has determined that such Stock Awards
comply with the distribution requirements of Section 409A of the Code. 
 (b) Ten Percent Stockholders. A Ten Percent
Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date
of grant. 
 (c) Consultants. A Consultant will not be eligible for the grant of a Stock Award if, at the time of grant,
either the offer or sale of the Company’s securities to such Consultant is not exempt under Rule 701 because of the nature of the services that the Consultant is providing to the Company, because the Consultant is not a natural person, or
because of any other provision of Rule 701, unless the Company determines that such grant need not comply with the requirements of Rule 701 and will satisfy another exemption under the Securities Act as well as comply with the securities
laws of all other relevant jurisdictions. 

  
 5. 

 5. Provisions Relating to Options and Stock Appreciation Rights. 

Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated
Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option
is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option
(or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical; provided, however, that each Stock Award Agreement will conform to (through incorporation of provisions hereof by
reference in the applicable Stock Award Agreement or otherwise) the substance of each of the following provisions: 
 (a) Term.
Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of 10 years from the date of its grant or such shorter period specified in the Stock Award Agreement. 

(b) Exercise Price. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the exercise or strike price of
each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Stock Award is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike
price lower than 100% of the Fair Market Value of the Common Stock subject to the Stock Award if such Stock Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate
Transaction and in a manner consistent with the provisions of Section 409A of the Code and, if applicable, Section 424(a) of the Code. Each SAR will be denominated in shares of Common Stock equivalents. 

(c) Purchase Price for Options. The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to
the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board will have the authority to grant Options that do not permit all of the following
methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment. The permitted methods of payment are as follows: 

(i) by cash, check, bank draft, electronic funds transfer or money order payable to the Company; 

(ii) subject to Company and/or Board consent at the time of exercise and provided that at the time of exercise the Common Stock is
publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of
irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise”, “same day sale”, or “sell to cover”; 

(iii) subject to Company and/or Board consent at the time of exercise and provided that at the time of exercise the Common Stock is
publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market
Value on the date of exercise. “Delivery” for these purposes, in the sole discretion of the Company and/or the Board, at the time 

  
 6. 

 
Participant exercises their Option, will include delivery to the Company of Participant’s attestation of ownership of such shares of Common Stock in a form approved by the Company.
Participant may not exercise their option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company’s stock; 

(iv) subject to Company and/or Board consent at the time of exercise, and provided that the Option is a Nonstatutory Stock Option, by a
“net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of the Option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate
exercise price plus, to the extent permitted by the Company and/or Board at the time of exercise, the aggregate withholding obligations in respect of the Option exercise; provided, further that Participant must pay any remaining balance of the
aggregate exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Shares of Common Stock will no longer be subject to the Option and will not be exercisable thereafter to the extent that
(A) shares issuable upon exercise are used to pay the exercise price pursuant to the “net exercise,” (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding
obligations; 
 (v) according to a deferred payment or similar arrangement with the Optionholder; provided, however, that
interest will compound at least annually and will be charged at the minimum rate of interest necessary to avoid (A) the imputation of interest income to the Company and compensation income to the Optionholder under any applicable provisions of
the Code, and (B) the classification of the Option as a liability for financial accounting purposes; or 
 (vi) in any other form
of legal consideration that may be acceptable to the Board. 
 (d) Exercise and Payment of a SAR. To exercise any outstanding
SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR will be not
greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested
under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such
date. The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Stock Award Agreement evidencing such SAR. 

(e) Transferability of Options and SARs. The Board may, in its sole discretion, impose such limitations on the transferability of
Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs will apply: 

(i) Restrictions on Transfer. An Option or SAR will not be transferable except by will or by the laws of descent and distribution (or
pursuant to subsections (ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. The Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and
securities laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration. 

  
 7. 

 (ii) Domestic Relations Orders. Subject to the approval of the Board or a duly
authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2). If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. 

(iii) Beneficiary Designation. Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering
written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or
other consideration resulting from such exercise. In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant’s estate will be entitled to exercise the Option or SAR and receive the
Common Stock or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the
provisions of applicable laws. 
 (f) Vesting Generally. The total number of shares of Common Stock subject to an Option or SAR
may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the
satisfaction of performance goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the
minimum number of shares of Common Stock as to which an Option or SAR may be exercised. 
 (g) Termination of Continuous Service.
Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates (other than for Cause and other than upon the Participant’s
death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Stock Award as of the date of termination of Continuous Service) within the period of time ending on the
earlier of (i) the date three months following the termination of the Participant’s Continuous Service (or such longer or shorter period specified in the applicable Stock Award Agreement, which period will not be less than
30 days if necessary to comply with applicable laws unless such termination is for Cause) and (ii) the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the
Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR will terminate. 

(h) Extension of Termination Date. If the exercise of an Option or SAR following the termination of the Participant’s
Continuous Service (other than for Cause and other than upon the Participant’s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the
Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the
Participant’s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, and (ii) the expiration of the term of the Option or SAR as set forth in the applicable Stock
Award Agreement. In addition, unless otherwise provided in a Participant’s Stock Award Agreement, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant’s Continuous Service
(other than for Cause) would violate the Company’s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of the period of time (that need not be consecutive) equal to the applicable
post-termination exercise period after the termination of the Participant’s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company’s insider trading
policy, and (ii) the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement. 

  
 8. 

 (i) Disability of Participant. Except as otherwise provided in the applicable
Stock Award Agreement or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates as a result of the Participant’s Disability, the Participant may exercise his or her Option or SAR (to the
extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination of
Continuous Service (or such longer or shorter period specified in the Stock Award Agreement, which period will not be less than six months if necessary to comply with applicable laws unless such termination is for Cause), and (ii) the
expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR (as
applicable) will terminate. 
 (j) Death of Participant. Except as otherwise provided in the applicable Stock Award Agreement or other
agreement between the Participant and the Company, if (i) a Participant’s Continuous Service terminates as a result of the Participant’s death, or (ii) the Participant dies within the period (if any) specified in the Stock Award
Agreement for exercisability after the termination of the Participant’s Continuous Service (for a reason other than death), then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of
the date of death) by the Participant’s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant’s death, but only
within the period ending on the earlier of (i) the date 18 months following the date of death (or such longer or shorter period specified in the Stock Award Agreement, which period will not be less than six months if necessary to
comply with applicable laws unless such termination is for Cause), and (ii) the expiration of the term of such Option or SAR as set forth in the Stock Award Agreement. If, after the Participant’s death, the Option or SAR is not exercised
within the applicable time frame, the Option or SAR (as applicable) will terminate. 
 (k) Termination for Cause. Except as
explicitly provided otherwise in a Participant’s Stock Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant’s Continuous Service is terminated for Cause, the
Option or SAR will terminate immediately upon such Participant’s termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR (whether vested or unvested) from and after the date of such
termination of Continuous Service. 
 (l) Non-Exempt Employees. If an Option or SAR is granted
to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six
months following the date of grant of the Option or SAR (although the Stock Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such
non-exempt Employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or
(iv) upon the Participant’s retirement (as such term may be defined in the Participant’s Stock Award Agreement, in another agreement between the Participant and the Company, or, if no such definition, in accordance with the
Company’s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six months following the date of grant. The foregoing provision is intended to operate so that any income
derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt 

  
 9. 

 
from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee’s regular rate of pay, the provisions of this
Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements. 
 (m) Early
Exercise of Options. An Option may, but need not, include a provision whereby the Optionholder may elect at any time before the Optionholder’s Continuous Service terminates to exercise the Option as to any part or all of the shares of
Common Stock subject to the Option prior to the full vesting of the Option. Subject to the “Repurchase Limitation” in Section 8(l), any unvested shares of Common Stock so purchased may be subject to a repurchase right in favor of
the Company or to any other restriction the Board determines to be appropriate. Provided that the “Repurchase Limitation” in Section 8(l) is not violated, the Company will not be required to exercise its repurchase right until at
least six months (or such longer or shorter period of time required to avoid classification of the Option as a liability for financial accounting purposes) have elapsed following exercise of the Option unless the Board otherwise specifically
provides in the Option Agreement. 
 (n) Right of Repurchase. Subject to the “Repurchase Limitation” in
Section 8(l), the Option or SAR may include a provision whereby the Company may elect to repurchase all or any part of the vested shares of Common Stock acquired by the Participant pursuant to the exercise of the Option or SAR. 

(o) Right of First Refusal. The Option or SAR may include a provision whereby the Company may elect to exercise a right of first
refusal following receipt of notice from the Participant of the intent to transfer all or any part of the shares of Common Stock received upon the exercise of the Option or SAR. Such right of first refusal will be subject to the
“Repurchase Limitation” in Section 8(l). Except as expressly provided in this Section 5(o) or in the Stock Award Agreement, such right of first refusal will otherwise comply with any applicable provisions of the bylaws of
the Company. 
 6. Provisions of Stock Awards Other than Options and SARs. 

(a) Restricted Stock Awards. Each Restricted Stock Award Agreement will be in such form and will contain such terms and
conditions as the Board will deem appropriate. To the extent consistent with the Company’s bylaws, at the Board’s election, shares of Common Stock underlying a Restricted Stock Award may be (i) held in book entry form subject to the
Company’s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board. The terms and conditions of
Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. Each Restricted Stock Award Agreement will conform to (through incorporation of the
provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: 
 (i) Consideration.
A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration
(including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. 
 (ii)
Vesting. Subject to the “Repurchase Limitation” in Section 8(l), shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to
be determined by the Board. 

  
 10. 

 (iii) Termination of Participant’s Continuous Service. If a Participant’s
Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right, any or all of the shares of Common Stock held by the Participant that have not vested as of the date of termination of Continuous Service
under the terms of the Restricted Stock Award Agreement. 
 (iv) Transferability. Rights to acquire shares of Common Stock under the
Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock
awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement. 
 (v)
Dividends. A Restricted Stock Award Agreement may provide that any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which
they relate. 
 (b) Restricted Stock Unit Awards. Each Restricted Stock Unit Award Agreement will be in such form and will
contain such terms and conditions as the Board will deem appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements
need not be identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions: 

(i) Consideration. At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to
be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may
be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. 

(ii) Vesting. At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or
conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate. 
 (iii)
Payment. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the
Restricted Stock Unit Award Agreement. 
 (iv) Additional Restrictions. At the time of the grant of a Restricted Stock
Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such
Restricted Stock Unit Award. 
 (v) Dividend Equivalents. Dividend equivalents may be credited in respect of shares of
Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of
Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same
terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate. 

  
 11. 

 (vi) Termination of Participant’s Continuous Service.
Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant’s termination of Continuous Service. 

 (vii) Compliance with Section 409A of the Code. Notwithstanding anything to the contrary set forth herein, any
Restricted Stock Unit Award granted under the Plan that is not exempt from the requirements of Section 409A of the Code will contain such provisions so that such Restricted Stock Unit Award will comply with the requirements of Section 409A
of the Code. Such restrictions, if any, will be determined by the Board and contained in the Restricted Stock Unit Award Agreement evidencing such Restricted Stock Unit Award. For example, such restrictions may include, without limitation, a
requirement that any Common Stock that is to be issued in a year following the year in which the Restricted Stock Unit Award vests must be issued in accordance with a fixed pre-determined schedule. 

(c) Other Stock Awards. Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common
Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to
Stock Awards provided for under Section 5 and the preceding provisions of this Section 6. Subject to the provisions of the Plan, the Board will have sole and complete authority to determine the persons to whom and the time or times at
which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards. 

7. Covenants of the Company. 

(a) Availability of Shares. The Company will keep available at all times the number of shares of Common Stock reasonably required
to satisfy then-outstanding Stock Awards. 
 (b) Securities Law Compliance. The Company will seek to obtain from each regulatory
commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; provided, however, that this undertaking will not
require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from
any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common
Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of a Stock Award or the subsequent issuance of cash or Common Stock pursuant to the Stock Award if such grant or
issuance would be in violation of any applicable securities law. 
 (c) No Obligation to Notify or Minimize Taxes. The Company
will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending
termination or expiration of a Stock Award or a possible period in which the Stock Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award. 

  
 12. 

 8. Miscellaneous. 

(a) Use of Proceeds from Sales of Common Stock. Proceeds from the sale of shares of Common Stock pursuant to Stock Awards will
constitute general funds of the Company. 
 (b) Corporate Action Constituting Grant of Stock Awards. Corporate action constituting a
grant by the Company of a Stock Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Stock Award
is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (e.g., exercise
price, vesting schedule or number of shares) that are inconsistent with those in the Stock Award Agreement or related grant documents as a result of a clerical error in the papering of the Stock Award Agreement or related grant documents, the
corporate records will control and the Participant will have no legally binding right to the incorrect term in the Stock Award Agreement or related grant documents. 

(c) Stockholder Rights. No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any
shares of Common Stock subject to a Stock Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Stock Award pursuant to its terms, and (ii) the
issuance of the Common Stock subject to the Stock Award has been entered into the books and records of the Company. 
 (d) No Employment
or Other Service Rights. Nothing in the Plan, any Stock Award Agreement or any other instrument executed thereunder or in connection with any Stock Award granted pursuant thereto will confer upon any Participant any right to continue to serve
the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without
cause, (ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any
applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be. 
 (e)
Change in Time Commitment. In the event a Participant’s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an
Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Stock Award to the Participant, the Board has the right in its
sole discretion to (x) make a corresponding reduction in the number of shares subject to any portion of such Stock Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in
combination with such a reduction, extend the vesting or payment schedule applicable to such Stock Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Stock Award that is so reduced or
extended. 
 (f) Incentive Stock Option Limitations. To the extent that the aggregate Fair Market Value (determined at the time of
grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit
established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such
rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). 

  
 13. 

 (g) Investment Assurances. The Company may require a Participant, as a condition of
exercising or acquiring Common Stock under any Stock Award, (i) to give written assurances satisfactory to the Company as to the Participant’s knowledge and experience in financial and business matters and/or to employ a purchaser
representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that the Participant is capable of evaluating, alone or together with the purchaser representative, the merits and risks
of exercising the Stock Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant’s own account and not with any present
intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of
Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such
requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or
appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock. 

(h) Withholding Obligations. Unless prohibited by the terms of a Stock Award Agreement, the Company may, in its sole discretion,
satisfy any federal, state or local tax withholding obligation relating to a Stock Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of
Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award; provided, however, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax
required to be withheld by law (or such lesser amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from a Stock Award settled in cash;
(iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Stock Award Agreement. 

(i) Electronic Delivery. Any reference herein to a “written” agreement or document will include any agreement or document
delivered electronically or posted on the Company’s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). 

(j) Deferrals. To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common
Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Stock Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will
be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company. The Board is
authorized to make deferrals of Stock Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant’s termination of Continuous Service, and implement such
other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law. 

  
 14. 

 (k) Compliance with Section 409A of the Code. To the extent
that the Board determines that any Stock Award granted hereunder is subject to Section 409A of the Code, the Stock Award Agreement evidencing such Stock Award will incorporate the terms and conditions necessary to avoid the consequences
specified in Section 409A(a)(1) of the Code. To the extent applicable, the Plan and Stock Award Agreements will be interpreted in accordance with Section 409A of the Code. Notwithstanding anything to the contrary in the Plan (and unless
the Stock Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding a Stock Award that constitutes “deferred compensation” under Section 409A of the Code is a
“specified employee” for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a “separation from service” (as defined in Section 409A of the Code without regard to
alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant’s “separation from service” (as defined in Section 409A of the Code without regard to
alternative definitions thereunder) or, if earlier, the date of the Participant’s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a
lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule. 
 (l)
Repurchase Limitation. The terms of any repurchase right will be specified in the Stock Award Agreement. The repurchase price for vested shares of Common Stock will be the Fair Market Value of the shares of Common Stock on the date of
repurchase. The repurchase price for unvested shares of Common Stock will be the lower of (i) the Fair Market Value of the shares of Common Stock on the date of repurchase or (ii) their original purchase price. However, the Company will
not exercise its repurchase right until at least six months (or such longer or shorter period of time necessary to avoid classification of the Stock Award as a liability for financial accounting purposes) have elapsed following delivery of
shares of Common Stock subject to the Stock Award, unless otherwise specifically provided by the Board. 
 9. Adjustments upon Changes in Common Stock;
Other Corporate Events. 
 (a) Capitalization Adjustments. In the event of a Capitalization Adjustment, the Board will
appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise
of Incentive Stock Options pursuant to Section 3(c), and (iii) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board will make such adjustments, and its determination will be
final, binding and conclusive. 
 (b) Dissolution or Liquidation. Except as otherwise provided in the Stock Award Agreement, in the
event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company’s right of repurchase)
will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company’s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the
Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, provided, however, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no
longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. 

(c) Corporate Transaction. The following provisions will apply to Stock Awards in the event of a Corporate Transaction unless
otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of a Stock Award. In the
event of a Corporate Transaction, then, notwithstanding any other provision of the Plan, the Board may take one or more of the following actions with respect to Stock Awards, contingent upon the closing or completion of the Corporate Transaction:

  
 15. 

 (i) arrange for the surviving corporation or acquiring corporation (or the surviving
or acquiring corporation’s parent company) to assume or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an award to acquire the same consideration paid to the stockholders of
the Company pursuant to the Corporate Transaction); 
 (ii) arrange for the assignment of any reacquisition or repurchase rights held
by the Company in respect of Common Stock issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company); 

(iii) accelerate the vesting, in whole or in part, of the Stock Award (and, if applicable, the time at which the Stock Award may be
exercised) to a date prior to the effective time of such Corporate Transaction as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective date of the Corporate Transaction),
with such Stock Award terminating if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction; provided, however, that the Board may require Participants to complete and deliver to the Company a notice of
exercise before the effective date of a Corporate Transaction, which exercise is contingent upon the effectiveness of such Corporate Transaction; 

(iv) arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the Stock
Award; 
 (v) cancel or arrange for the cancellation of the Stock Award, to the extent not vested or not exercised prior to the
effective time of the Corporate Transaction, in exchange for such cash consideration (including no consideration) as the Board, in its sole discretion, may consider appropriate; and 

(vi) make a payment, in such form as may be determined by the Board equal to the excess, if any, of (A) the value of the property
the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Corporate Transaction, over (B) any exercise price payable by such holder in connection with such exercise. For clarity,
this payment may be zero ($0) if the value of the property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company’s Common Stock
in connection with the Corporate Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies. 
 The Board need not take
the same action or actions with respect to all Stock Awards or portions thereof or with respect to all Participants. The Board may take different actions with respect to the vested and unvested portions of a Stock Award. 

(d) Change in Control. A Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in
Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration
will occur. 

  
 16. 

 10. Plan Term; Earlier Termination or Suspension of the Plan. 

(a) Plan Term. The Board may suspend or terminate the Plan at any time. Unless terminated sooner by the Board, the Plan will
automatically terminate on the day before the 10th anniversary of the earlier of (i) the date the Plan is adopted by the Board, or (ii) the date the Plan is approved by the stockholders of the Company. No Stock Awards may be granted under
the Plan while the Plan is suspended or after it is terminated. 
 (b) No Impairment of Rights. Suspension or termination of the Plan
will not impair rights and obligations under any Stock Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan. 

11. Effective Date of Plan. 
 This
Plan will become effective on the Effective Date.  
 12. Choice of Law. 

The laws of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan,
without regard to that state’s conflict of laws rules. 
 13. Definitions. As used in the Plan, the following definitions will apply to
the capitalized terms indicated below: 
 (a) “Affiliate” means, at the time of determination, any
“parent” or “majority-owned subsidiary” of the Company, as such terms are defined in Rule 405. The Board will have the authority to determine the time or times at which “parent” or “majority-owned
subsidiary” status is determined within the foregoing definition. 
 (b) “Board” means the Board of
Directors of the Company. 
 (c) “Capitalization Adjustment” means any change that is made in, or other events
that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization,
reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or any similar
equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible
securities of the Company will not be treated as a Capitalization Adjustment. 
 (d) “Cause”
will have the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of
the following events: (i) such Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) such Participant’s attempted
commission of, or participation in, a fraud or act of dishonesty against the Company, or any of its employees or directors; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant and
the Company, the Company’s employment policies, or of any statutory or other duty owed to the Company; (iv) such Participant’s unauthorized use or disclosure of the Company’s confidential information or trade

  
 17. 

 
secrets; or (v) such Participant’s gross misconduct. The determination that a termination of the Participant’s Continuous Service is either for Cause or without Cause will be made
by the Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Stock Awards held by such Participant will have no effect upon
any determination of the rights or obligations of the Company or such Participant for any other purpose. 
 (e) “Change in
Control” means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: 

(i) any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the
combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control will not be deemed to occur (A) on account of the
acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company’s
securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities or (C) solely because the level of Ownership held by any Exchange Act
Person (the “Subject Person”) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the
Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the
Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the
designated percentage threshold, then a Change in Control will be deemed to occur;  
 (ii) there is consummated a merger,
consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own,
directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the
combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company
immediately prior to such transaction; or 
 (iii) there is consummated a sale, lease, exclusive license or other disposition of all
or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more
than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such
sale, lease, license or other disposition. 
 Notwithstanding the foregoing definition or any other provision of this Plan, (A) the term Change in
Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B) the definition of Change in Control (or any analogous term) in an individual written
agreement between the Company or any Affiliate and the Participant will supersede the 

  
 18. 

 
foregoing definition with respect to Stock Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an
individual written agreement, the definition set forth herein will apply, and (C) if at any time the Company’s Certificate of Incorporation provides definitions of various analogous transactions that would be deemed a liquidation event for
the Company, then such definition will apply as if it were the definition set forth herein except as is otherwise expressly provided in an individual written agreement between the Company or any Affiliate and the Participant. 

(f) “Code” means the Internal Revenue Code of 1986, as amended, including any applicable regulations and
guidance thereunder. 
 (g) “Committee” means a committee of one or more Directors to whom authority has been
delegated by the Board in accordance with Section 2(c). 
 (h) “Common Stock” means the common stock of
the Company. 
 (i) “Company” means Vigil Neuroscience, Inc., a Delaware corporation. 

(j) “Consultant” means any person, including an advisor, who is (i) engaged by the Company or an Affiliate
to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a
fee for such service, will not cause a Director to be considered a “Consultant” for purposes of the Plan.  
 (k)
“Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the
Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the
Participant’s service with the Company or an Affiliate, will not terminate a Participant’s Continuous Service; provided, however, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as
determined by the Board in its sole discretion, such Participant’s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the
Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may
determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or
(ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in
the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. 

(l) “Corporate Transaction” means the consummation, in a single transaction or in a series of related
transactions, of any one or more of the following events: 
 (i) a sale or other disposition of all or substantially all, as
determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries; 

  
 19. 

 (ii) a sale or other disposition of more than 50% of the outstanding securities of
the Company; 
 (iii) a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or

 (iv) a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of
Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or
otherwise. 
 (m) “Director” means a member of the Board. 

(n) “Disability” means, with respect to a Participant, the inability of such Participant to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than
twelve (12) months as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. 

(o) “Effective Date” means the effective date of this Plan, which is the earlier of (i) the date that this
Plan is first approved by the Company’s stockholders, and (ii) the date this Plan is adopted by the Board. 
 (p)
“Employee” means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for
purposes of the Plan. 
 (q) “Entity” means a corporation, partnership, limited liability company or other
entity. 
 (r) “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder. 
 (s) “Exchange Act Person” means any natural person,
Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary of the Company, (ii) any employee
benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding
securities pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or
(v) any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more
than 50% of the combined voting power of the Company’s then outstanding securities. 
 (t) “Fair Market
Value” means, as of any date, the value of the Common Stock determined by the Board in compliance with Section 409A of the Code or, in the case of an Incentive Stock Option, in compliance with Section 422 of the Code. 

  
 20. 

 (u) “Good Reason” will have the meaning
ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, a material and unreasonable diminution of such
Participant’s duties (as determined by the Board in its sole discretion) without such Participant’s consent; provided, however, that the following shall not constitute Good Reason: (i) a change of title; (ii) a reduction in such
Participant’s duties by virtue of the Company undergoing a Change in Control and/or being made part of a larger entity or group of entities; and/or (iii) cessation of such Participant’s service, if any, on the Board or a
committee thereof. For such Participant to receive the benefits under the applicable written agreement between such Participant and the Company as a result of a voluntary resignation for Good Reason, unless otherwise provided in such agreement, all
of the following requirements must be satisfied: (A) such Participant must provide notice to the Company of such Participant’s intent to assert Good Reason within thirty (30) days of the initial existence of the condition set forth in
the previous sentence; (B) the Company will have thirty (30) days (the “Company Cure Period”) from the date of such notice to remedy the condition and, if it does so, such Participant may withdraw such
Participant’s resignation or such Participant may resign with no benefits under the applicable written agreement; and (C) any termination of such Participant’s Continuous Service under this provision must occur within ten
(10) days of the earlier of expiration of the Company Cure Period or written notice from the Company that it will not undertake to cure the applicable condition. Unless otherwise set forth in the applicable written agreement, should the
Company remedy the condition as set forth above and then such condition arises again, such Participant may assert Good Reason again subject to all of the conditions set forth herein. Unless otherwise set forth in the applicable written agreement,
the term “Company” for purposes of “Good Reason” will be interpreted to include any Affiliate of the Company to which such Participant provides services, if appropriate, as determined by the Board in its sole discretion. 

(v) “Incentive Stock Option” means an option granted pursuant to Section 5 of the Plan that is intended to
be, and that qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code. 
 (w)
“Nonstatutory Stock Option” means an option granted pursuant to Section 5 of the Plan that does not qualify as an Incentive Stock Option. 

(x) “Officer” means any person designated by the Company as an officer. 

(y) “Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock
granted pursuant to the Plan. 
 (z) “Option Agreement” means a written agreement between the Company and an
Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan. 

(aa) “Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Option. 
 (bb) “Other Stock Award” means an award based in whole or in
part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(c). 
 (cc)
“Other Stock Award Agreement” means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be
subject to the terms and conditions of the Plan. 

  
 21. 

 (dd) “Own,” “Owned,”
“Owner,” “Ownership” A person or Entity will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if
such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. 

(ee) “Participant” means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Stock Award. 
 (ff) “Plan” means this 2020 Equity Incentive Plan. 

(gg) “Restricted Stock Award” means an award of shares of Common Stock which is granted pursuant to the terms
and conditions of Section 6(a). 
 (hh) “Restricted Stock Award Agreement” means a written agreement
between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan. 

(ii) “Restricted Stock Unit Award” means a right to receive shares of Common Stock which is
granted pursuant to the terms and conditions of Section 6(b). 
 (jj) “Restricted Stock Unit Award
Agreement” means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement
will be subject to the terms and conditions of the Plan. 
 (kk) “Rule 405” means Rule 405 promulgated under
the Securities Act. 
 (ll) “Rule 701” means Rule 701 promulgated under the Securities Act. 

(mm) “Securities Act” means the Securities Act of 1933, as amended. 

(nn) “Stock Appreciation Right” or “SAR” means a right to receive the appreciation on
Common Stock that is granted pursuant to the terms and conditions of Section 5. 
 (oo) “Stock Appreciation Right
Agreement” means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the
terms and conditions of the Plan. 
 (pp) “Stock Award” means any right to receive Common Stock granted under
the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right or any Other Stock Award. 

(qq) “Stock Award Agreement” means a written agreement between the Company and a Participant evidencing the
terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan. 

  
 22. 

 (rr) “Subsidiary” means, with respect to the Company,
(i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or
classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in
which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%. 

(ss) “Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of
the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. 

  
 23. 

 VIGIL NEUROSCIENCE, INC. 

2020 Equity Incentive Plan 

OPTION AGREEMENT 

(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION) 

Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, Vigil Neuroscience, Inc. (the
“Company”) has granted you an option under its 2020 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise
price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is any conflict between the terms in this Option Agreement and
the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan. 

The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows: 

1. Vesting. Your option will vest as provided in your Grant Notice. Vesting will cease upon the termination of your Continuous Service.

 2. Number of Shares and Exercise Price. The number of shares of Common Stock subject to your option and your exercise price per
share in your Grant Notice will be adjusted for Capitalization Adjustments. 
 3. Exercise Restriction for
Non-Exempt Employees. If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a
“Non-Exempt Employee”), and except as otherwise provided in the Plan, you may not exercise your option until you have completed at least six months of Continuous Service measured from
the Date of Grant, even if you have already been an employee for more than six months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such six month anniversary
in the case of (i) your death or disability, (ii) a Corporate Transaction in which your option is not assumed, continued or substituted, (iii) a Change in Control or (iv) your termination of Continuous Service on your
“retirement” (as defined in the Company’s benefit plans). 
 4. Exercise prior to Vesting (“Early Exercise”).
If permitted in your Grant Notice (i.e., the “Exercise Schedule” indicates “Early Exercise Permitted”) and subject to the provisions of your option, you may elect at any time that is both (i) during the period of your
Continuous Service and (ii) during the term of your option, to exercise all or part of your option, including the unvested portion of your option; provided, however, that: 

a. a partial exercise of your option will be deemed to cover first vested shares of Common Stock and then the earliest vesting
installment of unvested shares of Common Stock; 
 b. any shares of Common Stock so purchased from installments that have not vested
as of the date of exercise will be subject to the purchase option in favor of the Company as described in the Company’s form of Early Exercise Stock Purchase Agreement; 

  
 24. 

 c. you will enter into the Company’s form of Early Exercise Stock Purchase
Agreement with a vesting schedule that will result in the same vesting as if no early exercise had occurred; and 
 d. if your option
is an Incentive Stock Option, then, to the extent that the aggregate Fair Market Value (determined at the Date of Grant) of the shares of Common Stock with respect to which your option plus all other Incentive Stock Options you hold are exercisable
for the first time by you during any calendar year (under all plans of the Company and its Affiliates) exceeds $100,000, your option(s) or portions thereof that exceed such limit (according to the order in which they were granted) will be treated as
Nonstatutory Stock Options. 
 5. Method of Payment. You must pay the full amount of the exercise price for the shares you wish to
exercise. The permitted methods of payment are as follows: 
 a. by cash, check, bank draft, electronic funds transfer or money order
payable to the Company; 
 b. subject to Company and/or Board consent at the time of exercise and provided that at the time of
exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company
or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise”, “same day sale”, or “sell to
cover”; 
 c. subject to Company and/or Board consent at the time of exercise and provided that at the time of exercise the
Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are
valued at Fair Market Value on the date of exercise. “Delivery” for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such
shares of Common Stock in a form approved by the Company. You may not exercise your option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the
Company’s stock; 
 d. subject to Company and/or Board consent at the time of exercise, and provided that the Option is a
Nonstatutory Stock Option, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of the Option by the largest whole number of shares with a Fair Market Value
that does not exceed the aggregate exercise price plus, to the extent permitted by the Company and/or Board at the time of exercise, the aggregate withholding obligations in respect of the Option exercise; provided, further that you must pay any
remaining balance of the aggregate exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Shares of Common Stock will no longer be subject to the Option and will not be exercisable thereafter to
the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the “net exercise,” (B) shares are delivered to you as a result of such exercise, and (C) shares are withheld to satisfy tax
withholding obligations; 
 e. subject to the consent of the Company and/or Board at the time of exercise, according to a deferred
payment or similar arrangement with you; provided, however, that interest will compound at least annually and will be charged at the minimum rate of interest necessary to avoid (A) the imputation of interest income to the Company and
compensation income to the Optionholder under any applicable provisions of the Code, and (B) the classification of the Option as a liability for financial accounting purposes; or 

  
 25. 

 f. in any other form of legal consideration that may be acceptable to the Board. 

6. Whole Shares. You may exercise your option only for whole shares of Common Stock. 

7. Securities Law Compliance. In no event may you exercise your option unless the shares of Common Stock issuable upon exercise are then
registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act. The exercise of your option also must
comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any
restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable). 

8. Term. You may not exercise your option before the Date of Grant or after the expiration of the option’s term. Except as set
forth in your Grant Notice, the term of your option expires, subject to the provisions of Section 5(h) of the Plan, upon the earliest of the following: 

a. immediately upon the termination of your Continuous Service for Cause; 

b. three months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death
(except as otherwise provided in Section 8(d) below); provided, however, that if during any part of such three month period your option is not exercisable solely because of the condition set forth in the section above relating to
“Securities Law Compliance,” your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three months after the termination of your Continuous Service; provided
further, that if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six months after the Date of Grant, and (iii) you have vested in a portion of your option at the time of your termination of
Continuous Service, your option will not expire until the earlier of (x) the later of (A) the date that is seven months after the Date of Grant, and (B) the date that is three months after the termination of your Continuous Service,
and (y) the Expiration Date; 
 c. 12 months after the termination of your Continuous Service due to your Disability (except as
otherwise provided in Section 8(d)) below; 
 d. 18 months after your death if you die either during your Continuous Service or
within three (3) months after your Continuous Service terminates for any reason other than Cause; 
 e. the Expiration Date
indicated in your Grant Notice; or 
 f. the day before the 10th anniversary of the Date of Grant. 

If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option,
the Code requires that at all times beginning on the Date of Grant and ending on the day three months before the date of your option’s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or
Disability. The Company 

  
 26. 

 
has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option
if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three months after the date your employment with the Company or an
Affiliate terminates. 
 9. Exercise. 

a. You may exercise the vested portion of your option (and the unvested portion of your option if your Grant Notice so permits) during
its term by delivering a Notice of Exercise (in a form designated by the Company) together with the exercise price to the Secretary of the Company, or to such other person as the Company may designate, during regular business hours. If required by
the Company, your exercise may be made contingent on your execution of any additional documents specified by the Company (including, without limitation, any voting agreement or other agreement between the Company and some or all of its
stockholders). 
 b. By exercising your option you agree that, as a condition to any exercise of your option, the Company may require
you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to
which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise. 

c. If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within
15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two years after the Date of Grant or within one year after such shares of Common Stock are transferred upon
exercise of your option. 
 d. By exercising your option you agree that you will not sell, dispose of, transfer, make any short sale
of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for a period of 180 days
following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with applicable FINRA rules (the “Lock-Up Period”); provided, however, that nothing contained in this section will prevent the exercise of a repurchase option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give
further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of
Common Stock (or other securities) of the Company held by you will be bound by this Section 9(d). The underwriters of the Company’s stock are intended third party beneficiaries of this Section 9(d) and will have the right, power and
authority to enforce the provisions hereof as though they were a party hereto. You further agree that the obligations contained in this Section 9(d) shall also, if so determined by the Company’s Board of Directors, apply in the
Company’s initial listing of its Common Stock on a national securities exchange by means of a registration statement on Form S-1 under the Securities Act (or any successor registration form under the
Securities Act subsequently adopted by the Securities and Exchange Commission) filed by the Company with the Securities and Exchange Commission that registers shares of existing capital stock of the Company for resale (a “Direct
Listing”), provided that all holders of at least 5% of the Company’s outstanding Common Stock (after giving effect to the conversion into Common Stock of any outstanding Preferred Stock of the Company) are subject to substantially
similar obligations with respect to such Direct Listing. 

  
 27. 

 10. Transferability. Except as otherwise provided in this Section 10, your
option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you. 

a. Certain Trusts. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a
trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust. You and the trustee must enter into transfer and other agreements required by
the Company. 
 b. Domestic Relations Orders. Upon receiving written permission from the Board or its duly authorized designee, and
provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital settlement agreement or other
divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed
terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement
agreement. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. 

c. Beneficiary Designation. Upon receiving written permission from the Board or its duly authorized designee, you may, by delivering
written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and receive the
Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the Common Stock or
other consideration resulting from such exercise. 
 11. Right of First Refusal. Shares of Common Stock that you acquire upon exercise
of your option are subject to any right of first refusal that may be described in the Company’s bylaws in effect at such time the Company elects to exercise its right; provided, however, that if there is no right of first refusal
described in the Company’s bylaws at such time, the right of first refusal described below will apply. The Company’s right of first refusal will expire on the first date upon which any security of the Company is listed (or approved for
listing) upon notice of issuance on a national securities exchange or quotation system (the “Listing Date”). 
 a.
Prior to the Listing Date, you may not validly Transfer (as defined below) any shares of Common Stock acquired upon exercise of your option, or any interest in such shares, unless such Transfer is made in compliance with the following
provisions: 
 1) Before there can be a valid Transfer of any shares of Common Stock or any interest therein, the record holder of
the shares of Common Stock to be transferred (the “Offered Shares”) will give written notice (by registered or certified mail) to the Company. Such notice will specify the identity of the proposed transferee, the cash price
offered for the Offered Shares by the proposed transferee (or, if the proposed Transfer is one in which the holder will not receive cash, such as an involuntary transfer, gift, donation or pledge, the holder will state that no purchase price is
being proposed), 

  
 28. 

 
and the other terms and conditions of the proposed Transfer. The date such notice is mailed will be hereinafter referred to as the “Notice Date” and the record holder of
the Offered Shares will be hereinafter referred to as the “Offeror.” If, from time to time, there is any stock dividend, stock split or other change in the character or amount of any of the outstanding Common Stock which is
subject to the provisions of your option, then in such event any and all new, substituted or additional securities to which you are entitled by reason of your ownership of the shares of Common Stock acquired upon exercise of your option will be
immediately subject to the Company’s Right of First Refusal (as defined below) with the same force and effect as the shares subject to the Right of First Refusal immediately before such event. 

2) For a period of 30 calendar days after the Notice Date, or such longer period as may be required to avoid the classification of your
option as a liability for financial accounting purposes, the Company will have the option to purchase all (but not less than all) of the Offered Shares at the purchase price and on the terms set forth in Section 11(a)(iii) (the Company’s
“Right of First Refusal”). In the event that the proposed Transfer is one involving no payment of a purchase price, the purchase price will be deemed to be the Fair Market Value of the Offered Shares as determined in good
faith by the Board in its discretion. The Company may exercise its Right of First Refusal by mailing (by registered or certified mail) written notice of exercise of its Right of First Refusal to the Offeror prior to the end of said 30 days
(including any extension required to avoid classification of the option as a liability for financial accounting purposes). 
 3) The
price at which the Company may purchase the Offered Shares pursuant to the exercise of its Right of First Refusal will be the cash price offered for the Offered Shares by the proposed transferee (as set forth in the notice required under
Section 11(a)(i)), or the Fair Market Value as determined by the Board in the event no purchase price is involved. To the extent consideration other than cash is offered by the proposed transferee, the Company will not be required to pay any
additional amounts to the Offeror other than the cash price offered (or the Fair Market Value, if applicable). The Company’s notice of exercise of its Right of First Refusal will be accompanied by full payment for the Offered Shares and, upon
such payment by the Company, the Company will acquire full right, title and interest to all of the Offered Shares. 
 4) If, and only
if, the option given pursuant to Section 11(a)(ii) is not exercised, the Transfer proposed in the notice given pursuant to Section 11(a)(i) may take place; provided, however, that such Transfer must, in all respects, be exactly as
proposed in said notice except that such Transfer may not take place either before the 10th calendar day after the expiration of the 30 day option exercise period or after the ninetieth 90th calendar day after the expiration of the 30 day option exercise period, and if such Transfer has not taken place prior to said 90th day, such
Transfer may not take place without once again complying with this Section 11(a). The option exercise periods in this Section 11(a)(iv) will be adjusted to include any extension required to avoid the classification of your option as a
liability for financial accounting purposes. 
 b. As used in this Section 11, the term “Transfer” means
any sale, encumbrance, pledge, gift or other form of disposition or transfer of shares of Common Stock or any legal or equitable interest therein; provided, however, that the term Transfer does not include a transfer of such shares or
interests by will or intestacy to your Immediate Family (as defined below). In such case, the transferee or other recipient will receive and hold the shares of Common Stock so transferred subject to the provisions of this Section, and there will be
no further transfer of such shares except in accordance with the terms of this Section 11. As used herein, the term “Immediate Family” will mean your spouse, the lineal descendant or antecedent, father, mother, brother
or sister, child, adopted child, grandchild or adopted grandchild of you or your spouse, or the spouse of any child, adopted child, grandchild or adopted grandchild of you or your spouse. 

  
 29. 

 c. None of the shares of Common Stock purchased on exercise of your option will be
transferred on the Company’s books nor will the Company recognize any such Transfer of any such shares or any interest therein unless and until all applicable provisions of this Section 11 have been complied with in all respects. The
certificates of stock evidencing shares of Common Stock purchased on exercise of your option will bear an appropriate legend referring to the transfer restrictions imposed by this Section 11. 

d. To ensure that the shares subject to the Company’s Right of First Refusal will be available for repurchase by the Company, the
Company may require you to deposit the certificates evidencing the shares that you purchase upon exercise of your option with an escrow agent designated by the Company under the terms and conditions of an escrow agreement approved by the Company. If
the Company does not require such deposit as a condition of exercise of your option, the Company reserves the right at any time to require you to so deposit the certificates in escrow. As soon as practicable after the expiration of the
Company’s Right of First Refusal, the agent will deliver to you the shares and any other property no longer subject to such restriction. In the event the shares and any other property held in escrow are subject to the Company’s exercise of
its Right of First Refusal, the notices required to be given to you will be given to the escrow agent, and any payment required to be given to you will be given to the escrow agent. Within 30 days after payment by the Company for the Offered Shares,
the escrow agent will deliver the Offered Shares that the Company has repurchased to the Company and will deliver the payment received from the Company to you. 

12. Option not a Service Contract. Your option is not an employment or service contract, and nothing in your option will be deemed to
create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an
Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate. 

13. Withholding Obligations. 

a. At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby
authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “same day sale” pursuant to a program developed under Regulation T as promulgated by the
Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your
option. 
 b. If this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company, and
compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair
Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for
financial accounting purposes). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the preceding sentence will not be permitted unless
you make a proper and timely election under Section 83(b) 

  
 30. 

 
of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of
such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock will be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of
your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure will be your sole responsibility. 

c. You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied.
Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any
escrow provided for herein, if applicable, unless such obligations are satisfied. 
 14. Tax Consequences. You hereby agree that the
Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees or
Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant
Notice is at least equal to the “fair market value” per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option. Because the Common Stock is not traded on an
established securities market, the Fair Market Value is determined by the Board, perhaps in consultation with an independent valuation firm retained by the Company. You acknowledge that there is no guarantee that the Internal Revenue Service will
agree with the valuation as determined by the Board, and you will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that the valuation determined
by the Board is less than the “fair market value” as subsequently determined by the Internal Revenue Service. 
 15.
Notices. Any notices provided for in your option or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five days
after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option
by electronic means or to request your consent to participate in the Plan by electronic means. By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. 

16. Governing Plan Document. Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of
your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of
the Plan, the provisions of the Plan will control. 

  
 31.EX-10.11

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. 

Exhibit 10.11 
 EXECUTION
VERSION 
 EXCLUSIVE LICENSE AGREEMENT 

by and between 
 AMGEN
INC. 
 and 

VIGIL NEUROSCIENCE, INC. 

Dated as of July 9, 2020 
 Amgen
Proprietary – Confidential 
 Amgen Proprietary – Confidential/Vigil Proprietary & Confidential 

Amgen Contract No. 2020044836 

 TABLE OF CONTENTS 

 

							
	 ARTICLE 1. DEFINITIONS
	  	 	1	 
	 ARTICLE 2. LICENSE GRANT
	  	 	13	 
	 Section 2.1
	 	Grant	  	 	13	 
	 Section 2.2
	 	Sublicenses	  	 	14	 
	 Section 2.3
	 	Retained Rights and Limitations	  	 	14	 
	 Section 2.4
	 	[***]	  	 	14	 
	 Section 2.5
	 	Transfer of Licensed Know-How and Licensed Materials	  	 	15	 
	 Section 2.6
	 	Covenant Not to Sue	  	 	20	 
	 Section 2.7
	 	No Other Rights	  	 	21	 
	 Section 2.8
	 	Restrictions	  	 	21	 
	 ARTICLE 3. EQUITY, MILESTONES, ROYALTIES AND PAYMENTS
	  	 	21	 
	 Section 3.1
	 	Equity in VIGIL	  	 	21	 
	 Section 3.2
	 	Upfront and Milestone Payments	  	 	21	 
	 Section 3.3
	 	Royalties	  	 	22	 
	 Section 3.4
	 	Method of Payment	  	 	24	 
	 Section 3.5
	 	Royalty Reports	  	 	24	 
	 Section 3.6
	 	Currency Conversion	  	 	24	 
	 Section 3.7
	 	Late Payments	  	 	25	 
	 Section 3.8
	 	Records and Audits	  	 	25	 
	 Section 3.9
	 	Taxes	  	 	25	 
	 ARTICLE 4. PATENT PROSECUTION, MAINTENANCE, & INFRINGEMENT
	  	 	27	 
	 Section 4.1
	 	Intellectual Property Ownership	  	 	27	 
	 Section 4.2
	 	Prosecution and Maintenance	  	 	28	 
	 Section 4.3
	 	Enforcement	  	 	29	 
	 Section 4.4
	 	Defense of Third Party Claims	  	 	30	 
	 Section 4.5
	 	Recovery	  	 	30	 
	 Section 4.6
	 	Patent Term Extensions and Filings for Regulatory Exclusivity Periods	  	 	30	 
	 Section 4.7
	 	Patent Marking	  	 	30	 
	 ARTICLE 5. OBLIGATIONS OF THE PARTIES
	  	 	31	 
	 Section 5.1
	 	Responsibility	  	 	31	 
	 Section 5.2
	 	Diligence	  	 	31	 
	 Section 5.3
	 	Reports	  	 	31	 
	 Section 5.4
	 	Distracting Programs	  	 	31	 
	 Section 5.5
	 	Amgen Restrictions	  	 	33	 
	 Section 5.6
	 	Reasonable Restrictions	  	 	33	 
	 ARTICLE 6. REPRESENTATIONS
	  	 	33	 
	 Section 6.1
	 	Mutual Representations and Warranties	  	 	33	 
	 Section 6.2
	 	Additional AMGEN Warranties	  	 	34	 
	 Section 6.3
	 	Disclaimer	  	 	35	 
	 Section 6.4
	 	Additional VIGIL Warranties	  	 	35	 
	 Section 6.5
	 	VIGIL Covenants	  	 	36	 
	 Section 6.6
	 	AMGEN Covenants	  	 	39	 
	 ARTICLE 7. INDEMNIFICATION
	  	 	39	 
	 Section 7.1
	 	Indemnity	  	 	39	 
	 Section 7.2
	 	LIMITATION OF DAMAGES	  	 	40	 

  

  
 Amgen Proprietary –
Confidential/Vigil Proprietary & Confidential 
 Amgen Contract No. 2020044836 

i 

							
	 Section 7.3
	 	Insurance	  	 	40	 
	 ARTICLE 8. CONFIDENTIALITY
	  	 	41	 
	 Section 8.1
	 	Confidential Information	  	 	41	 
	 Section 8.2
	 	Terms of this Agreement; Publicity	  	 	42	 
	 Section 8.3
	 	Publications	  	 	43	 
	 Section 8.4
	 	Relationship to the Confidentiality Agreement	  	 	44	 
	 Section 8.5
	 	Attorney-Client Privilege	  	 	44	 
	 ARTICLE 9. TERM & TERMINATION
	  	 	44	 
	 Section 9.1
	 	Term	  	 	44	 
	 Section 9.2
	 	Termination by AMGEN	  	 	44	 
	 Section 9.3
	 	Termination by VIGIL	  	 	46	 
	 Section 9.4
	 	Termination Upon Bankruptcy	  	 	47	 
	 Section 9.5
	 	Effects of Termination	  	 	47	 
	 Section 9.6
	 	Survival	  	 	50	 
	 ARTICLE 10. MISCELLANEOUS
	  	 	51	 
	 Section 10.1
	 	Entire Agreement; Amendment	  	 	51	 
	 Section 10.2
	 	Section 365(n) of the Bankruptcy Code	  	 	51	 
	 Section 10.3
	 	Independent Contractors	  	 	51	 
	 Section 10.4
	 	Dispute Resolution; Governing Law; Jurisdiction	  	 	52	 
	 Section 10.5
	 	Notice	  	 	52	 
	 Section 10.6
	 	Compliance With Law; Severability	  	 	53	 
	 Section 10.7
	 	Non-Use of Names	  	 	53	 
	 Section 10.8
	 	Successors and Assigns	  	 	53	 
	 Section 10.9
	 	Sale Transaction or AMGEN Acquisition	  	 	53	 
	 Section 10.10
	 	Waivers	  	 	54	 
	 Section 10.11
	 	No Third Party Beneficiaries	  	 	54	 
	 Section 10.12
	 	Headings; Exhibits	  	 	54	 
	 Section 10.13
	 	Interpretation	  	 	54	 
	 Section 10.14
	 	Equitable Relief	  	 	54	 
	 Section 10.15
	 	Force Majeure	  	 	55	 
	 Section 10.16
	 	Further Assurances	  	 	55	 
	 Section 10.17
	 	Counterparts	  	 	55	 

 Exhibit List 
  

			
	Exhibit A	  	Licensed Know-How & Licensed Materials
	Exhibit B	  	Licensed Patents
	Exhibit C	  	Permitted CMOs/CROs
	Exhibit D	  	Licensed Compounds
	Exhibit E	  	Supplemental Confidentiality Agreement
	Exhibit F	  	Reservation Agreement
	Exhibit G	  	Ongoing Studies
	Exhibit H	  	[***] Order Summary

  
 ii 

 EXCLUSIVE LICENSE AGREEMENT 

This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of July 9, 2020 (the “Effective
Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“AMGEN”), and VIGIL NEUROSCIENCE, INC., a Delaware corporation having an address at 400
Technology Square, 10th Floor, Cambridge, MA 02139 (“VIGIL”). VIGIL and AMGEN are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

RECITALS 
 WHEREAS,
AMGEN possesses certain rights to patents and other intellectual property related to compounds binding to TREM2 (as hereinafter defined); and 

WHEREAS, VIGIL desires to license from AMGEN such patents and intellectual property rights, and to commercially develop, manufacture,
use and distribute products containing compounds that bind to TREM2, and AMGEN desires to grant such a license to VIGIL in accordance with the terms and conditions of this Agreement; and 

WHEREAS, simultaneous with the execution of this Agreement, AMGEN and Atlas Venture Life Science Advisors LLC
(“Atlas”) have executed that certain Guarantee pursuant to which Atlas has guaranteed the performance of VIGIL’s payment obligations under Section 2.5.3; and 

WHEREAS, simultaneous with the execution of this Agreement, Amgen and VIGIL have executed that certain Side Letter (the “Equity
Side Letter”), pursuant to which, VIGIL has committed to issue to AMGEN equity of VIGIL and Amgen has been further granted certain rights with respect to [***], as partial consideration for the licenses and covenants granted in this
Agreement. 
 NOW, THEREFORE, in consideration of the premises and the mutual promises and covenants contained in this Agreement, and
for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 

ARTICLE 1. DEFINITIONS 
 All references to
particular Exhibits, Articles or Sections shall mean the Exhibits to, and Articles and Sections of, this Agreement, unless otherwise specified. For the purposes of this Agreement and the Exhibits hereto, the following words and phrases shall have
the following meanings: 
  

			
		
	Section 1.1	  	“Abandoned Patent Right” has the meaning set forth in 4.2.2(AMGEN Step-In Right).
		
	Section 1.2	  	“Acquisition Transaction” has the meaning set forth in Section 2.4 [***].
		
	Section 1.3	  	“Agreement” has the meaning set forth in the Preamble.

  
 -1- 

			
		
	Section 1.4	  	“Affiliate” means, with respect to any Person, any other Person that, directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, for as long
as such control exists. For purposes of this Section, “control” means the direct or indirect ownership of more than fifty percent (50%) of the voting or economic interest of a Person, or the power, whether pursuant to contract, ownership
of securities or otherwise, to direct the management and policies of a Person. For clarity, once a Person ceases to be an Affiliate of a Party, then, without any further action, such Person shall cease to have any rights, including license and
sublicense rights, under this Agreement by reason of being an Affiliate of such Party.
		
	Section 1.5	  	“AMGEN” has the meaning set forth in the Preamble.
		
	Section 1.6	  	“AMGEN Acquiree” has the meaning set forth in Section 10.9 (Sale Transaction or AMGEN Acquisition).
		
	Section 1.7	  	“AMGEN Acquisition” has the meaning set forth in Section 10.9 (Sale Transaction or AMGEN Acquisition).
		
	Section 1.8	  	“AMGEN Cell Line” means the [***].
		
	Section 1.9	  	“AMGEN Indemnified Parties” has the meaning set forth in Section 7.1.2 (By VIGIL).
		
	Section 1.10	  	“AMGEN Shares” has the meaning set forth in Section 3.1.
		
	Section 1.11	  	“Anti-Corruption Laws” means Laws, regulations, or orders prohibiting the provision of a financial or other advantage for a corrupt purpose or otherwise in connection with the improper performance of a relevant
function, including without limitation, the U.S. Foreign Corrupt Practices Act (FCPA) as amended, the UK Bribery Act 2010, as amended, and any other applicable laws, rules and regulations relating to or concerning public or commercial bribery or
corruption.
		
	Section 1.12	  	“Audited Party” has the meaning set forth in Section 3.8 (Records and Audits).
		
	Section 1.13	  	“Calendar Quarter” means a three-month period beginning on January, April, July or October 1st.
		
	Section 1.14	  	“Calendar Year” means a one-year period beginning on January 1st and ending on December 31st.
		
	Section 1.15	  	“Change of Control” means (a) the closing of the sale, transfer, exclusive license or other disposition of all or substantially all of VIGIL’s assets or intellectual property, (b) the consummation of
the merger or consolidation of VIGIL with or into another entity (except a merger or consolidation in which the holders of capital stock of VIGIL immediately prior to such merger or consolidation continue to hold at least fifty percent (50%) of the
voting power of the capital stock of VIGIL or the surviving or acquiring entity), (c) the closing of the transfer (whether by merger, consolidation or otherwise), in one transaction or a series of related transactions, to a person or group of
affiliated persons (other than an underwriter of VIGIL’s securities), of VIGIL’s securities if, after such closing, such person or group of affiliated persons would hold fifty percent (50%) or more of the outstanding voting stock of VIGIL
(or the surviving or acquiring entity) or (d) a liquidation, dissolution or winding up of VIGIL.

  
 -2- 

			
		
	Section 1.16	  	“CNS Field” means diseases of the central nervous system.
		
	Section 1.17	  	“Commercially Reasonable Efforts” means those efforts and resources commensurate with those efforts commonly used in the pharmaceutical industry by [***] in connection with the development or commercialization of
pharmaceutical products that are of similar status, taking into account the proprietary position of the product (including intellectual property scope, subject matter and coverage), safety and efficacy, product profile, competitiveness of the
marketplace, the regulatory status and approval process, anticipated or approved labeling, present and future market potential, the probable profitability of the applicable product (including pricing and reimbursement status achieved or likely to be
achieved) and other relevant factors such as technical, legal, scientific or medical factors. In determining the level of efforts constituting “Commercially Reasonable Efforts,” the following shall not be taken into account:
(a) any other pharmaceutical product VIGIL or any of its Affiliates is then researching, developing or commercializing, alone or with one or more collaborators or (b) any payment required to be made to AMGEN hereunder.
		
	Section 1.18	  	“Confidential Information” has the meaning set forth in Section 8.1.1 (Confidential Information).
		
	Section 1.19	  	“Consulting Support” means any work or services to be performed by AMGEN and is requested by VIGIL and agreed upon by Amgen that is related to the Exploitation of the Licensed Materials and Licensed Know
How.
		
	Section 1.20	  	“Control” or “Controlled” means, with respect to any Know-How, material, Patent Right, or other intellectual property right, the possession (whether by
ownership or license) by a Party or its Affiliate of the ability to grant to the other Party a license, sublicense or access as provided herein to such Know-How, material, Patent Right, or other intellectual
property right, without violating Laws or the terms of any agreement or other arrangement with any Third Party, or being obligated to pay any royalties or other consideration therefor, in existence as of the time such Party or its Affiliates would
first be required hereunder to grant the other Party such license, sublicense or access.
		
	Section 1.21	  	“Cover” means (a) with respect to Know-How, such Know-How was used in the Exploitation of the product, and (b) with respect
to a Patent Right, (1) a Valid Claim would (absent a license thereunder or ownership thereof) be Infringed by the Exploitation of the product or (2) such Patent Right includes generic or specific disclosure of the product or use thereof
wherein such disclosure is not claimed but a claim to such disclosure would be a Valid Claim; provided, however, that in determining whether a Valid Claim that is a claim of a pending application would be Infringed, it
shall be treated as if issued as then currently being prosecuted. Cognates of the word “Cover” shall have correlative meanings.
		
	Section 1.22	  	“Covered Individuals and Entities” (or, in the singular, “Covered Individual and Entity”) means any one or more of an HCP, HCI, Payor, Purchaser, Healthcare Industry Professional Society and Trade
Association, and entities owned or operated by any one or more of an HCP, HCI, Payor, Purchaser, or Healthcare Industry Professional Societies or Trade Association.

  
 -3- 

			
		
	Section 1.23	  	“Defending Party” has the meaning set forth in Section 4.4.1.
		
	Section 1.24	  	“De Novo Compound” means any and all [***] that are discovered, researched, developed or otherwise Exploited by VIGIL, its Affiliates or Sublicensees that [***], but specifically excludes all Licensed Compounds and
Program Compounds.
		
	Section 1.25	  	“De Novo Product” means any pharmaceutical or biopharmaceutical product containing a De Novo Compound in any form or formulation, and optionally in combination with one or more other active agents, provided that if
a product includes any Licensed Compound or Program Compound, such product constitutes a “Licensed Product” not a De Novo Product.
		
	Section 1.26	  	“Disclosing Party” has the meaning set forth in Section 8.1.1 (Confidential Information).
		
	Section 1.27	  	“Distracting Product” means any compound or product (but excluding any Licensed Product) that binds to TREM2 [***] (specifically including a De Novo Product) unless and until VIGIL has elected to treat such compound
or product as a “Newly Added Product” pursuant to Section 5.4.2.
		
	Section 1.28	  	“Distracting Program” means the clinical development, commercialization or manufacture of any Distracting Product.
		
	Section 1.29	  	“Distracting Transaction” means any transaction entered into by VIGIL or its Affiliates after the Effective Date whereby a Third Party that is engaged in a Distracting Program becomes an Affiliate of
VIGIL.
		
	Section 1.30	  	“Distracting Transaction Affiliates” means those entities that are or would become Affiliates of VIGIL by virtue of a Distracting Transaction.
		
	Section 1.31	  	“Divest” means, with respect to any Distracting Program, the sale, exclusive license or other transfer of substantially all of the right, title and interest in and to such Distracting Program, including technology, Know-How, intellectual property and other assets materially relating thereto, to an independent Third Party, without the retention or reservation of any rights or interest (other than an economic interest) in such
Distracting Program by the relevant Party or its Affiliates.
		
	Section 1.32	  	“Dollars” or “$” means U.S. Dollars.
		
	Section 1.33	  	“Effective Date” has the meaning set forth in the Preamble.
		
	Section 1.34	  	“EMA” means the European Medicines Agency or any successor entity thereto.
		
	Section 1.35	  	“Enforcing Party” has the meaning set forth in Section 4.3.3 (Progress Reports).
		
	Section 1.36	  	“Exclusively Licensed Know-How” means the Licensed Non-Manufacturing Know-How set forth on
Exhibit A under the heading “Exclusively Licensed Know-How”.
		
	Section 1.37	  	“Exploit” means to research, develop, make, have made, use, offer for sale, sell, import, export or otherwise exploit, or transfer possession of or title in, a product. Cognates of the word
“Exploit” shall have correlative meanings.

  
 -4- 

			
		
	Section 1.38	  	“FDA” means the United States Food and Drug Administration or any successor entity thereto.
		
	Section 1.39	  	“Financing Agreements” means those agreements by and among VIGIL, AMGEN and the various investors to effect the Series A Financing.
		
	Section 1.40	  	“First Commercial Sale” means, with respect to a product in any country, the first sale for end use or consumption of such product in such country after Marketing Approval has been granted in such country. First
Commercial Sale excludes any sale or other distribution of such product for use in a clinical trial or other development activity, promotional use (including samples) prior to Marketing Approval or for compassionate use or on a named patient
basis.
		
	Section 1.41	  	“FTE Rate” means $[***] per hour. The FTE Rate shall be increased by [***] percent ([***]%) each calendar year, beginning with the [***] calendar year.
		
	Section 1.42	  	[***]
		
	Section 1.43	  	“GAAP” means the then current generally accepted accounting principles in the United States as established by the Financial Accounting Standards Board or any successor entity or other entity generally recognized as
having the right to establish such principles in the United States, in each case consistently applied.
		
	Section 1.44	  	“Generic Product” means, with respect to a Small Molecule Product in a particular regulatory jurisdiction, on a Small Molecule
Product-by- Small Molecule Product and country-by-country basis, any pharmaceutical
product (other than a Small Molecule Product under this Agreement) that (a) is approved by the Regulatory Authority in such country for at least one indication for which such Small Molecule Product obtained Regulatory Approval from the
applicable Regulatory Authority in such jurisdiction through an abbreviated new drug application as defined in 21 U.S.C. 355(j) (or equivalent outside the United States) and (b) is sold in such jurisdiction by a Third Party that is not a
Sublicensee and did not purchase such product in a chain of distribution that included any of VIGIL or its Affiliates or Sublicensees.
		
	Section 1.45	  	“Governmental Authority” means any court, agency, department, authority or other instrumentality of any national, state, county, city or other political subdivision.
		
	Section 1.46	  	“Government Official” means (i) any Person employed by or acting on behalf of a Governmental Authority; (ii) any political party, party official or candidate; (iii) any Person who holds or performs
the duties of an appointment, office or position created by custom or convention; and (iv) any Person who holds himself out to be the authorized intermediary of any of the foregoing.
		
	Section 1.47	  	“Healthcare Industry Professional Society and Trade Association” means a non-profit or tax exempt healthcare industry organization seeking to further a particular profession,
the interests of individuals engaged in that profession, or the public interest (examples of such include without limitation the American Society of Hematology, the North American Society for Dialysis and Transplantation, the American Society of
Hypertension, the American Cancer Society and the American Society of Clinical Oncology).

  
 -5- 

			
		
	Section 1.48	  	“Healthcare Institution” or “HCI” means a facility that provides health maintenance, or treats illness and injury, and can include without limitation any hospital, convalescent hospital, dialysis
center, health clinic, nursing home, extended care facility, or other institution devoted to the care of sick, infirm, or aged persons, and is in a position to purchase or influence a purchasing decision for any human therapeutic product marketed,
distributed, or sold or any service related thereto provided by or on behalf of Amgen or any of its Affiliates (each an “Amgen Therapeutic Product”).
		
	Section 1.49	  	“Healthcare Professional” or “HCP” means any person licensed to prescribe an Amgen Therapeutic Product, as well as anyone working for a person licensed to prescribe an Amgen Therapeutic Product
and/or in a position to influence a purchasing decision, including without limitation physicians and other providers (e.g., nurses, pharmacists), dialysis providers, and other office personnel.
		
	Section 1.50	  	“Infringe” or “Infringement” means any infringement as determined by Law, including, without limitation, direct infringement, contributory infringement or any inducement to infringe.
		
	Section 1.51	  	“Initiation” means, with respect to a human clinical trial, the first dosing in the first patient in such clinical trial.
		
	Section 1.52	  	“International Trade Laws” means all applicable United States laws, regulations, and orders pertaining to trade and economic sanctions, export controls, and customs, including, such laws, regulations, and orders
administered and enforced by the U.S. Department of the Treasury, the U.S. Department of Commerce, the U.S. Department of State and the U.S. Customs and Border Protection agency, including but not limited to the sanctions administered and enforced
by the Office of Foreign Assets Control (OFAC), the United States Export Administration Act of 1979, as amended, and the Export Control Reform Act of 2018, and implementing Export Administration Regulations (EAR); the Arms Export Control Act and
implementing International Traffic in Arms Regulations (ITAR); and all comparable applicable export and import Laws outside the United States for each country where the Parties or their agents and representatives conduct business.
		
	Section 1.53	  	“IPO” means VIGIL’s initial public offering or another transaction, including a reverse merger, pursuant to which VIGIL (or its successor) first has its equity securities listed on a recognized stock exchange
or trading system (e.g., NYSE or NASDAQ).
		
	Section 1.54	  	“Issuing Party” has the meaning set forth in Section 8.2.2 (Review).
		
	Section 1.55	  	“Know-How” means techniques, technology, trade secrets, inventions (whether patentable or not), methods, data (both primary and summary), reports and results (including
pharmacological, toxicological and clinical data and results), analytical and quality control data and results, regulatory documents, cell line technology and development information, manufacturing process information and other
information.

  
 -6- 

			
		
	Section 1.56	  	“Law” means, individually and collectively, any and all laws, ordinances, rules, directives, administrative circulars and regulations of any kind whatsoever of any Governmental Authority within the applicable
jurisdiction, including, but not limited to, Anti-Corruption Laws, International Trade Laws, those concerning data privacy and protection, and healthcare compliance.
		
	Section 1.57	  	“Licensed Compound” means any compound that: (a) is Controlled by AMGEN or its Affiliates; (b)(1) for a monoclonal antibody, binds to TREM2 [***] and (2) for a small molecule, binds to TREM2 and has
agonist activity on TREM2 [***]; and (c) was discovered, researched or developed in the conduct of the Licensed MAB Program or the Licensed Small Molecule Program by AMGEN or its Affiliates prior to the Effective Date. The Licensed Compounds
are listed or referenced on Exhibit D.
		
	Section 1.58	  	“Licensed Field” means any and all uses.
		
	Section 1.59	  	“Licensed Non-Manufacturing Know-How” means all proprietary Know-How that both (a) is
Controlled by AMGEN or its Affiliates and (b) [***] in the Licensed MAB Program and Licensed Small Molecule Program, in each case (a) and (b) prior to the Effective Date, as set forth on Exhibit A; provided, however,
“Licensed Non-Manufacturing Know-How” excludes (1) any Know-How relating to AMGEN’s or its Affiliates
manufacturing platform or activities, including, specifically, the Licensed Manufacturing Know-How and (2) any Know-How solely relating to the research,
development, manufacture or use of [***].
		
	Section 1.60	  	“Licensed Know-How” means the Licensed Non-Manufacturing Know-How together with the Licensed
Manufacturing Know-How, in each case, as set forth on Exhibit A.
		
	Section 1.61	  	“Licensed Lead Antibody Compound” means the Licensed Compound known as [***] or [***].
		
	Section 1.62	  	“Licensed Manufacturing Know-How” means all proprietary manufacturing process-related Know-How directly relating to the manufacture of
the Licensed Lead Antibody Compound that both (i) is Controlled by AMGEN or its Affiliates and (ii) [***], in each case (i) and (ii) prior to the Effective Date, as set forth on Exhibit A; provided, however, that
“Licensed Manufacturing Know-How” excludes (1) any Know-How relating to AMGEN’s or its Affiliates commercial manufacturing platform and (2) any Know-How solely relating to the research, development or manufacture of [***].
		
	Section 1.63	  	“Licensed Materials” means those certain materials set forth on Table 1 of Exhibit A, all to the extent Controlled by AMGEN or its Affiliates as of the Effective Date.
		
	Section 1.64	  	“Licensed MAB Program” means AMGEN’s research and development activities prior to the Effective Date with respect to monospecific monoclonal antibody agonists of TREM2.
		
	Section 1.65	  	“Licensed Patents” means the Patent Rights Controlled by AMGEN or its Affiliates as of the Effective Date and set forth on Exhibit B.
		
	Section 1.66	  	“Licensed Product” means any pharmaceutical or biopharmaceutical product containing a Licensed Compound or Program Compound in any form or formulation, and optionally in combination with one or more other active
agents.

  
 -7- 

			
		
	Section 1.67	  	“Licensed Small Molecule Program” means AMGEN’s research and development activities prior to the Effective Date with respect to small molecule agonists of TREM2.
		
	Section 1.68	  	“Losses” has the meaning set forth in Section 7.1.1 (By AMGEN).
		
	Section 1.69	  	“MAB Product” means a Product that contains a monoclonal antibody agonist of TREM2.
		
	Section 1.70	  	“Marketing Approval” means all approvals, licenses, registrations or authorizations of the Regulatory Authority in a country, necessary for the manufacture, use, storage, import, marketing and sale of the Product in
such country.
		
	Section 1.71	  	“MPA” means that certain Amended and Restated Master Purchase Agreement dated [***] by and between [***] and [***].
		
	Section 1.72	  	“[***] Period” has the meaning set forth in Section 2.4 [***].
		
	Section 1.73	  	“Net Sales” means, with respect to a certain time period, the gross invoiced sales prices charged for Products sold by or for VIGIL, its Affiliates and Sublicensees (the “Selling Party”) in
arm’s length transactions to Third Parties during such time period, less the total of the following charges or expenses as determined in accordance with GAAP:
		
		  	 (a)   [***]

		
		  	 (b)   [***]

		
		  	 (c)   [***]

		
		  	 (d)   [***]

		
		  	 (e)   [***]

		
		  	 (f)   [***]

		
		  	 (g)   [***]

		
		  	Any disposal of Products for, or use of Products in, clinical or pre-clinical trials, given as free samples, or distributed for indigent programs shall not be included in Net Sales.
		
		  	Upon any sale or other disposal of any Product that should be included within Net Sales for any consideration other than an exclusively monetary consideration on bona fide arm’s length terms, then for purposes of calculating
the Net Sales under this Agreement, such Product shall be deemed to be sold exclusively for money at the average sales price during the applicable reporting period generally achieved for such Product in the country in which such sale or other
disposal occurred when such Product is sold alone and not with other products.

  
 -8- 

			
		
		  	Where a Product is sold together with another pharmaceutically active ingredient for a single price (including any combination product including the Product) (a “Bundle”), then for the purposes of calculating the
Net Sales under this Agreement, such Product shall be deemed to be sold for an amount equal to (X/(X+Y)) * Z, where: X is the average sales price during the applicable reporting period for such Product being sold alone (in the same dosage form) (or,
should more than one Product be included in a Bundle with a product other than a Product, the sum of such average sales prices for the included Products) in the particular country of sale; Y is the sum of the average sales price during the
applicable reporting period in the particular country of sale, when sold alone, of each pharmaceutical (other than the included Product(s)) included in the Bundle (in the same dosage form); and Z equals the Net Sales of such Bundle. In the event
that a Product or one or more of the other pharmaceuticals in the Bundle are not sold separately (in the same dosage form), the Parties will discuss in good faith to determine an equitable fair market price to apply to such Product or other
pharmaceutical in the Bundle.
		
	Section 1.74	  	“Order” means a statement of work or work order under the MPA pursuant to which [***] related to the manufacture of the Licensed Lead Antibody Compound drug substance.
		
	Section 1.75	  	“Ongoing Studies” means those preclinical research studies conducted by AMGEN and [***] and ongoing as of the Effective Date, as listed on Exhibit G.
		
	Section 1.76	  	“Ongoing Studies Agreement” means that certain Preclinical Research Program Agreement by and between AMGEN and [***] effective [***].
		
	Section 1.77	  	“Patent Rights” means any provisional and non-provisional patents and patent applications, together with all additions, divisions, continuations, continuations-in- part, substitutions, and reissues claiming priority thereto, as well as any reexaminations, extensions, registrations, patent term extensions, supplemental
protection certificates, renewals and the like with respect to any of the foregoing and all foreign counterparts thereof.
		
	Section 1.78	  	“Party” has the meaning set forth in the Preamble.
		
	Section 1.79	  	“Payor” means an organization, including without limitation its directors, officers, employees, contractors and agents, whether private or governmental (e.g., Centers for Medicare and Medicaid Services, Veterans
Administration), that provides medical and/or pharmacy plans for covering and reimbursing patients and/or Healthcare Professionals from medical expenses incurred, including without limitation managed care organizations, pharmacy benefit managers,
health maintenance organizations, other healthcare coverage providers, and any similar such organization.
		
	Section 1.80	  	“Permitted CMO/CRO” means (a) [***] or (b) any other party deemed to be a Permitted CMO/CRO pursuant to the terms of Section 2.5.3.
		
	Section 1.81	  	“Permitted CMO/CRO Agreement” has the meaning set forth in Section 2.5.3(b).
		
	Section 1.82	  	“Permitted CMO/CRO Request” has the meaning set forth in Section 2.5.3(g).
		
	Section 1.83	  	“Person” means any corporation, limited or general partnership, limited liability company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body,
or an individual.

  
 -9- 

			
		
	Section 1.84	  	“Product” means any (1) Licensed Product, or (2) any Distracting Product (including, for clarity, a De Novo Product) that Vigil has elected to treat as a Newly Added Product pursuant to Section 5.4.2
on and after the date of such election.
		
	Section 1.85	  	“Program Compound” means any and all compounds (including both small molecule and monoclonal antibodies) that are discovered, researched or developed by VIGIL, its Affiliates or Sublicensees that [***] and
(a) the discovery, research, development, manufacture or commercialization of which incorporates or uses any (i) Exclusively Licensed Know-How, (ii) Licensed Compound (other than use as
described in (z) below (i.e., any such Licensed Compound was not known to VIGIL to be included in a library of compounds used for screening)), or (iii) any improvement, modification, variant, derivative, salt, prodrug, polymorph or
stereoisomer of any of the foregoing (i) - (ii), or (b) is Covered by a Licensed Patent. For clarification, a small molecule compound shall not be considered a Program Compound (and would instead be considered a De Novo Compound) if such small
molecule (x) is not Covered by any Licensed Patent; (y) [***]; and (z) results from and/or is identified by screening a library of compounds [***], and, conversely, a small molecule compound would be considered a Program Compound if any of
clauses (x), (y), or (z) were untrue. For further clarification, a monoclonal antibody shall not be considered a Program Compound (and would instead be considered a De Novo Compound) if such antibody (1) is produced with [***], (2) [***],
and (3) has a lineage that is not derived from a Licensed Compound and, conversely, a monoclonal antibody would be considered a Program Compound if any of clauses (1), (2), or (3) were untrue.
		
	Section 1.86	  	“Program Patent” means Patent Rights (excluding the Licensed Patents) owned or licensed by VIGIL, its Affiliates or Sublicensees, as of the Effective Date or thereafter, that Cover [***].
		
	Section 1.87	  	“Proper Conduct Practices” means, in relation to any Person, such Person and each of its Representatives, not, directly or indirectly, (a) making, offering, authorizing, providing or paying anything of value in
any form, whether in money, property, services or otherwise to any Governmental Authority, Government Official, or other Person charged with similar public or quasi-public duties, or to any customer, supplier, or any other Person, or to any employee
thereof, or failing to disclose fully any such payments in violation of the laws of any relevant jurisdiction to (i) obtain favorable treatment in obtaining or retaining business for it or any of its Affiliates, (ii) pay for favorable
treatment for business secured, (iii) obtain special concessions or for special concessions already obtained, for or in respect of it or any of its Affiliates, in each case which would have been in violation of any Law, (iv) influence an
act or decision of the recipient (including a decision not to act) in connection with the Person’s or its Affiliate’s business, (v) induce the recipient to use his or her influence to affect any government act or decision in
connection with the Person’s or its Affiliate’s business, or (vi) induce the recipient to violate his or her duty of loyalty to his or her organization, or as a reward for having done so; (b) engaging in any transactions,
establishing or maintaining any fund or assets in which it or any of its Affiliates shall have proprietary rights that have not been recorded in the books and records of it or any

  
 -10- 

			
		  	of its Affiliates; (c) making any unlawful payment to any agent, employee, officer or director of any Person with which it or any of its Affiliates does business for the purpose of influencing such agent, employee, officer or
director to do business with it or any of its Affiliates; (d) violating any provision of applicable Anti-Corruption Laws; (e) making any payment in the nature of bribery, fraud, or any other unlawful payment under the Law of any
jurisdiction where it or any of its Affiliates conducts business or is registered; or (f) if such Person or any of its Representatives is a Government Official, improperly using his or her position as a Government Official to influence the
award of business or regulatory approvals to or for the benefit of such Person, its Representatives or any of their business operations, or failing to recuse himself or herself from any participation as a Government Official in decisions relating to
such Person, its Representatives or any of their business operations.
		
	Section 1.88	  	“Purchaser” means an individual or entity, including without limitation wholesalers, pharmacies, and group purchasing organizations, that purchase an Amgen Therapeutic Product to sell to members of the healthcare
community or that are authorized to act as a purchasing agent for a group of individuals or entities who furnish healthcare services.
		
	Section 1.89	  	“Transaction Notice” has the meaning set forth in Section 2.4 [***].
		
	Section 1.90	  	“Receiving Party” has the meaning set forth in Section 8.1.1 (Confidential Information).
		
	Section 1.91	  	“Regulatory Authority” means any Governmental Authority or other authority responsible for granting Marketing Approvals for the Product, including the FDA, European Commission/EMA and any corresponding national or
regional regulatory authorities.
		
	Section 1.92	  	“Regulatory Exclusivity” means, with respect to the Product, any exclusive marketing rights or data exclusivity rights conferred by the applicable Regulatory Authority with respect to the Product other than a Patent
Right.
		
	Section 1.93	  	“Regulatory Filing” means any all (a) submissions, material correspondence, notifications, registrations, licenses, authorizations, applications and other filings with any Governmental Authority with respect to
the research, development, manufacture, distribution, pricing, reimbursement, marketing or sale of the Product and (b) Marketing Approvals for the Product.
		
	Section 1.94	  	“Release” has the meaning set forth in Section 8.2.2 (Review).
		
	Section 1.95	  	“Representatives” means, as to any Person, such Person’s Affiliates and its and their successors, owners, controlling Persons, directors, officers, employees, agents, representatives, subcontractors, or other
third party acting for or on its behalf.
		
	Section 1.96	  	“Reservation Agreement” means that certain [***], in the form substantially similar to that attached as Exhibit E.
		
	Section 1.97	  	“Reservation Fee” has the meaning set forth in the Reservation Agreement.
		
	Section 1.98	  	“Reservation Agreement Process Consumables Fees” means those amounts payable by [***] under the Reservation Agreement in connection with [***].

  
 -11- 

			
		
	Section 1.99	  	“Reviewing Party” has the meaning set forth in Section 8.2.2 (Review).
		
	Section 1.100	  	“Royalty Term” has the meaning set forth in Section 3.3.1 (Royalty Rate; Royalty Term).
		
	Section 1.101	  	“Sale Transaction” has the meaning set forth in Section 10.8 (Successors and Assigns).
		
	Section 1.102	  	“Sanctioned Country” means Cuba, Iran, Syria, North Korea, and the Crimea Region of Ukraine, and any other country or region subject to comprehensive sanctions under applicable Law.
		
	Section 1.103	  	“Sanctioned Person” means any natural or legal person (i) identified on the Specially Designated Nationals and Blocked Persons List administered by the U.S. Department of Treasury Office of Foreign Assets
Control (OFAC), on the Entity List, the Unverified List, or the Denied Persons List administered by the U.S. Department of Commerce Bureau of Industry and Security (BIS), or on any equivalent lists maintained by the United Nations; (ii) fifty
percent (50%) or greater owned, directly or indirectly, in the aggregate, or otherwise controlled by a person or persons described in clause (i); or (iii) that is organized, resident, or located in a Sanctioned Country.
		
	Section 1.104	  	“Sensitive Manufacturing Know-How” means highly confidential Licensed Manufacturing Know-How [***].
		
	Section 1.105	  	“Series A Financing” means the funding of VIGIL through the sale of Series A Preferred Shares (as defined in the Financing Agreements) raising not less than [***].
		
	Section 1.106	  	“Significant Territorial Rights” means rights to develop or commercialize a Product in (a) the [***], (b) [***] or (c) at least three (3) of the [***].
		
	Section 1.107	  	“Small Molecule Product” means a Product that contains a small molecule agonist of TREM2.
		
	Section 1.108	  	“Sublicensee(s)” means any Person other than an Affiliate of VIGIL to which VIGIL has granted a sublicense under this Agreement.
		
	Section 1.109	  	“Term” has the meaning set forth in Section 9.1 (Term).
		
	Section 1.110	  	“Territory” means the entire world.
		
	Section 1.111	  	“Third Party” means a Person other than (a) AMGEN or any of its Affiliates and (b) VIGIL or any of its Affiliates.
		
	Section 1.112	  	“Third Party Acquirer” has the meaning set forth in Section 10.9 (Sale Transaction or AMGEN Acquisition).
		
	Section 1.113	  	“TREM2” means triggering receptor expressed on myeloid cells 2 (TREM2)
		
	Section 1.114	  	“United States” or “U.S.” means the United States of America, including its territories and possessions (including the District of Columbia and Puerto Rico).

  
 -12- 

			
		
	Section 1.115	  	“Valid Claim” means a claim of any issued and unexpired patent or patent application within the Licensed Patents or Program Patents and that has not been held invalid or unenforceable by a final decision of a court
or governmental agency of competent jurisdiction, which decision can no longer be appealed or was not appealed within the time allowed; provided, however, that if a claim of a pending patent application within the Licensed Patents or
Program Patents shall not have issued within [***] years after the earliest filing date from which such claim takes priority, such claim shall not constitute a Valid Claim for the purposes of this Agreement unless and until a Patent Right issues
with such claim (from and after which time the same would be deemed a Valid Claim).
		
	Section 1.116	  	“VAT” has the meaning set forth in Section 3.9.3 (VAT).
		
	Section 1.117	  	“VIGIL” has the meaning set forth in the Preamble.
		
	Section 1.118	  	“VIGIL Indemnified Parties” has the meaning set forth in Section 7.1.1 (By AMGEN).

 ARTICLE 2. LICENSE GRANT 

Section 2.1 Grant. Subject to the terms and conditions of this Agreement, AMGEN hereby grants to VIGIL: 

(a) an exclusive (even as to AMGEN, but subject to Section 2.3), royalty bearing, sublicensable (but only in accordance with Section 2.2
(Sublicenses)), license under AMGEN’s rights in and to the Licensed Patents and 
 (b) a non-exclusive, royalty bearing, sublicensable
(but only in accordance with Section 2.2 (Sublicenses)) license under AMGEN’s rights in and to the Licensed Know-How and 

(c) an exclusive, (even as to AMGEN, but subject to Section 2.3), royalty bearing sublicensable (but only in accordance with Section 2.2
(Sublicenses)) license under AMGEN’s rights in and to the Exclusively Licensed Know-How, 
 in each case (a),
(b) and (c), solely to Exploit Products in the Licensed Field in the Territory during the Term. 
 Notwithstanding the foregoing, the Licensed Know-How shall be sublicensable only in connection with the rights of VIGIL with respect to Products and not with respect to any other products or services. During the Term, neither AMGEN nor any of its Affiliates
will enter into any agreement or otherwise license, grant, assign, transfer, convey, or otherwise encumber or dispose any right, title, or interest in or to any of the Licensed Patents or Licensed Know-How,
which agreement, license, grant, assignment, transfer, conveyance, encumbrance, or disposition would conflict with the rights granted to VIGIL hereunder. 
  

  
 -13- 

 Section 2.2 Sublicenses. VIGIL shall be entitled, without the prior
consent of AMGEN, to grant one or more sublicenses, in full or in part, by a written agreement to Third Parties (with the right to sublicense through multiple tiers), provided, however, that as a condition precedent to
and requirement of any such sublicense: (a) any such permitted sublicense shall be consistent with and subject to the terms and conditions of this Agreement; and (b) VIGIL will continue to be responsible for full performance of
VIGIL’s obligations under the Agreement and will be responsible for all actions of such Sublicensee as if such Sublicensee were VIGIL hereunder. Notwithstanding the foregoing, (i) VIGIL shall have no right to grant any such sublicenses to
research, develop or commercialize the Product prior to the expiration of [***] without AMGEN’s prior written consent, except to contractors acting in support of VIGIL’s development efforts as described in Section 5.2 (Diligence); and
(ii) VIGIL shall have no right to grant any such sublicenses, without AMGEN’s prior written consent in its sole discretion, under any Licensed Manufacturing Know-How (except to a Permitted CMO/CRO in
accordance with Section 2.5.3). For clarification, a Sublicensee shall not be obligated to comply with Section 2.4 [***]. 

Section 2.3 Retained Rights and Limitations. Notwithstanding the licenses granted to VIGIL in this Article 2 (License
Grant), AMGEN retains (1) a research-only right under AMGEN’s rights in and to the Licensed Patents and Exclusively Licensed Know-How solely for AMGEN’s research use as tool molecules, but
expressly excluding any right for AMGEN to use Licensed Compounds or Exclusively Licensed Know-How to [***], in each case for purposes of identifying therapeutic candidates, clinically develop, interact with
any regulatory authority with respect to, or commercialize, any Licensed Compound or Program Compound; (2) all rights necessary for AMGEN (a) to continue collaboration with [***] in accordance with the Ongoing Studies Agreement, (b) to
complete activities contemplated by the Ongoing Studies Agreement and (c) to collaborate with [***] to publish the results of the Ongoing Studies in accordance with Section 8.3; (3) all rights necessary for AMGEN to [***] and license [***]
to conduct the Licensed Lead Antibody Compound manufacturing and related activities under the Order in accordance with Section 2.5.3; and (4) all rights necessary for AMGEN to [***] and license [***] to complete [***] in accordance with
Section 2.5.3(j) and for AMGEN to conduct [***] as contemplated in Section 2.5.3(k). 
 Section 2.4 [***]. 

2.4.1 If VIGIL (or any assignee or surviving party) elects to [***] for a Product with a Third Party (a “Proposed
Transaction”), VIGIL will provide AMGEN with prompt written notice of such Proposed Transaction with appropriate detail of the structure and material details of such Proposed Transaction (the “Transaction Notice”). 

2.4.2 If AMGEN desires to engage on the Proposed Transaction (e.g. to [***]), then AMGEN will notify VIGIL thereof (the “AMGEN
Election Notice”) within [***] of AMGEN’s receipt of the Transaction Notice. If Amgen provides the AMGEN Election Notice within such time period, for [***] following AMGEN’s receipt of the Transaction Notice (the “[***]
Period”), AMGEN will have an exclusive right to [***] such a Proposed Transaction. During the [***] Period, VIGIL shall [***] for such Proposed Transaction or related transaction between the Parties (an “Acquisition
Transaction”) and shall not [***] from any Third Party that would interfere with such [***]. If either (a) Amgen declines the opportunity to [***] or fails to respond to the Transaction Notice with [***] of receipt or (b) [***], then
VIGIL will be free to negotiate such Proposed Transaction for such Product with any Third Party and, provided a definitive agreement for such Proposed Transaction is executed within [***] of the Transaction Notice (or, if AMGEN provides an AMGEN
Election Notice, VIGIL will have a period of [***]), VIGIL will have no 

  
 -14- 

 
further obligations to Amgen under this Section 2.4 (subject to the terms of Section 2.2 (Sublicenses), as applicable) with respect to such Proposed Transaction. In the event VIGIL
fails to enter into a definitive agreement for any Proposed Transaction in such [***] period, Amgen’s rights and VIGIL’s obligations under Sections 2.4.1 and 2.4.2 will continue with respect to such Proposed Transaction. 

2.4.3 AMGEN’s rights under Sections 2.4.1 and 2.4.2 will terminate upon an IPO or Change of Control of VIGIL. 

2.4.4 For the sake of clarity, the foregoing provision shall not apply to the grant of a sublicense to a contract manufacturer or a
contract research organization solely for the purpose of manufacturing or developing a Product for VIGIL or to a Third Party distributor selling finished Product purchased from or on behalf of VIGIL. 

Section 2.5 Transfer of Licensed Know-How and Licensed Materials. 

2.5.1 Licensed Non-Manufacturing Know-How and
Licensed Materials. AMGEN shall transfer to VIGIL the Licensed Non-Manufacturing Know-How and Licensed Materials (other than [***]) listed on Exhibit A, in
accordance with a schedule specified on Exhibit A or as mutually agreed by the Parties (provided, the Parties will use reasonable efforts to ensure such transfer is completed within [***] after the Effective Date). The Parties
acknowledge that there are extensive documents, materials and information related to the Licensed Compounds, and that it is the intent of the Parties that the transfer of documents, materials and information hereunder be limited to that information
within the Licensed Non-Manufacturing Know-How that are necessary or reasonably useful to VIGIL’s Exploitation of Licensed Compounds. Accordingly, AMGEN shall not
have any obligation to transfer to VIGIL any Licensed Non-Manufacturing Know-How or Licensed Materials other than those set forth on Exhibit A. AMGEN will provide notice
to VIGIL when AMGEN has completed the transfer of all Licensed Non-Manufacturing Know-How and Licensed Materials listed in Exhibit A. Within ten (10) days of
receipt of such notice VIGIL will confirm that such transfer is complete or will provide written notice to AMGEN of any remaining Licensed Non-Manufacturing Know-How or
Licensed Materials that have not been transferred. In the event that VIGIL is unable to accept any Licensed Materials in such [***] transfer period, AMGEN reserves the right to charge VIGIL for any further storage of such Licensed Materials at a
rate reflecting AMGEN’s costs and expenses with respect to such continued storage. In the event that VIGIL determines in good faith that any Licensed Non-Manufacturing
Know-How or Licensed Materials other than those set forth on Exhibit A is [***], [***] or is [***], the Parties shall in good faith discuss such necessity, and, if unable to agree, the issue will be escalated
to each Party’s designated representative for further discussion. If the Parties agree on the necessity of such Licensed Non-Manufacturing Know-How or Licensed
Materials, AMGEN shall [***], with such support subject to Section 2.5.2. 
 2.5.2 Consulting Support. AMGEN shall
provide, [***], Consulting Support with respect to the matters described in 2.5.1 in connection with [***] until the earlier of (a) AMGEN has provided [***] total of Consulting Support or (b) the [***] ([***])-month anniversary of the
Effective Date. Without limiting the generality of the foregoing, Consulting Support will include [***]. If VIGIL requires additional Consulting Support in excess of [***], then VIGIL may request such additional Consulting Support in writing. AMGEN
shall notify VIGIL within [***] ([***]) days after receipt of such request whether it, in its sole discretion, is willing to provide such additional Consulting Support, which shall be at VIGIL’s expense, at the FTE Rate for the relevant AMGEN
employees. 

  
 -15- 

 2.5.3 AMGEN Cell Line and Licensed Manufacturing
Know-How. With respect to AMGEN’s transfer of the AMGEN Cell Line and Licensed Manufacturing Know-How, the Parties agree that the following procedures shall
apply: 
 (a) [***]. 

(i) Concurrent with the execution of this Agreement, Amgen [***]. In connection with the execution of the [***], VIGIL shall
pay to [***] the [***], in each case in the time frames contemplated in the [***]. Subject to AMGEN’s receipt of the [***] from VIGIL in such timeframes, AMGEN will [***] to [***] in accordance with the [***]. 

(ii) Promptly following the Effective Date, [***] will [***] draft, review and align upon the contents of the Order outlining
the specific activities to be undertaken by [***] in connection with [***], together with the applicable standards and specifications for the manufacture, testing, release and delivery such cGMP batch, to allow [***] and [***] to execute the Order
no later than [***]. The Order will include those items set forth in Exhibit H and such other items, if applicable, as may be agreed by the Parties and [***]. 

(iii) Promptly following the execution of the Order, AMGEN shall undertake the transfer of the AMGEN Cell Line, related
Licensed Manufacturing Know-How and related Licensed Materials to [***] in connection with activities to take place under the Order. Amgen will [***], in no instance will Amgen be obligated to [***] ([***]) in
connection with activities under or related to the Order. The Parties anticipate that [***]; provided, however, Amgen does not bear responsibility for the success or failure of [***]. AMGEN shall continue to [***] (both before and after the [***]
through [***] until [***] of such Licensed Lead Antibody Compound. VIGIL will use its Commercially Reasonable Efforts to support the activities under the Order and shall [***] under the Order. Amgen has no further [***] obligations after [***] under
the Order. 
 (iv) VIGIL shall be responsible for all fees and expenses of [***] in connection with the Order, including for
all activities described in Exhibit H and separately any fees resulting from additional items included in the Order and subsequent amendments or modifications to the Order. The Parties expect [***] fees and expenses for the Order (for the activities
described on Exhibit H) to be approximately $[***] (inclusive of [***]). [***] represents and warrants that the estimate set forth in Exhibit H reflects [***] the costs of the activities described therein and [***]. The Parties expect that until the
Contractual Transition Date, [***] in a time frame consistent with the payment terms of the Order and [***]; provided, the Parties may mutually agree on an [***] and that after the Contractual Transition Date, [***]. 

  
 -16- 

 (v) VIGIL shall use Commercially Reasonable Efforts to, as soon as
reasonably practicable after the Effective Date, negotiate and enter into a binding agreement with [***] (including a quality agreement) (the “[***] Agreement”) to allow VIGIL to [***] (such time point, the “Operational
Transition Date”). After VIGIL [***] with respect to such activities under [***], Amgen will continue to [***]; however, VIGIL will thereafter take lead responsibility for the [***] under [***]. The Parties expect, and [***], such GMP
documentation activities to take place in [***]. Once the [***] Agreement has been executed, [***] (the “Contractual Transition Date”). 

(vi) Each Party will bear its own internal costs and expenses in connection with performing activities under this
Section 2.5.3(a), including for clarity, all activities each Party undertakes to support [***] activities under the Order (such costs and expenses, the “[***] Support Costs”); provide, however, in the event [***]. 

(b) VIGIL must employ a Permitted CMO/CRO for any manufacturing or research related activities that require access to the AMGEN Cell Line or
other Sensitive Manufacturing Know-How. The [***] Agreement and VIGIL’s agreements with any other Permitted CMO/CRO that will have access to the AMGEN Cell Line or Sensitive Licensed Manufacturing Know-How shall provide for, among other things, (i) [***]; provided, (ii) [***], except as otherwise expressly contemplated in this Agreement and (iii) such additional provisions as are required to comply with
the manufacturing and other limitations set forth in this Section 2.5.3 (such agreement, the “Permitted CMO/CRO Agreement”). Upon AMGEN’s reasonable request, VIGIL shall [***]. For clarification, the requirement that VIGIL
employ a Permitted CMO/CRO and enter into a Permitted CMO/CRO Agreement apply with respect to the use of the AMGEN Cell Line or other Sensitive Manufacturing Know-How (including the manufacture of drug
substance) but does not apply with respect to other contract manufacturing or contract research activities that do not involve the use [***]. For clarity, without Amgen’s express written approval, VIGIL is not authorized to and shall [***] and
all VIGIL use and access to [***] will be pursuant to a confidentiality agreement pursuant to clause (e) of this section. For further clarification, VIGIL may arrange for storage of the AMGEN Cell Line at such Third Party storage facility as
VIGIL may determine and that is approved by Amgen in writing as a Permitted CMO/CRO. 
 (c) VIGIL acknowledges that the transfer of the [***]
to the Permitted CMO/CRO is solely to [***]. Notwithstanding the foregoing or anything to the contrary, except as contemplated below, Amgen shall not be required to transfer any Manufacturing Know-How relating
to [***]; however, (1) AMGEN expressly permits VIGIL to engage [***] to perform the [***] and other contract research organizations that are Permitted CMO/CROs for any [***] that may be necessary to support any Regulatory Filings with respect
to the Licensed Product containing Licensed Lead Antibody Compound and (2) AMGEN agrees to provide reasonable samples of [***] directly to any such Permitted CMO/CRO to facilitate such assays or tests. VIGIL shall receive the data and reports
from such assays or tests conducted by such Permitted CMO/CROs and, without Amgen’s express written approval, VIGIL is not authorized to and shall not [***]. 

  
 -17- 

 (d) VIGIL agrees that it shall not, and it shall use Commercially Reasonable Efforts to
cause the Permitted CMO/CRO not to: (i) reverse engineer or otherwise deconstruct the [***], or to determine or to seek to determine [***], other than as expressly required to manufacture the Licensed Lead Antibody Compound or a Licensed
Product containing the Licensed Lead Antibody Compound; (ii) [***], other than as expressly permitted under this Agreement or as may be expressly required to conduct the assays and tests contemplated in clause (c); (iii) notwithstanding anything to
the contrary in Section 8.3.1 (Right to Publish), publish or otherwise publicly disclose the [***]; or (iv) permit [***] to a Third Party or any of its Affiliates, other than as expressly required to manufacture the Licensed Lead Antibody
Compound or a Licensed Product containing the Licensed Lead Antibody Compound or [***] (provided such access or transfer is in accordance with this Agreement). AMGEN agrees to provide VIGIL with [***] by a Permitted CMO/CRO in accordance with this
Agreement from AMGEN or from an AMGEN-approved vendor on reasonable and customary commercial terms. 
 (e) Upon VIGIL’s written request
(and in any event prior to Amgen providing to VIGIL [***]), the Parties shall enter into the supplemental confidentiality agreement in the form attached hereto on Exhibit E to ensure that [***] provided to VIGIL shall be limited to [***], each of
whom need such information for purposes of [***] for the Licensed Product containing the Licensed Lead Antibody Compound and [***] (such [***], the “Clean Team,” and such purpose, the “Manufacturing Know-How Purpose”) and that such [***] shall be used solely for the Manufacturing Know-How Purpose. Prior to providing [***] to [***] of the Clean Team, the identity
of such [***] shall be provided to Amgen, and VIGIL shall enter into written agreements with such [***] containing confidentiality and non-use provisions no less restrictive than those contained in
Section 8.1 (Confidential Information) (“[***] Confidentiality Agreement”). Any act or omission of any such [***] that would be a breach of its [***] Confidentiality Agreement shall be deemed a breach of this Agreement by VIGIL
(and treated as if VIGIL breached Article 8). Upon the request of either Party, the Parties shall discuss in good faith and establish other reasonable arrangements, systems and protocols to ensure that [***] provided to VIGIL will be disclosed or
made available only to the Clean Team and will be used by such Clean Team solely for the Manufacturing Know-How Purpose. 

(f) In the event [***], VIGIL shall first seek support for such request from the Permitted CMO/CRO and, to the extent that the Permitted
CMO/CRO (or another applicable contract manufacturing or contract research organization) is unable to provide the necessary support [***], Amgen will [***]. 

  
 -18- 

 (g) In the event of a VIGIL Change of Control, VIGIL shall ensure that the acquiror,
successor or Sublicensee, as applicable, holds the same rights and obligations as VIGIL in respect of [***] (including, without limitation, with respect to establishing and abiding by the supplemental confidentiality agreement described above). For
clarity, any such acquirer, successor or Sublicensee shall, as a condition to gaining access [***], enter into a supplemental confidentiality agreement with Amgen in the form attached hereto on Exhibit E subject to such revisions as AMGEN may
reasonably implement taking into account specific concerns arising with regard to the acquiror, successor or Sublicensee. 
 (h) Upon a
termination or expiration of the Permitted CMO/CRO Agreement (including, for clarity the [***] Agreement and including as a result of the appointment, with prior written notice to AMGEN, by VIGIL of a replacement Permitted CMO/CRO), the Permitted
CMO/CRO shall, as directed by VIGIL, promptly return any [***] to AMGEN or shall transfer [***] to the replacement Permitted CMO/CRO. If, at any time, VIGIL desires to add a new Third Party contract manufacturer or contract research organization to
Exhibit C, it shall notify AMGEN in writing (a “Permitted CMO/CRO Request”), and AMGEN shall have the right, for [***] ([***]) days after receipt of such Permitted CMO/CRO Request [***]. If AMGEN rejects a Permitted CMO/CRO Request
pursuant to the foregoing, it will notify VIGIL thereof (and its reasons therefor). [***]. 
 (i) Notwithstanding anything in this Agreement
to the contrary, AMGEN shall have no obligation under this Agreement to transfer to VIGIL, its Affiliates or any Third Party any [***], except as expressly provided in this Section 2.5.3. 

(j) Promptly following the Effective Date, the Parties will cooperatively arrange for the transfer from AMGEN to VIGIL of all rights and
obligations to [***] at [***] (“[***]”). Each Party will [***], however, AMGEN does not bear responsibility for the success or failure of [***]. AMGEN shall [***]. AMGEN covenants to VIGIL that AMGEN will (i) comply with the
applicable agreement(s) with [***] to the extent [***], (ii) will promptly provide to VIGIL or VIGIL’s designated representative all [***]; (iii) will not amend or waive its rights under the applicable agreement(s) with [***] in a way that
affects the [***] without Vigil’s consent, (iv) [***] under or with respect to the applicable agreement(s) with [***]. Without limiting the generality of the foregoing, (a) any Patent Rights or
Know-How arising under the applicable agreement(s) with [***], arising from [***] and Controlled by AMGEN shall constitute Licensed Patents or Licensed Know-How under
this Agreement. AMGEN is responsible for (and shall pay) the [***] fees and expenses incurred on or before the Effective Date and VIGIL is responsible for (and shall pay) such fees and expenses arising after the Effective Date. VIGIL shall use
Commercially Reasonable Efforts to enter into a Permitted CMO/CRO Agreement with [***] (the “[***] Agreement”) as soon as reasonably practicable after the Effective Date to allow VIGIL to assume primary operational and contractual
responsibilities with respect to [***]. Until such time as VIGIL has entered into the [***] Agreement, VIGIL will [***] under AMGEN’s agreement with [***] to AMGEN (in accordance with Section 3.4) in a time frame consistent with [***] the
AMGEN-[***] agreement and AMGEN will [***]; provided, the Parties may mutually agree on [***]. After such time as VIGIL has entered into the [***] Agreement and the Parties have transitioned the contractual responsibilities for [***] to VIGIL, VIGIL
will make payments [***] directly to [***]. 

  
 -19- 

 (k) Amgen will [***]. Once VIGIL has entered into the [***] Agreement, AMGEN will [***].

 2.5.4 Limited Warranties. 

(a) VIGIL acknowledges that any materials transferred by AMGEN to VIGIL (or the Permitted CMO/CRO) under this Agreement are experimental in
nature and may have unknown characteristics (including the hazardous and toxicological properties) and therefore agrees to use prudence and reasonable care in the use, handling, storage, transportation and disposition and containment of any such
materials. Accordingly, no such materials, shall be used in any human application, including any clinical trial. 
 (b) AMGEN is the sole and
exclusive owner of and has good and valid title to the [***]. Upon delivery to the Permitted CMO/CRO selected by VIGIL (and/or Third Party storage facility as VIGIL may designate), VIGIL will acquire good and valid title to such [***] free and clear
of all liens. AMGEN will provide to VIGIL (and [***], if applicable), a data sheet with respect to [***], which data sheet shall to Amgen’s knowledge, include accurate and complete information with respect to testing and analysis conducted by
or on behalf of AMGEN with respect to such material. AMGEN will also provide to VIGIL a data sheet (e.g., a record of analysis) with respect to certain [***] and provided to VIGIL for which such data sheet is available, which data sheet shall, to
Amgen’s knowledge, include accurate and complete information with respect to testing and analysis, if any, conducted by or on behalf of AMGEN with respect to such material. 

(c) EXCEPT AS SET FORTH IN SECTION 2.5.4(b), ALL MATERIAL IS BEING SUPPLIED TO VIGIL WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. VIGIL HEREBY ACKNOWLEDGES AND AGREES THAT ANY ANALYSIS OF THE REPORT OR RESULTS, OR OTHER DATA, PROVIDED BY AMGEN ARE, EXCEPT AS SET FORTH IN SECTION 2.5.4(b), PROVIDED “AS
IS” WITH NO WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THEY ARE FREE FROM THE RIGHTFUL CLAIM OF ANY THIRD PARTY, BY WAY OF INFRINGEMENT OR THE LIKE. 

Section 2.6 Covenant Not to Sue. Upon the closing of the Series A Financing and the grant of the AMGEN Shares pursuant to the Financing
Agreements, [***]. For purposes of this Section 2.6, Amgen Affiliates includes any Acquirees; provided, that [***]. 

  
 -20- 

 Section 2.7 No Other Rights. VIGIL acknowledges that the rights and licenses granted
under this Article 2 (License Grant) and elsewhere in this Agreement are limited to the scope expressly granted. Accordingly, except for the rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever is
granted whether by implication, estoppel, reliance, or otherwise, by AMGEN to VIGIL. All rights that are not specifically granted herein are reserved to AMGEN. For clarity, except as stated below with respect to Licensed Lead Antibody Compound drug
substance inventory and consumables included within the Licensed Materials, the transfer under this Agreement of Licensed Know-How and Licensed Material (including the AMGEN Cell Line) shall constitute a transfer of possession together with a
limited license to use such Licensed Know-How and Licensed Materials (including the AMGEN Cell Line) as contemplated under this Agreement and shall not constitute a transfer in title in and to such Licensed Know-How and Licensed Materials (including
the AMGEN Cell Line). The transfer of Licensed Lead Antibody Compound drug substance inventory and consumables within the Licensed Materials constitutes a transfer of all right, title and interest in and to such materials, provided that VIGIL may
use such materials solely to Exploit Licensed Products in accordance with this Agreement. 
 Section 2.8 Restrictions. During the term of
the definitive agreement, VIGIL shall not challenge the validity of any of the Licensed Patents. VIGIL agrees (on behalf of itself and its Affiliates), and shall cause each of its Sublicensees and contract manufacturers to agree as a condition to
the grant of a sublicense, (a) not to Exploit any Licensed Know-How or Licensed Patents for any products other than a Product and (b) not to Exploit the [***] or any Sensitive Manufacturing Know-How other than for the manufacture of the
Licensed Lead Antibody Compound or a Licensed Product containing the Licensed Lead Antibody Compound and as permitted by this Article 2. 

ARTICLE 3. EQUITY, MILESTONES, ROYALTIES AND PAYMENTS 

Section 3.1 Equity in VIGIL. As partial consideration for the rights granted to VIGIL hereunder, at each closing of the Series A Financing
(until such time as VIGIL has raised $45,000,000) and in accordance with the Financing Agreements and the Equity Side Letter, VIGIL shall issue to AMGEN an amount of Series A preferred shares such that Amgen’s equity ownership in VIGIL will be
equal to twenty-five percent (25%) of the fully-diluted equity interests in VIGIL post-closing (until such time as VIGIL has raised $45,000,000, with all such shares, whether issued at the first closing or thereafter comprising the
“AMGEN Shares”). 
 Section 3.2 Upfront and Milestone Payments. 

3.2.1 Upfront Payment. As partial consideration for the rights granted to VIGIL hereunder, VIGIL shall pay AMGEN a one-time
non-creditable, non-refundable upfront payment of Five Hundred Thousand Dollars ($500,000) within ten (10) days of the Effective Date, of which [***] ([***]) shall constitute full and complete payment for the Licensed Lead Antibody Compound
drug substance and all other items of tangible personal property (i) included in the Licensed Material and sold to VIGIL or (ii) otherwise transferred to VIGIL hereunder. 

  
 -21- 

 3.2.2 Milestone Payments. As partial consideration for the rights granted to VIGIL
hereunder, VIGIL shall pay AMGEN the following non-creditable, non-refundable payments (described in the table below under the column “Milestone Payment” and each such payment, a “Milestone Payment”) within [***]
([***]) days following the date that each milestone (described in the table below under the column “Milestone”) is achieved by VIGIL, its Affiliates or Sublicensees: 

 

					
	 	  	 Milestone
	  	Milestone
Payment
	 1
	  	[***]	  	[***] ($[***])
	 2
	  	[***]	  	[***] ($[***])
	 3
	  	[***]	  	[***] ($[***])
	Each of Milestone Payments numbers 1-3 are payable no more than twice in total: once for the first MAB Product achieving the applicable Milestone and once for the first Small Molecule Product achieving the applicable
Milestone.
	 4
	  	[***]	  	[***] ($[***])
	 5
	  	[***]	  	[***] ($[***])
	 6
	  	[***]	  	[***] ($[***])
	 7
	  	[***]	  	[***] ($[***])
	 5
	  	[***]	  	[***] ($[***])
	 6
	  	[***]	  	[***] ($[***])

 VIGIL will provide AMGEN with prompt written notice of the accomplishment of each such Milestones and the corresponding
Milestone Payment. 
 Section 3.3 Royalties. 

3.3.1 Royalty Rate; Royalty Term. On a Product-by-Product basis, VIGIL shall pay to AMGEN the following tiered royalties on
annual Net Sales of each Product sold by a Selling Party during the Royalty Term applicable to such Product: 
 (a) [***] percent
([***]%) on the portion of annual Net Sales of such Product less than [***] U.S. Dollars ($[***]); 
 (b) [***] percent ([***]%) on the
portion of annual Net Sales of such Product equal to or greater than [***] U.S. Dollars ($[***]) but less than [***] U.S. Dollars ($[***]); 

(c) [***] percent ([***]%) on the portion of annual Net Sales of such Product that is equal to or greater than [***] U.S. Dollars ($[***]) but
less than [***] U.S. Dollars ($[***]); and 

  
 -22- 

 (d) [***] percent ([***]%) on the portion of annual Net Sales of such Product that is equal
to or greater than [***] U.S. Dollars ($[***]). 
 Royalties will be payable on a quarterly basis; any such payments shall be made within [***] ([***]) days
after the end of the calendar quarter during which the applicable Net Sales occurred. VIGIL’s obligation to pay royalties with respect to each Product in a particular country shall commence upon the First Commercial Sale of such Product in such
country and shall expire on a country-by-country and Product-by-Product basis on the later of (i) the date on which the Exploitation of such Product is no longer Covered by a Valid Claim of a Licensed Patent or Program Patent in such country or
(ii) the tenth (10th) anniversary of the First Commercial Sale of such Product in such country (the “Royalty Term”). 

3.3.2 Royalty Reductions. 

(a) On a country-by-country basis, in the event that the Exploitation of a Licensed Product is not Covered by a Valid Claim of a [***] in such
country, then the royalty rates set forth in Section 3.3.1 (Royalty Rate; Royalty Term) with respect to Net Sales for such Licensed Product in such country shall be reduced by [***] effective as of the date such Licensed Product is no longer
Covered by a Valid Claim of a [***] in such country. 
 (b) On a country-by-country basis, in the event that the Exploitation of a Product is
not Covered by either (1) a Valid Claim of a [***] or (2) a Valid Claim of a [***] in such country, then the royalty rates set forth in Section 3.3.1 (Royalty Rate; Royalty Term) with respect to Net Sales for such Product in such
country shall be reduced by [***] effective as of the date such Product is no longer Covered by a Valid Claim of a [***] in such country. 

(c) On a country-by-country basis, in the event that one or more Generic Products to a Small Molecule Product is launched in any country in the
Territory during the Royalty Term for such Small Molecule Product in such country, and the average quarterly Net Sales of such Small Molecule Product in such country during the subsequent [***] ([***]) Calendar Quarters decrease by more than [***]
percent ([***]%) of the average quarterly Net Sales of such Small Molecule Product in such country during the [***] ([***]) Calendar Quarters immediately preceding the Calendar Quarter in which the first Generic Product is launched in such country,
the royalty rates provided in Section 3.3.1 for such Small Molecule Product shall be reduced in such country by [***] for each Calendar Quarter in the remainder of such Royalty Term. For the purposes of this Section 3.3.2(c), the term
“launched” shall refer to the listing of a wholesale acquisition cost (WAC) price for the Generic Product on the applicable pricing compendium. 

3.3.3 Third Party Royalties. If VIGIL, its Affiliates or any Sublicensee is required by (a) a future order by a court of
competent jurisdiction, (b) settlement agreement, (c) license or contract, or (d) other legally binding commitment to make royalty payments to a Third Party, in each case in exchange for a license or other right under Patent Rights held by
such Third Party and such license or other rights are necessary for the Exploitation of any Licensed Compound or 

  
 -23- 

 
Program Compound that is derived from a Licensed Compound and the Exploitation of such Licensed Compound would also require a license to such Patent Rights in a given country, then VIGIL shall be
entitled to deduct from royalties due to AMGEN under this Agreement with respect to Net Sales on all Licensed Products containing such Licensed Compound or Program Compound in a given Calendar Quarter in each such country an amount equal to [***] of
the royalties actually paid to such Third Party in such Calendar Quarter as consideration for such license under such Patent Rights, up to a maximum amount of [***] of the royalties due to AMGEN in each affected country in such Calendar Quarter.

 3.3.4 Maximum Reduction. Notwithstanding anything to the contrary, the maximum aggregate reduction with respect to
royalties payable on any Product in any calendar quarter during the applicable Royalty Term in any country pursuant to Section 3.3.2 (Royalty Reductions) and Section 3.3.3 (Third Party Royalties) shall be [***]. 

3.3.5 Mutual Convenience of the Parties. The royalty and other payment obligations set forth hereunder have been agreed to by
the Parties for the purpose of reflecting and advancing their mutual convenience, including the ease of calculating and paying royalties and other amounts to AMGEN. 

Section 3.4 Method of Payment. [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 Section 3.5 Royalty
Reports. After the First Commercial Sale of the first Product and until expiration of the last Royalty Term, VIGIL shall prepare and deliver to AMGEN royalty reports of the sale of the Products by the Selling Parties for each calendar
quarter within forty-five (45) days of the end of each such calendar quarter specifying in the aggregate and on the Product-by-Product and country-by-country basis: (a) total gross amounts for each Product sold or otherwise disposed of by
a Selling Party; (b) amounts deducted by category in accordance with the definition of “Net Sales” in Article 1 (Definitions) from gross amounts to calculate Net Sales; (c) Net Sales; and (d) royalties payable. 

Section 3.6 Currency Conversion. With respect to Net Sales invoiced in U.S. Dollars, such Net Sales invoiced shall be expressed in U.S.
Dollars. With respect to Net Sales invoiced in a currency other than U.S. Dollars, such Net Sales invoiced shall be converted into the U.S. Dollar equivalent using a rate of exchange which corresponds to the rate used by the Selling Party in
recording such receipt, for the respective reporting period, related to recording such Net Sales in its books and records that are maintained in accordance with GAAP. If a Selling Party is not required to perform such currency conversion for its
GAAP reporting with respect to the applicable period, then for such period such Selling Party shall convert its amounts received incurred into U.S. Dollars using a rate of exchange which corresponds to the noon buying rate as published in the Wall
Street Journal, Eastern U.S. Edition on the second to last business day of the Calendar Quarter (or such other publication as agreed-upon by the Parties). Any royalty amount shall be calculated based upon the U.S. Dollar equivalent calculated
in accordance with the foregoing. 

  
 -24- 

 Section 3.7 Late Payments. In the event that any payment due hereunder is not made when
due, the payment shall accrue interest beginning on the day following the due date thereof, calculated at the annual rate of the sum of (a) [***] plus (b) the prime rate effective for the date that payment was due, as published by the Wall
Street Journal, Eastern U.S. Edition, the interest being compounded on the last day of each calendar quarter; provided, however, that in no event shall said annual interest rate exceed the maximum rate permitted by Law. Each such
payment when made shall be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof shall not negate or waive the right of any Party to seek any other remedy, legal or equitable, to which it may be entitled
because of the delinquency of any payment including, but not limited to termination of this Agreement as set forth in Article 10 (Term & Termination). 

Section 3.8 Records and Audits. VIGIL will keep complete and accurate records of the underlying revenue and expense data relating to the
calculations of Net Sales generated in the then current calendar year and payments required under this Agreement, and during the preceding three (3) calendar years. AMGEN will have the right, once annually at its own expense, to have a
nationally recognized, independent, certified public accounting firm, selected by it and subject to VIGIL’s prior written consent (which shall not be unreasonably withheld), review any such records of VIGIL and its Affiliates and Sublicensees
(the “Audited Party”) in the location(s) where such records are maintained by the Audited Party upon reasonable written notice (which shall be no less than thirty (30) days’ prior written notice) and during regular
business hours and under obligations of strict confidence, for the sole purpose of verifying the basis and accuracy of payments made under Section 3.3 Section 3.1 (Royalties) within the thirty-six (36) month period preceding the date
of the request for review. No calendar year or portion thereof will be subject to audit under this Section more than once. VIGIL will receive a copy of each such report concurrently with receipt by AMGEN. Should such inspection lead to the discovery
of a discrepancy to AMGEN’s detriment, VIGIL will, within forty-five (45) days after receipt of such report from the accounting firm, pay any undisputed amount of the discrepancy together with interest at the rate set forth in
Section 3.7 (Late Payments). AMGEN will pay the full cost of the review unless the underpayment of amounts due to AMGEN is [***] for the entire period being examined, in which case VIGIL will pay the cost charged by such accounting firm for
such review. Should the audit lead to the discovery of a discrepancy to VIGIL’s detriment, VIGIL may credit the amount of the discrepancy, without interest, against future payments payable to AMGEN under this Agreement, and if there are no such
payments payable, then AMGEN shall pay to VIGIL the amount of the discrepancy, without interest, within [***] days of AMGEN’s receipt of the report. 

Section 3.9 Taxes. 

3.9.1 Use Tax. VIGIL is responsible for the payment of any state or local sales or use, or similar fees or taxes arising as a
result of the transfer of Licensed Materials, including, specifically the Licensed Lead Antibody Compound drug substance inventory and consumables within the Licensed Materials, by AMGEN to VIGIL pursuant to Section 2.5 (Transfer of Licensed
Know-How and Licensed Materials), and VIGIL will remit such fees or taxes to the proper taxing jurisdiction, when deemed taxable by VIGIL. To the extent VIGIL is unable to complete and file any required tax returns or other tax documents relating to
such fees or taxes itself, the Parties will 

  
 -25- 

 
cooperate in completing and filing such returns or documents relating to such fees or taxes. VIGIL will deliver to AMGEN a MA Resale Certificate (ST-4) or MA Exemption Certificate (ST-12), as may
be applicable to the transfer of the Licensed Materials. The Parties shall use their respective commercially reasonable efforts to deliver and receive the Licensed Materials, as appropriate, through electronic delivery (other than Licensed Lead
Antibody Compound drug substance and any other tangible inventory included in the Licensed Material) or in such other manner reasonably calculated in accordance with applicable law, and take all other commercially reasonable actions necessary, to
minimize or avoid the incurrence of any such taxes or fees. 
 3.9.2 Withholding. In the event that any Law requires VIGIL to
withhold taxes with respect to any payment to be made by VIGIL pursuant to this Agreement, VIGIL will notify AMGEN of such withholding requirement prior to making the payment to AMGEN and provide such assistance to AMGEN, including the provision of
such standard documentation as may be required by a tax authority, as may be reasonably necessary in AMGEN’s efforts to claim an exemption from or reduction of such taxes. VIGIL will, in accordance with such Law withhold taxes from the amount
due, remit such taxes to the appropriate tax authority, and furnish AMGEN with proof of payment of such taxes within thirty (30) days following the payment. If taxes are paid to a tax authority, VIGIL shall provide reasonable assistance to
AMGEN to obtain a refund of taxes withheld, or obtain a credit with respect to taxes paid. Taxes withheld pursuant to this Section 3.9.2 will be treated as payments to AMGEN hereunder, and shall reduce payments otherwise required to be made to
AMGEN by the amount withheld. 
 3.9.3 VAT. All payments due to AMGEN from VIGIL pursuant to this Agreement shall be
paid exclusive of any value-added tax (“VAT”) (which, if applicable, shall be payable by VIGIL upon receipt of a valid VAT invoice). If AMGEN determines that it is required to report any such tax, VIGIL shall promptly provide AMGEN
with applicable receipts and other documentation necessary or appropriate for such report. For clarity, this Section 3.9.3 (VAT) is not intended to limit VIGIL’s right to deduct value-added taxes in determining Net Sales. 

3.9.4 Tax Treatment of Equity and Payments. 

(a) AMGEN and VIGIL intend to treat the issuance to AMGEN of the AMGEN Shares and the payment of any Milestone Payments and any royalties
pursuant to this Article 3 as consideration for the transfer of Licensed Patents and Licensed Know-How to VIGIL for U.S. federal income Tax purposes (and applicable state, local or non-U.S. Tax purposes). 

(b) AMGEN and VIGIL intend to treat the transfer of the Licensed Patents and Licensed Know-How to VIGIL in exchange for the AMGEN Shares , any
Milestone Payments and any royalties pursuant to this Article 3 as part of an integrated transaction constituting a transfer described in Section 351 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and any analogous
provision of applicable state, local or non-U.S. law, and agree that the fair market value of the AMGEN Shares as of the issuance date thereof shall be equal to the product of the price per share paid by investors for such shares multiplied by the
number of shares issued to AMGEN. 

  
 -26- 

 (c) AMGEN and VIGIL intend to treat the issuance of the AMGEN Shares issued after the first
closing and the payment of any Milestone Payments or royalties under this Agreement as additional consideration in respect of the transfer of the Licensed Patents and Licensed Know-How to VIGIL for U.S. federal income tax purposes and for applicable
state, local and non-U.S. purposes as part of an integrated transaction constituting a transfer described in Section 351 of the Code and any analogous provision of applicable state, local or non-U.S. law, and agree that the AMGEN shares issued
at or after the initial closing of the Series A Financing shall have a fair market value equal to the product of the price per share paid by investors for such shares multiplied by the number of shares issued to AMGEN. 

(d) AMGEN and VIGIL shall file all Tax returns, reports, schedules, information statements and other documents consistently with the
understandings set forth in this Section 3.9.4, and shall take no contrary position on any such Tax return, or in any audit, claim, investigation or proceeding in respect of Taxes unless otherwise by applicable Federal, state, local or non-U.S.
law. 
 (e) AMGEN represents that the Licensed Patents, the Licensed Know How and any other property contributed or licensed to VIGIL
pursuant to this Agreement (i) constitute “property” within the meaning of Section 351 of the Code and (ii) do not have an adjusted tax basis for applicable tax purposes in AMGEN’s hands. 

(f) AMGEN (i) will not elect out of the installment method of reporting under Section 453 of the Code with respect to the
transactions set forth in this Agreement and (ii) represents and warrants to VIGIL that Section 362(e)(2)(C) of the Code does not and will not apply to the transactions set forth in this Agreement. 

ARTICLE 4. PATENT PROSECUTION, MAINTENANCE, & INFRINGEMENT 

Section 4.1 Intellectual Property Ownership. 

4.1.1 Except to the extent expressly specified to the contrary in this Agreement: (i) each Party shall retain and own all right,
title, and interest in and to all Patent Rights, trade secrets, proprietary rights and other intellectual property rights (collectively “Inventions”) conceived or created solely by such Party; (ii) the Parties shall jointly own
all right, title, and interest in and to Inventions conceived or created jointly by the Parties pursuant to this Agreement (“Joint Inventions”) and, subject to the provisions of this Agreement, neither Party shall have any duty to
account or obtain the consent of the other Party (such consent deemed given hereunder) in order to exploit, license or assign its respective rights in Joint Inventions; and (iii) inventorship and authorship of any Invention or work of
authorship conceived or created by either Party or jointly by the Parties pursuant to this Agreement, shall follow the rules of the U.S. Patent and Trademark Office and the Laws of the U.S. (without reference to any conflict of law principles). For
clarification, any interest of AMGEN in or with respect to Joint Inventions shall constitute Licensed Patents or Licensed Know-How, as the case may be, licensed to VIGIL pursuant to the terms of this Agreement. 

  
 -27- 

 4.1.2 Notwithstanding the foregoing, all right, title, and interest in and to
Inventions exclusively related to Program Compounds (and any associated Patent Rights) shall be owned exclusively by VIGIL regardless of inventorship. Amgen hereby assigns to VIGIL all of its entire right and title in any Program Compounds and
inventions related thereto. 
 Section 4.2 Prosecution and Maintenance. 

4.2.1 VIGIL shall have the first right to file, prosecute and maintain all Patent Rights specified under
Licensed Patents and Program Patents at VIGIL’s sole expense using outside counsel selected by VIGIL and reasonably acceptable to AMGEN. VIGIL will use Commercially Reasonable Efforts to prepare, file, prosecute, defend and maintain all Patent
Rights specified under Licensed Patents and Program Patents. AMGEN shall reasonably cooperate with VIGIL’s requests for data, affidavits, and other information and assistance to support prosecution and maintenance of the Patent Rights in the
Licensed Patents; provided, however, that VIGIL shall reimburse AMGEN for its reasonable, documented out-of-pocket expenses with respect to such cooperation. VIGIL shall promptly upon receipt forward to AMGEN copies of
any significant office actions, communications, and correspondence relating to the Licensed Patents and Program Patents. AMGEN shall have the right to comment on and to discuss prosecution and maintenance activities with VIGIL, and VIGIL shall
consider the same in good faith. For purpose of clarity, VIGIL may at its discretion file new patent applications for Program Patents and may include in such applications data or discoveries included within the Licensed Know-How; provided, however,
VIGIL, its Affiliates and Sublicensees may not file patent applications claiming any AMGEN Cell Line or any Licensed Manufacturing Know-How. 

4.2.2 Notwithstanding the foregoing, if VIGIL declines to file, prosecute or maintain any Patent Rights, elects to allow any Patent
Rights to lapse in any country, or elects to abandon any Patent Rights (in each case to the extent contained in the Licensed Patents or Program Patents) before all appeals within the respective patent office have been exhausted (each, an
“Abandoned Patent Right”), then: 
 (a) VIGIL shall provide AMGEN with reasonable notice of such decision so as to
permit AMGEN to decide whether to file, prosecute or maintain such Abandoned Patent Rights and to take any necessary action (which notice shall, in any event, be given no later than [***] ([***]) days prior to the next deadline for any action that
may be taken with respect to such Abandoned Patent Right with the U.S. Patent & Trademark Office or any foreign patent office). 

(b) AMGEN, at AMGEN’s expense, may assume control of the filing, prosecution and/or maintenance of such Abandoned Patent Rights. 

(c) AMGEN shall have the right to transfer the responsibility for such filing, prosecution and maintenance of such Abandoned Patent Rights to
patent counsel (outside or internal) selected by AMGEN. 
 (d) VIGIL shall assist and cooperate with AMGEN’s reasonable requests to
support prosecution and maintenance of such Abandoned Patent Rights; provided, however, that AMGEN shall reimburse VIGIL for its reasonable expenses with respect to such cooperation (including VIGIL’s employee’s time at the FTE Rate). 

  
 -28- 

 (e) In the event a patent issues with respect to any such Abandoned Patent Rights, AMGEN
shall provide reasonable notice to VIGIL thereof and such Abandoned Patent Right shall be excluded from the license granted by AMGEN to VIGIL under Section 2.1 (Grant), unless VIGIL (i) reimburses AMGEN for its reasonable, documented,
internal and external costs and expenses related to the prosecution and maintenance of such Abandoned Patent Right within [***] ([***]) days of notice of issuance of any such patent and (ii) assumes, in writing, the responsibility for the
continued prosecution and maintenance of such Patent Rights in accordance with the provisions of Section 4.1 (Prosecution and Maintenance). For the avoidance of doubt, the Abandoned Patent Rights shall not be excluded from the license granted
by AMGEN to VIGIL under Section 2.1 (Grant) unless and until after expiry of the [***] ([***]) day period referred to under (i) above and if VIGIL elects not to exercise its rights under (i) and (ii) above. 

Section 4.3 Enforcement. 

4.3.1 VIGIL Enforcement. Each Party will notify the other promptly in writing when any Infringement of a Licensed Patent or a
Program Patent by a Third Party is uncovered or reasonably suspected. VIGIL shall have the first right to enforce any patent within the Licensed Patents or Program Patents against any Infringement or alleged Infringement thereof, and shall at all
times keep AMGEN informed as to the status thereof. VIGIL may, at its own expense, institute suit against any such infringer or alleged infringer and control and defend and settle such suit in a manner consistent with the terms and provisions hereof
and recover any damages, awards or settlements resulting therefrom, subject to Section 4.5 (Recovery). AMGEN shall reasonably cooperate in any such litigation (including joining or being named a necessary party thereto) at VIGIL’s expense.
VIGIL shall not enter into any settlement of any claim described in this Section 4.3.1 (VIGIL Enforcement) that admits to the invalidity or unenforceability of the Licensed Patents or Program Patents, incurs any financial liability on the part
of AMGEN or requires an admission of liability, wrongdoing or fault on the part of AMGEN, without AMGEN’s prior written consent, in each case, such consent not to be unreasonably withheld. 

4.3.2 AMGEN Enforcement. If VIGIL elects not to enforce any patent within the Licensed Patents or Program Patents, then it shall
so notify AMGEN in writing within [***] ([***]) months of receiving notice that an Infringement exists (or such shorter period as may be necessary to prevent exhaustion of a statute of limitations (or laches) applicable to such Infringement). VIGIL
shall consider in good faith a request by AMGEN to at its own expense, take steps to enforce any such patent and control, settle, and defend such suit in a manner consistent with the terms and provisions hereof. If AMGEN pursues such action, it may
recover any damages, awards or settlements resulting therefrom, subject to Section 4.5 (Recovery). VIGIL shall reasonably cooperate in any such litigation (including joining or being named a necessary party thereto) at AMGEN’s expense.
AMGEN shall not enter into any settlement of any claim described in this Section 4.3.2 (AMGEN Enforcement) that admits to the invalidity or unenforceability of the Licensed Patents or Program Patents, incurs any financial liability on the part
of VIGIL or requires an admission of liability, wrongdoing or fault on the part of VIGIL without VIGIL’s prior written consent. 

  
 -29- 

 4.3.3 Progress Reports. The Party initiating or defending any such enforcement
action (the “Enforcing Party”) shall keep the other Party reasonably informed of the progress of any such enforcement action, and such other Party shall have the individual right to participate with counsel of its own choice at its
own expense. 
 Section 4.4 Defense of Third Party Claims. If either (a) any Licensed Product Exploited by or under authority
of VIGIL becomes the subject of a Third Party’s claim or assertion of Infringement of a patent relating to the manufacture, use, sale, offer for sale or importation of such Licensed Product in the Licensed Field in the Territory, or (b) a
declaratory judgment action is brought naming either Party as a defendant and alleging invalidity or unenforceability of any of the Licensed Patents or Program Patents, the Party first having notice of the claim or assertion shall promptly notify
the other Party, and the Parties shall promptly confer to consider the claim or assertion and the appropriate course of action. Subject to Article 8 (Indemnification), unless the Parties otherwise agree in writing, each Party shall have the right to
defend itself against a suit that names it as a defendant (the “Defending Party”). Neither Party shall enter into any settlement of any claim described in this Section 4.4 that admits to the invalidity or unenforceability of
the Licensed Patents or, Program Patents, incurs any financial liability on the part of the other Party, requires an admission of liability, wrongdoing or fault on the part of the other Party or, without such other Party’s prior written
consent, in each case, such consent not to be unreasonably withheld. In any event, the other Party shall reasonably assist the Defending Party and cooperate in any such litigation at the Defending Party’s request and expense. 

Section 4.5 Recovery. Except as otherwise provided, the costs and expenses of the Party bringing suit under Section 4.3 (Enforcement)
shall be borne by such Party, and any damages, settlements or other monetary awards recovered shall be shared as follows: (a) the amount of such recovery actually received by the Party controlling such action shall first be applied to the
out-of-pocket costs of each Party in connection with such action; and then (b) the remainder of the recovery shall be shared as follows: 

(i) If VIGIL is the Enforcing Party, [***]; and 

(ii) If AMGEN is the Enforcing Party, [***]. 

Section 4.6 Patent Term Extensions and Filings for Regulatory Exclusivity Periods. VIGIL will advise AMGEN when it is considering any
patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents. AMGEN will cooperate with VIGIL in the preparation and filing of any patent term extension application with respect to the Licensed Patents.
With respect to any patent listings required for any Regulatory Exclusivity for a Licensed Product, [***]. 
 Section 4.7 Patent Marking.
VIGIL will mark, and will cause all other Selling Parties to mark, the Licensed Product with all Licensed Patents in accordance with applicable Law, which marking obligation will continue for as long as (and only for as long as) required under
applicable Law. 

  
 -30- 

 ARTICLE 5. OBLIGATIONS OF THE PARTIES 

Section 5.1 Responsibility. Following the Effective Date and at all times during the Term (except as expressly stated otherwise herein),
VIGIL shall be solely responsible for, and shall bear all costs associated with, the research, development and commercialization of the Products in the Territory, including regulatory, manufacturing, distribution, marketing and sales activities.
Subject to the express written terms of this Agreement, all decisions concerning the development, marketing and sales of Products in the Territory including the clinical and regulatory strategy, design, sale, price and promotion of Products covered
under this Agreement shall be within the sole discretion of VIGIL. 
 Section 5.2 Diligence. VIGIL shall (directly and/or through one or
more Affiliates and/or Sublicensees) use Commercially Reasonable Efforts to develop, manufacture, gain Marketing Authorization and commercialize at least one (1) MAB Product and at least one (1) Small Molecule Product in each of the [***].
Within twelve (12) months of the Effective Date, VIGIL will prepare and provide to AMGEN a development plan for the MAB Product and [***] (which development plans shall describe generally the activities for conducting development with respect
to such Products under this Agreement, including by specifying activities to be conducted and anticipated development activities for the Products). For the purpose of clarity, VIGIL may from time to time amend each development plan in its sole
discretion. VIGIL shall notify AMGEN immediately upon obtaining Marketing Approval for the Product in each country. 
 Section 5.3
Reports. Within [***] of the beginning of each Calendar Year, VIGIL shall submit to AMGEN a report providing the status of VIGIL’s and its Affiliates’ and Sublicensees’ activities related to the research and development of
and Marketing Approval for the MAB Products and the Small Molecule Products during the [***], and plans for future activities related to the research and development of and Marketing Approval for the MAB Products and the Small Molecule Products
during [***], in each case in relation to the last updated development plan, as may be applicable, including any updates to the related clinical plans. 

Section 5.4 Distracting Programs. 

5.4.1 Distracting Programs. Except as set forth in Section 5.4.3 (Post-Effective Date Affiliates) and 5.4.4 (Termination or
Divestiture) and subject to Section 5.4.2 (VIGIL Election), during the Term until the [***] anniversary of the First Commercial Sale of the first Licensed Product in the [***], VIGIL shall not (and shall ensure its Affiliates and Sublicensees
do not) directly or indirectly conduct, enable, or participate in any Distracting Program. For clarity, any failure of any VIGIL Affiliate or Sublicensee to comply with this Section 5.4.1 shall be deemed a breach by VIGIL. 

5.4.2 VIGIL Election. 

(a) Distracting Program. In the event that VIGIL or its Affiliates gains rights to a Distracting Program, then VIGIL shall provide
prompt written notice (in all events within fifteen days of gaining such rights) to AMGEN and include in such notice whether VIGIL elects to treat all such related Distracting Product(s) as “Product(s)” under this Agreement. 

  
 -31- 

 (b) De Novo Compounds. In the event that VIGIL or its Affiliates gains rights to a De
Novo Compound or De Novo Product, then VIGIL shall provide prompt written notice (promptly following the filing of any patent application with respect to a De Novo Compound or De Novo Product and in all cases before any Licensed Patent or Licensed
Know How is used or practiced in connection with such De Novo Compound or De Novo Product) to AMGEN and include in such notice whether VIGIL elects to treat any such De Novo Compound and related De Novo Product as a “Product” under this
Agreement. 
 (c) Newly Added Products. If VIGIL makes such election in such notice, then any such Distracting Product (including, for
clarity, a De Novo Compound) will thereafter be considered a “Product” for purposes of this Agreement (a “Newly Added Product”) and would cease to be considered a “Distracting Product” giving rise to a
“Distracting Program” that is prohibited under Section 5.4.1. VIGIL’s exploitation of the Newly Added Product would be subject to all diligence and reporting obligations under this Agreement as well as Milestone Payment and
royalty obligations contemplated under this Agreement in each case from and after the time such Product becomes a Newly Added Product (for clarification, there shall be no obligation to make any back-payment of Milestone Payments that would have
been triggered by such Newly Added Product had such Newly Added Product been considered a “Product” at the time such Milestone occurred). Any Patent Rights controlled by VIGIL or its Affiliates (including, for clarity, any in-licensed
Patent Rights) Covering such Newly Added Product would be considered “Program Patents” for purposes of determining the Royalty Term, royalties, royalty reductions (for clarification, the [***] reduction under Section 3.3.2(a) would be
inapplicable) and milestone payment obligations applicable to such Newly Added Product. 
 5.4.3 Post-Effective Date
Affiliates. In the event that VIGIL or its Affiliates enters into a Distracting Transaction with a Third Party (and for clarity, VIGIL has not elected to treat such Distracting Product as a Newly Added Product pursuant to Section 5.4.2),
then VIGIL shall provide prompt written notice to AMGEN. Until the provisions of Section 5.4.4 (Termination or Divestiture) are effectuated, VIGIL shall ensure that information and materials relating to the Product or activities hereunder are
not shared with or used for the benefit of, and are sequestered from, Distracting Transaction Affiliate(s). 
 5.4.4 Termination or
Divestiture. The notice provided pursuant to Section 5.4.3 (Post-Effective Date Affiliates) shall include a notification as to whether VIGIL intends to: (a) Divest the Distracting Program, in which case VIGIL shall hold separate such
Distracting Program (including ensuring that no manufacturing, process development, research, or clinical development personnel working on the Product or activities hereunder works on a Distracting Program (and vice versa), and ensuring that
information from the Product (including all Licensed Know-How) or activities hereunder is sequestered from manufacturing, process development, research, or clinical development personnel working on the Distracting Program (and vice versa)) and use
its commercially reasonable, good-faith efforts to Divest such Distracting Program; or (b) terminate such Distracting Program, in which case VIGIL shall terminate all manufacturing, clinical development and/or commercialization activities of
such program within [***] days after the 

  
 -32- 

 
closing of the Distracting Transaction (provided that any ongoing clinical studies may continue if necessary or advisable for patient safety and provided further than out-licensing and similar
business development efforts may continue), during which period VIGIL shall hold separate such Distracting Program (including ensuring that no manufacturing, process development, research, or clinical development personnel working on the Product(s)
or activities hereunder works on a Distracting Program (and vice versa), and ensuring that information from the Product or activities hereunder is sequestered from manufacturing, process development, research, or clinical development personnel
working on the Distracting Program (and vice versa)). In the event VIGIL elects to Divest the Distracting Program under subsection (a) and fails to complete such Divestiture within [***] of the closing of the Distracting Transaction, then VIGIL
shall be deemed to have chosen to terminate such Distracting Program and shall promptly, and no later than within [***] days, comply with the requirements of subsection (b), above. 

Section 5.5 Amgen Restrictions. During the Term until the [***] of the Effective Date, AMGEN will not and will ensure its Affiliates do not
directly or indirectly conduct, enable, or participate in the research (other than the use as tool molecules), manufacture, clinical development or commercialization of any [***] that binds to TREM2 [***] and [***]. Except in connection with the
Ongoing Studies, AMGEN will not and will ensure its Affiliates do not directly or indirectly [***] that (x) binds to TREM2 [***] and (y) includes complementarity-determining region (CDRs) [***] (without regard to intended
therapeutic use). [***] 
 Section 5.6 Reasonable Restrictions. Each of the Parties acknowledges that the provisions of Sections
5.4 (Distracting Programs) and 5.5 (Amgen Restrictions) are reasonable and necessary to protect the legitimate interests of the other Party and to encourage the free sharing of information between the Parties with respect to the Products and each of
the Parties agrees not to contest such limitations in any proceeding. 
 ARTICLE 6. REPRESENTATIONS 

Section 6.1 Mutual Representations and Warranties. Each of AMGEN and VIGIL represent and warrant that: 

(a) it is duly organized and validly existing under the Law of the jurisdiction of its formation, and has full power and authority to enter
into this Agreement and to carry out the provisions hereof; 
 (b) it is duly authorized to execute and deliver this Agreement and to perform
its obligations hereunder, and the individual executing this Agreement on its behalf has been duly authorized to do so by all requisite action; 

(c) it shall comply with all applicable Law (including applicable Law relating to data protection and privacy), Proper Conduct Practices, and
Anti-Corruption Laws in connection with the performance of its rights, duties and obligations under this Agreement; and 
 (d) this Agreement
is legally binding upon it and enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by
which it may be bound, nor violate any material applicable Law. 

  
 -33- 

 Section 6.2 Additional AMGEN Warranties. AMGEN warrants to VIGIL that, as of the
Effective Date (except with respect to clause (f) below): 
 (a) AMGEN has full legal or beneficial title and ownership to the Licensed
Patents listed on Exhibit B as is necessary to grant the licenses to VIGIL to such Licensed Patents that AMGEN grants pursuant to this Agreement; 

(b) AMGEN has the rights necessary to grant the licenses to VIGIL to Licensed Know-How that AMGEN grants pursuant to this Agreement; 

(c) The Patent Rights included in the Licensed Patents are not subject to any liens or encumbrances and AMGEN has not granted to any Third
Party any rights or licenses under such Patent Rights and has not granted to any Third Party any rights or licenses under such Licensed Know-How that would conflict with the licenses granted to VIGIL hereunder including, for clarity under any
research or manufacturing agreements entered into by AMGEN with respect to the Licensed Compounds. No patent application or registration within the Licensed Patents is the subject of any pending interference, opposition, cancellation or patent
protest pursuant to 37 C.F.R. §1.291 or any foreign counterpart; 
 (d) No Third Party has made any claim or allegation to AMGEN or its
Affiliates in writing that a Third Party has any right or interest in or to the Licensed Patents listed on Exhibit B; and 
 (e) To
the knowledge of AMGEN’s patent litigation attorneys and patent attorneys involved in the prosecution or management of the Licensed Patents, no claim or litigation has been brought or threatened in writing by any Third Party alleging that
(i) the Licensed Patents are invalid or unenforceable or (ii) the manufacture, sale, offer for sale, or importation of Licensed Product in the Licensed Field in the Territory infringes or misappropriates or would infringe or misappropriate
any Patent Rights or other right of any Third Party; 
 (f) The compounds listed on Exhibit D comprise all compounds that: (a) are
Controlled by AMGEN or its Affiliates; (b)(1) for a monoclonal antibody, binds to TREM2 [***] and has agonist activity on TREM2 [***] and (2) for a small molecule, binds to TREM2 and has agonist activity on TREM2 [***]; and (c) were
discovered, researched or developed in the conduct of the Licensed MAB Program or the Licensed Small Molecule Program by AMGEN or its Affiliates prior to the Effective Date. 

(g) Exhibit A attached hereto lists a complete and accurate list of all final reports or electronic lab notebook entries for all completed
preclinical studies related to the Licensed Compounds conducted by or on behalf of AMGEN and its Affiliates prior to the Effective Date. Such studies were conducted in accordance with applicable legal and professional standards. 

  
 -34- 

 (h) As of the Effective Date, neither AMGEN, its Affiliates nor its respective employees,
agents or contractors have employed or otherwise used in any capacity in connection with the development of the Licensed Compound the services of any Person debarred or excluded under United States Law, including under 21 U.S.C. § 335a and 42
U.S.C. § 1320a-7(a), or any foreign equivalent thereof, including any Person that has been: (i) debarred by the FDA (or subject to a similar sanction of a Regulatory Authority), or that is subject of an FDA debarment investigation or
proceeding (or similar proceeding of a Regulatory Authority), or is otherwise ineligible to participate in federal healthcare programs or federal procurement or non-procurement programs; or (ii) has been convicted of a criminal offense that
falls within the scope of 42 U.S.C. § 1320a-7(a), but has not yet been excluded, debarred, suspended or otherwise declared ineligible. 

Section 6.3 Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS ARTICLE 6 (REPRESENTATIONS)_OR, WITH RESPECT TO AMGEN, SECTIONS
2.5.3(a)(iv), 2.5.4 AND 3.9.4(e) and (f), NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT,
OR VALIDITY OF PATENT CLAIMS. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY EITHER PARTY THAT EITHER PARTY WILL BE SUCCESSFUL IN OBTAINING ANY PATENT RIGHTS, OR THAT ANY PATENTS WILL ISSUE BASED ON A
PENDING APPLICATION. WITHOUT LIMITING THE RESPECTIVE RIGHTS AND OBLIGATIONS OF THE PARTIES EXPRESSLY SET FORTH HEREIN, EACH PARTY SPECIFICALLY DISCLAIMS ANY GUARANTEE THAT THE PRODUCTS WILL BE SUCCESSFUL, IN WHOLE OR IN PART. 

Section 6.4 Additional VIGIL Warranties. VIGIL warrants to AMGEN that, as of the Effective Date: 

(a) Neither VIGIL nor its directors, officers or employees have been debarred, excluded or the subject of debarment or exclusion proceedings by
any Governmental Authority; 
 (b) Neither VIGIL nor its officers or directors are Sanctioned Persons, nor are they owned fifty percent
(50%) or more individually, or in the aggregate by, or Controlled by, any Sanctioned Person; 
 (c) VIGIL has established and maintains
(or shall establish within 180 days of the Effective Date and thereafter maintain) reasonable internal policies and controls, including codes of conduct and ethics and reasonable reporting requirements, intended to ensure compliance with
Anti-Corruption Laws, International Trade Laws and other applicable Law, to the extent applicable to VIGIL under the laws of the jurisdiction of its incorporation, including healthcare compliance, privacy laws and data protection laws; and 

(d) VIGIL is not a Covered Individual and Entity. 

  
 -35- 

 Section 6.5 VIGIL Covenants. VIGIL covenants to AMGEN that: 

(a) it will conduct, and will cause its contractors to conduct, all preclinical and clinical studies for the Product and manufacturing of the
Product, in accordance with (i) all U.S. Laws and the Laws of the country in which such clinical studies are conducted, and (ii) the known or published standards of the FDA and the Regulatory Authority in such country, including but not
limited to good laboratory practice, good clinical practice, and current good manufacturing practices. Neither VIGIL, nor any officer, employee or agent of VIGIL, will knowingly make an untrue statement of a material fact to any Regulatory Authority
with respect to the Product (whether in any submission to such Regulatory Authority or otherwise), and neither will knowingly fail to disclose a material fact required to be disclosed to any Regulatory Authority with respect to the Product; 

(b) it (and its Affiliates) will use Commercially Reasonable Efforts to not employ or otherwise use in any capacity the services of any Person
debarred or excluded under United States Law, including under 21 U.S.C. § 335a and 42 U.S.C. § 1320a-7(a), or any foreign equivalent thereof, including any Person that has been: (i) debarred by the FDA (or subject to a similar
sanction of a Regulatory Authority), or that is subject of an FDA debarment investigation or proceeding (or similar proceeding of a Regulatory Authority), or is otherwise ineligible to participate in federal healthcare programs or federal
procurement or non-procurement programs; or (ii) has been convicted of a criminal offense that falls within the scope of 42 U.S.C. § 1320a-7(a), but has not yet been excluded, debarred, suspended or otherwise declared ineligible; 

(c) if, during any period in which AMGEN owns [***] or more of the outstanding voting shares of VIGIL, VIGIL becomes aware that any Person
employed or retained by it to perform any of its obligations under, or services related to, this Agreement: (i) comes under investigation by the FDA, or a similar Regulatory Authority, (ii) is debarred, excluded, suspended, disqualified or
subject to a similar sanction of a Regulatory Authority, or (iii) engages in any conduct or activity that could lead to any of the aforementioned actions or similar sanctions of a Regulatory Authority, VIGIL shall immediately notify AMGEN; 

(d) it shall comply with all applicable Law, International Trade Law, Proper Conduct Practices, and Anti-Corruption Laws in connection with the
performance of its rights, duties and obligations under this Agreement; 
 (e) upon reasonable request, it shall provide AMGEN with any
information under its control that is required by Amgen to comply with International Trade Laws; 
 (f) it shall, during any period in which
Amgen owns [***] ([***]%) or more of the outstanding voting shares of VIGIL, promptly provide AMGEN with written notice upon receiving a formal notification that it is the target of a formal or informal request for information, subpoena,
investigation, litigation, penalty, or claim from any Governmental Authority, for violation or potential violation of any applicable Anti-Corruption Law, International Trade Laws or Proper Conduct Practices; 

  
 -36- 

 (g) during any period in which AMGEN owns [***] ([***]%) or more of the outstanding voting
shares of VIGIL, prior to beginning any commercialization of any Product under this Agreement, each of its employees, agents, independent contractors or Affiliates involved in the commercialization of any Product shall be required to undergo
compliance training with respect to Proper Conduct Practices and Anti-Corruption Laws; 
 (h) it shall use only legitimate and ethical
business practices (including Proper Conduct Practices) in connection with activities conducted in connection with this Agreement whether directly, through the use of Representatives or otherwise, and shall not take any action that would subject any
other Party to penalties under any applicable Law; 
 (i) it shall cause Affiliates under its control and its and their officers, directors,
employees and agents engaged in activities involving Product to comply with this Agreement, including the covenants in this Section 6.5; 

(j) (i) it shall comply with all applicable U.S. Laws prohibiting the re-export, directly or indirectly, of certain controlled U.S.-origin
items without a license to parties located in certain countries or appearing on certain U.S. Government lists of restricted parties; (ii) it shall comply with all applicable U.S. Laws prohibiting participation in non-U.S. boycotts that the
United States does not support; (iii) it shall comply with all applicable U.S. Laws prohibiting the sale of products to parties from any country subject to U.S. economic sanctions or who are identified on related U.S. Government lists of
restricted parties; (iv) it shall use Commercially Reasonable Efforts to comply with all applicable International Trade Laws, and (v) it shall use Commercially Reasonable Efforts to comply with all applicable data privacy laws of the
applicable jurisdiction, including the General Data Protection Regulation (Regulation (EU) 2016/679), and all data breach notification and information securities laws and regulations specific thereto; and 

(k) as of the Effective Date to and through the expiration or termination of this Agreement, (i) it, and, to the best of its knowledge,
its Representatives, shall not, directly or indirectly, offer, pay, promise to pay, or authorize such offer, promise or payment, of anything of value, to any Person for the purposes of obtaining or retaining business through any improper advantage
in connection with this Agreement, or that would otherwise violate any applicable Laws, rules and regulations concerning or relating to public or commercial bribery or corruption, (ii) that its books, accounts, records and invoices related to
this Agreement or related to any work conducted for or on behalf of the other Party are and will be complete and accurate, and (iii) that AMGEN may terminate this Agreement if (a) VIGIL or VIGIL’s Representatives fails to comply with
the Anti-Corruption Laws or with this provision, or (b) AMGEN has a good faith belief that VIGIL or VIGIL’s Representatives has violated, intends to violate, or has caused a violation of the Anti-Corruption Laws. AMGEN may request from
time to time that VIGIL complete a compliance certification regarding the foregoing; and 

  
 -37- 

 (l) if VIGIL engages one or more Covered Individuals and Entities contributes to or performs
any of VIGIL obligations hereunder (including the performance of clinical research with respect to a Product or in the commercialization of a Product), payments made by or on behalf of VIGIL to each such Covered Individual and Entity or other
compensation or consideration received by each such Covered Individual and Entity on account of its contributions to or performance of any of VIGIL obligations hereunder shall comply with all applicable Law, including, to the extent provided for in
applicable Law, (i) represent fair market value, (ii) not be determined in a manner that that takes into account the volume or value of any future business that might be generated between the Parties, and (iii) not be construed to
require a Covered Individual and Entity to promote, purchase, prescribe, or otherwise recommend an Amgen Therapeutic Product being marketed or under development. If VIGIL is or becomes a Covered Individual and Entity or if VIGIL becomes, owned,
operated or controlled by one or more Covered Individuals and Entities, VIGIL shall notify AMGEN of such and, after receipt of such notification or upon VIGIL becoming a Covered Individual and Entity, VIGIL agrees that AMGEN shall have the right,
upon notice to VIGIL, to initiate good faith negotiations with VIGIL to modify the terms of this Agreement as may be reasonably necessary or appropriate to address AMGEN’s bona fide concerns with respect to compliance by AMGEN’s or, as
applicable, one or more of its Affiliate’s requirements for interactions with a Covered Individual and Entity. VIGIL will give good faith consideration to any reasonable request, provided that nothing shall be construed to require VIGIL to
increase any payment obligations, to reduce the scope of the intellectual property rights licensed hereunder or to incur additional costs or expenses to satisfy AMGEN’s requests. VIGIL will not unreasonably refuse to meet any additional
reporting or documentation obligations, provided that it may deduct the reasonable costs of meeting any such obligations from amounts otherwise payable hereunder. Additionally and without limiting any other rights or remedies of AMGEN, if on or
after the Effective Date, VIGIL, is or becomes, a Covered Individual and Entity or is, or becomes, owned, operated or controlled by a Covered Individual and Entity, AMGEN shall have the right to assign this Agreement immediately, and AMGEN shall not
be liable to VIGIL for any costs, expenses, or losses arising out of such assignment. For purposes of this section, “owned, operated or controlled” shall mean that one or more Covered Individual and Entities is in a position to direct or
control the performance of VIGIL’s obligations hereunder, or that one or more Covered Individuals and Entities is in a position to direct or control VIGIL’s management or operations, including, without limitation, when a Covered Individual
and Entity owns a majority of the voting power or other equity interests in VIGIL. 

  
 -38- 

 Section 6.6 AMGEN Covenants. AMGEN covenants to VIGIL that until the completion of the
Ongoing Studies and all activities related thereto: It will (i) comply with the Ongoing Studies Agreement to the extent implicating to the Licensed Compounds, (ii) it will promptly provide to VIGIL or VIGIL’s designated representative
all study reports, invention disclosures, data and proposed presentations or manuscripts provided by [***] pursuant to the Ongoing Studies Agreement with respect to the Licensed Compounds or otherwise arising from the Ongoing Studies;
(iii) will not amend or waive its rights under the Ongoing Studies Agreement in a way that affects the Ongoing Studies or with respect to the Licensed Compounds without Vigil’s consent, (iv) take measures reasonably requested by Vigil
to provide Vigil with the benefits of AMGEN’s rights associated with the Licensed Compounds under or with respect to the Ongoing Studies Agreement. Without limiting the generality of the foregoing, (a) any Patent Rights or Know-How arising
under the Ongoing Studies and Controlled by AMGEN shall constitute Licensed Patents or Licensed Know-How under this Agreement and (b) if VIGIL desires to obtain a license to any intellectual property rights of [***] associated with the Licensed
Compounds, AMGEN shall use reasonable efforts to assist VIGIL to obtain such license. 
 ARTICLE 7. INDEMNIFICATION 

Section 7.1 Indemnity. 

7.1.1 By AMGEN. AMGEN agrees to defend VIGIL and its (and its Affiliates’) directors, officers, employees and agents (the
“VIGIL Indemnified Parties”) at AMGEN’s cost and expense, and will indemnify and hold VIGIL and the other VIGIL Indemnified Parties harmless from and against any claims, losses, costs, damages, fees or expenses (including legal
fees and expenses) (collectively, “Losses”) to the extent resulting from any Third Party claim (including product liability claims) arising out of or otherwise relating to (a) the negligence or willful misconduct of AMGEN or
its Affiliates in connection with its activities under this Agreement, (b) the material breach of this Agreement or the representations and warranties made hereunder by AMGEN, except, in the case of each of (a) or (b) of this
Section 7.1.1 (By AMGEN), to the extent such Losses result from clause (a), (b) or (c) of Section 7.1.2 (By VIGIL). In the event of any such claim against the VIGIL Indemnified Parties by a Third Party, the foregoing indemnity
obligations shall be conditioned upon (x) VIGIL promptly notifying AMGEN in writing of the claim (provided, however, that any failure or delay to notify shall not excuse any obligations of AMGEN except to the extent
AMGEN is actually materially prejudiced thereby) and (y) VIGIL granting AMGEN sole management and control, at AMGEN’s sole expense, of the defense of the claim and its settlement (provided, however, that AMGEN
shall not settle any such claim without the prior written consent of VIGIL if such settlement does not include a complete release from liability or if such settlement would involve VIGIL undertaking an obligation (including the payment of money by a
VIGIL Indemnified Party), would bind or impair a VIGIL Indemnified Party, or includes any admission of wrongdoing or that any intellectual property or proprietary right of VIGIL (including rights licensed hereunder from AMGEN) or this Agreement is
invalid, narrowed in scope or unenforceable), and (z) the VIGIL Indemnified Parties reasonably cooperating with AMGEN (at AMGEN’s expense). The VIGIL Indemnified Parties may, at their option and expense, be represented in any such action
or proceeding by counsel of their own choosing. 

  
 -39- 

 7.1.2 By VIGIL. VIGIL agrees to defend AMGEN and its (and its
Affiliates’) directors, officers, employees and agents (the “AMGEN Indemnified Parties”) at VIGIL’s cost and expense, and will indemnify and hold AMGEN and the other AMGEN Indemnified Parties harmless from and against any
Losses to the extent resulting from any Third Party claim (including product liability claims) arising out of or otherwise relating to (a) the negligence or willful misconduct of VIGIL, its Affiliates, or their respective Sublicensees in
connection with its activities under this Agreement, (b) the material breach of this Agreement or the representations, warranties and covenants made hereunder by VIGIL, or (c) the Exploitation of any Product by or on behalf of VIGIL, its
Affiliates, or their respective Sublicensees (including from product liability and intellectual property infringement claims); except, in each case, to the extent such Losses result from clause (a) or (b) of Section 7.1.1 (By AMGEN).
In the event of any such claim against the AMGEN Indemnified Parties by a Third Party, the foregoing indemnity obligations shall be conditioned upon (x) AMGEN promptly notifying VIGIL in writing of the claim (provided, however,
that any failure or delay to notify shall not excuse any obligation of VIGIL except to the extent VIGIL is actually materially prejudiced thereby) and (y) AMGEN granting VIGIL sole management and control, at VIGIL’s sole expense, the
defense of the claim and its settlement (provided, however, that VIGIL shall not settle any such claim without the prior written consent of AMGEN if such settlement does not include a complete release from liability or if such
settlement would involve undertaking an obligation (including the payment of money by an AMGEN Indemnified Party), would bind or impair an AMGEN Indemnified Party, or includes any admission of wrongdoing or that any intellectual property or
proprietary right of AMGEN (including rights licensed hereunder from AMGEN) or this Agreement is invalid, narrowed in scope or unenforceable), and (z) the AMGEN Indemnified Parties reasonably cooperating with VIGIL (at VIGIL’s expense).
The AMGEN Indemnified Parties may, at their option and expense, be represented in any such action or proceeding by counsel of their own choosing. 

Section 7.2 LIMITATION OF DAMAGES. IN NO EVENT SHALL EITHER PARTY BE LIABLE HEREUNDER TO THE OTHER PARTY FOR ANY PUNITIVE, INDIRECT,
SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING LOST REVENUE, LOST PROFITS, OR LOST SAVINGS) HOWEVER CAUSED AND UNDER ANY THEORY, EVEN IF IT HAS NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. THE LIMITATIONS SET FORTH IN THIS SECTION 7.2
(LIMITATION OF DAMAGES) SHALL NOT APPLY WITH RESPECT TO (A) ANY BREACH OF ARTICLE 8 (CONFIDENTIALITY) OR (B) THE INTENTIONAL MISCONDUCT OR GROSS NEGLIGENCE OF A PARTY. NOTHING IN THIS SECTION 7.2 (LIMITATION OF DAMAGES) IS INTENDED TO
LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF A PARTY UNDER THIS ARTICLE 7 (INDEMNIFICATION) WITH RESPECT TO ANY DAMAGES PAID BY THE OTHER PARTY TO A THIRD PARTY IN CONNECTION WITH A THIRD- PARTY CLAIM. 

Section 7.3 Insurance. At least [***] days prior to the Initiation of the first clinical trial of a Product, VIGIL shall at its own expense
procure and maintain during the Term (and for [***] years thereafter) clinical trial liability insurance coverage adequate to cover its obligations hereunder and which is/are consistent with normal business practices of prudent pharmaceutical
companies. Additionally, at least [***] days prior to First Commercial Sale of any Product in the Territory, VIGIL shall at its own expense procure and maintain during the Term (and for [***] years thereafter) product liability insurance coverage
adequate to cover its obligations hereunder and which is consistent with normal business practices of prudent pharmaceutical companies. Each insurance policy required by and procured by VIGIL under this Section 7.3 (Insurance) shall name AMGEN
as an additional insured. Such insurance shall not be construed to create a limit of VIGIL’s liability with respect to its indemnification obligations under this Article 7 

  
 -40- 

 
(Indemnification). VIGIL shall provide AMGEN with a certificate of insurance or other evidence of such insurance, upon request. VIGIL shall provide AMGEN with written notice at least [***] days
prior to the cancellation, non renewal or a material change in such insurance which materially adversely affects the rights of AMGEN hereunder, and [***] days prior written notice of cancellation for non-payment of premiums. VIGIL’s insurance
hereunder shall be primary with respect to the obligations for which VIGIL is liable hereunder. 
 ARTICLE 8. CONFIDENTIALITY 

Section 8.1 Confidential Information. 

8.1.1 Confidential Information. Each Party (“Disclosing Party”) may disclose to the other Party
(“Receiving Party”), and Receiving Party may acquire during the course and conduct of activities under this Agreement, certain proprietary or confidential information of Disclosing Party in connection with this Agreement. The term
“Confidential Information” will mean (a) all Licensed Know-How, (b) all Licensed Materials, and (c) all ideas and information of any kind, whether in written, oral, graphical, machine-readable or other form, whether
or not marked as confidential or proprietary, which are transferred, disclosed or made available by Disclosing Party or at the request of Receiving Party, including any of the foregoing of Third Parties. Without limiting the foregoing, Licensed
Know-How and Licensed Materials will be considered Confidential Information of AMGEN, and all research and development updates as well as financial and business disclosures from VIGIL to AMGEN will be considered Confidential Information of VIGIL.
During the Term, AMGEN shall keep confidential all Licensed Know-How and Licensed Materials to the extent disclosure of such Confidential Information would negatively impact in any material way the Exploitation of any Product in the Territory by
VIGIL or its Affiliates or Sublicensees. 
 8.1.2 Restrictions. During the Term and for [***] years thereafter,
Receiving Party will keep all Disclosing Party’s Confidential Information in confidence with the same degree of care with which Receiving Party holds its own confidential information (but in no event less than a commercially reasonable degree
of care). Receiving Party will not use Disclosing Party’s Confidential Information except in connection with the performance of its obligations and exercise of its rights under this Agreement. Receiving Party has the right to disclose
Disclosing Party’s Confidential Information without Disclosing Party’s prior written consent, to the extent and only to the extent reasonably necessary, to Receiving Party’s Affiliates and their employees, subcontractors, consultants
or agents who have a need to know such Confidential Information in order to perform its obligations and exercise its rights under this Agreement and who are required to comply with the restrictions on use and disclosure in this Section 8.1.2
(Restrictions). Receiving Party will use diligent efforts to cause those entities and persons to comply with the restrictions on use and disclosure in this Section 8.1.2 (Restrictions). Receiving Party assumes responsibility for those entities
and persons maintaining Disclosing Party’s Confidential Information in confidence and using same only for the purposes described herein. 

  
 -41- 

 8.1.3 Exceptions. Receiving Party’s obligation of nondisclosure and the
limitations upon the right to use the Disclosing Party’s Confidential Information will not apply to the extent that Receiving Party can demonstrate that the Disclosing Party’s Confidential Information: (a) was known to Receiving Party
or any of its Affiliates prior to the time of disclosure; (b) is or becomes public knowledge through no fault or omission of Receiving Party or any of its Affiliates; (c) is obtained by Receiving Party or any of its Affiliates from a Third
Party under no obligation of confidentiality to Disclosing Party; or (d) has been independently developed by employees, subcontractors, consultants or agents of Receiving Party or any of its Affiliates without the use of Disclosing Party’s
Confidential Information, as evidenced by contemporaneous written records. 
 8.1.4 Permitted Disclosures. Receiving Party may
disclose Disclosing Party’s Confidential Information to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 

(a) in order to comply with applicable law (including any securities law or regulation or the rules of a securities exchange) or with a legal
or administrative proceeding; 
 (b) in connection with prosecuting or defending litigation, Marketing Approvals and other regulatory filings
and communications, and filing, prosecuting and enforcing Patents in connection with Receiving Party’s rights and obligations pursuant to this Agreement; and 

(c) in connection with exercising its rights hereunder, to its Affiliates; potential and future collaborators (including Sublicensees where
VIGIL is the Receiving Party); potential and permitted acquirers or assignees; and potential investment bankers, investors and lenders; provided, however, that (1) with respect to Sections 8.1.4(a) or 8.1.4(b), where reasonably possible,
Receiving Party will notify Disclosing Party of Receiving Party’s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow Disclosing Party adequate time to take whatever action it may deem
appropriate to protect the confidentiality of the information to be disclosed, and (2) with respect to Section 8.1.4(c), each of those named people and entities are required to comply with the restrictions on use and disclosure in
Section 8.1.2 (Restrictions) (other than investment bankers, investors and lenders, which must be bound prior to disclosure by commercially reasonable obligations of confidentiality). 

Section 8.2 Terms of this Agreement; Publicity. 

8.2.1 Restrictions. The Parties agree that the terms of this Agreement will be treated as Confidential Information of both
Parties, and thus may be disclosed only as permitted by Section 8.1.4 (Permitted Disclosures). Except as required by Law, each Party agrees not to issue any press release or public statement disclosing information relating to this Agreement or
the transactions contemplated hereby or the terms hereof without the prior written consent of the other Party not to be unreasonably withheld (or as such consent may need to be obtained in accordance with Section 8.2.2 (Review) or 8.3.1 (Right
to Publish)). 

  
 -42- 

 8.2.2 Review. In the event either Party (the “Issuing Party”)
desires to issue a press release or other public statement disclosing information relating to this Agreement or the transactions contemplated hereby or the terms hereof, the Issuing Party will provide the other Party (the “Reviewing
Party”) with a copy of the proposed press release or public statement (the “Release”). The Issuing Party will specify with each such Release, taking into account the urgency of the matter being disclosed, a
reasonable period of time within which the Receiving Party may provide any comments on such Release (but in no event less than [***] business days). If the Receiving Party provides any comments, the Parties will consult on such Release and work in
good faith to prepare a mutually acceptable Release. Either Party may subsequently publicly disclose any information previously contained in any Release, provided that the other Party provided its written consent hereto as stated in 8.2.1
(Restrictions). For the avoidance of doubt (and notwithstanding anything contained in this Agreement to the contrary), VIGIL, in its sole discretion, may make disclosures relating to the grant of any Sublicense, the development or commercialization
of the Product, including the results of research and any clinical trial conducted by VIGIL, its Affiliates or Sublicensees or any health or safety matter related to the Product. 

Section 8.3 Publications. 

8.3.1 Right to Publish. Subject to the provisions of Sections 8.1 (Confidential Information), 8.2 (Terms of this Agreement;
Publicity) and 8.3.2 (Review), VIGIL shall have the right to publish with respect to the Products, and to make scientific presentations on the Products. Except with respect to the Ongoing Studies, AMGEN shall not publish with respect to the Products
nor make any scientific presentations on the Products. Neither Party shall publish the sequence of the Licensed Lead Antibody Compound or information concerning the manufacture of the Licensed Lead Antibody Compound without the prior written consent
of the other Party. The Parties acknowledge and agree that all VIGIL publications pursuant to this section shall be developed by VIGIL in accordance with VIGIL’s publications policies and practices. In addition, authorship by VIGIL of any
publication arising from this Agreement submitted to a medical or other peer- reviewed scientific journal will be undertaken in accordance with the International Committee of Medical Journal Editors (ICMJE) guidelines for authorship. Consistent with
those guidelines, authorship will be based upon substantial contribution to the design, analysis, interpretation of data, drafting and/or critically revising any publication(s) derived from the Agreement, and authors must engage in the drafting of
the publication or revise it critically for important intellectual content. VIGIL agrees to maintain evidence of its compliance with the ICMJE guidelines for authorship, and that it will provide such evidence to AMGEN upon request. Publications
shall acknowledge use of any AMGEN data, support, or other contributions as appropriate and consistent with medical journal guidelines. 

8.3.2 Review. 

(a) Except as required by Law or court order, for any proposed publication submitted by Vigil for presentation at a scientific meeting or to a
medical or other peer-reviewed scientific journal regarding any Licensed Product in the Territory if such publication does or may include any Licensed Know-How, patentable subject matter or AMGEN Confidential Information, VIGIL: (1) shall
transmit a copy of the proposed publication for review and comment to AMGEN at least [***] days for abstracts and presentations prior to submission to a Third Party and at least [***] [***] days prior to the submission for manuscripts of such
publication to a Third Party; (2) shall postpone such publication for up to an additional thirty (30) days upon request of AMGEN to allow the consideration of appropriate patent applications or other protection to be filed; (3) upon
request of AMGEN shall remove all Confidential Information of AMGEN (excluding, for clarity, anything permitted to be disclosed by VIGIL pursuant to the last sentence of Section 8.2.2 (Review)); and (4) shall consider all reasonable
comments made by AMGEN. 

  
 -43- 

 (b) For any proposed publication by AMGEN or [***] in connection with the Ongoing Studies,
AMGEN: (1) shall transmit a copy of the proposed publication for review and comment to VIGIL at least [***] days for manuscripts prior to the submission of such publication to a Third Party; (2) shall postpone such publication for up to an
additional [***] days upon request of VIGIL to allow the consideration of appropriate patent applications or other protection to be filed; and (3) shall consider all reasonable comments made by VIGIL. 

Section 8.4 Relationship to the Confidentiality Agreement. This Agreement supersedes that certain Confidential Disclosure Agreement between
AMGEN and Atlas Venture Life Science Advisors LLC dated November 11, 2019; provided, however, that all “Confidential Information” disclosed or received by the Parties thereunder will be deemed “Confidential
Information” hereunder and will be subject to the terms and conditions of this Agreement. 
 Section 8.5 Attorney-Client
Privilege. Neither Party is waiving, nor will be deemed to have waived or diminished, any of its attorney work product protections, attorney-client privileges or similar protections and privileges recognized under the applicable Law of any
jurisdiction as a result of disclosing information pursuant to this Agreement, or any of its Confidential Information (including Confidential Information related to pending or threatened litigation) to the receiving Party, regardless of whether the
disclosing Party has asserted, or is or may be entitled to assert, such privileges and protections. The Parties may become joint defendants in proceedings to which the information covered by such protections and privileges relates and may determine
that they share a common legal interest in disclosure between them that is subject to such privileges and protections, and in such event, may enter into a joint defense agreement setting forth, among other things, the foregoing principles but are
not obligated to do so. 
 ARTICLE 9. TERM & TERMINATION 

Section 9.1 Term. The term of this Agreement (the “Term”) shall commence on the Effective Date, and unless terminated
earlier as provided in this Article 9 (Term & Termination), shall continue in full force and effect until expiration of obligations to pay royalties under this Agreement for any Products in the Territory. Upon expiration of this Agreement,
the licenses granted to VIGIL by AMGEN under this Agreement to Exploit the Product shall be fully paid-up, irrevocable and non-exclusive. 

Section 9.2 Termination by AMGEN. 

9.2.1 Breach. AMGEN will have the right to terminate this Agreement upon delivery of written notice
to VIGIL in the event of material breach of this Agreement by VIGIL provided, however, 
 (a) that
such termination will not be effective if such breach has been cured within [***] days after written notice thereof is given by AMGEN to VIGIL specifying in reasonable detail the nature of the alleged breach; 

  
 -44- 

 (b) that to the extent such material breach involves the material undisputed failure to make
a payment when due, such breach must be cured within [***] days after written notice thereof is given by AMGEN to VIGIL; 
 (c) that if the
material breach is not reasonably capable of being cured within the [***] day cure period, and if VIGIL (i) proposes within such [***] day period a written plan, reasonably acceptable to AMGEN, to cure such breach, and (ii) makes good
faith efforts to cure such default and to implement such written cure plan, then, until the first anniversary of receipt of notice of termination, AMGEN may not terminate this Agreement for so long as VIGIL is diligently pursuing such cure in
accordance with such plan; 
 (d) that AMGEN will not have the right to terminate this Agreement under this Section 9.2.1 (Termination
for Breach) for any act or omission by any Sublicensee if VIGIL terminates such Sublicense within [***] days of AMGEN’s notice to VIGIL under this Section 9.2.1 (Termination for Breach); and 

(e) If VIGIL in good faith disputes such material breach and provides written notice of that dispute to AMGEN within [***] days of receipt of
AMGEN’s notice to VIGIL under this Section 9.2.1 (Termination for Breach), this Agreement shall not terminate unless and until the matter has been finally resolved in accordance with Section 10.4 and it has been determined under
Section 10.4 that VIGIL is in material breach of this Agreement. It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall
continue to perform all of their respective obligations hereunder. 
 9.2.2 Termination for IP Challenge. AMGEN will have the
right to terminate this Agreement in full upon written notice to VIGIL in the event that VIGIL or any of its Affiliates or Sublicensees directly challenges in a legal or administrative proceeding the patentability, enforceability or validity of any
Licensed Patents; provided, however, that AMGEN will not have the right to terminate this Agreement under this Section 9.2.2 (Termination for IP Challenge) for any such challenge by any
Sublicensee if (a) VIGIL terminates such Sublicense within [***] days of AMGEN’s notice to VIGIL under this Section 9.2.2 (Termination for IP Challenge) or (b) such challenge is dismissed within [***] days of AMGEN’s notice
to VIGIL under this Section 9.2.2 (Termination for IP Challenge) and not thereafter continued. 
 9.2.3 Termination for a
VIGIL Distracting Product. AMGEN will have the right to terminate this Agreement in full upon written notice to VIGIL in the event that VIGIL violates Section 5.4.1 (Distracting Programs) and does not elect to treat such Distracting
Product(s) as “Products” under this Agreement pursuant to Section 5.4.2 (VIGIL Election). 
 9.2.4 Termination
for Failure to Achieve Series A Financing. AMGEN will have the right to terminate this Agreement in full upon written notice to VIGIL in the event that either (i) the Series A Preferred Financing does not occur within [***] days of the
Effective Date or (ii) Amgen does not receive the Amgen Shares in association with the Series A Preferred Financing. 

  
 -45- 

 Section 9.3 Termination by VIGIL. 

9.3.1 Breach. VIGIL will have the right to terminate this Agreement in full upon delivery of written
notice to AMGEN in the event of any material breach by AMGEN of this Agreement; provided, however, 

(a) that such termination will not be effective if such breach has been cured within [***] days after written notice thereof is given by VIGIL
to AMGEN specifying the nature of the alleged breach; 
 (b) that if the material breach is not reasonably capable of being cured within the
[***] day cure period, and if AMGEN (i) proposes within such [***] day period a written plan, reasonably acceptable to VIGIL, to cure such breach, and (ii) makes good faith efforts to cure such default and to implement such written cure
plan, then, until the first anniversary of receipt of notice of termination, VIGIL may not terminate this Agreement for so long as AMGEN is diligently pursuing such cure in accordance with such plan; and 

(c) If AMGEN in good faith disputes such material breach and provides written notice of that dispute to VIGIL within [***] days of receipt of
VIGIL’s notice to AMGEN under this Section 9.3.1 (Breach), this Agreement shall not terminate unless and until the matter has been finally resolved in accordance with Section 10.4 and it has been determined under Section 10.4
that AMGEN is in material breach of this Agreement. It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all
of their respective obligations hereunder; and 
 (d) if VIGIL can reasonably establish pursuant to the dispute resolution provisions of
Section 10.4 that the material breach is limited to, and only has an impact on the MAB Program but not the Small Molecule Program or vice versa, then AMGEN shall only be entitled to terminate this Agreement with respect to the MAB Program or
the Small Molecule Program, as the case may be, and the termination of the Agreement with respect to the program (i.e. either the MAB Program or the Small Molecule Program) which is terminated due to breach shall not impact VIGIL’s rights with
respect to the other Program or the Products developed under the other Program. In such event, the provisions of Section 9.3.2 shall apply with respect to the Terminated Program and the Terminated Products within such Terminated Program. 

9.3.2 Discretionary Termination. VIGIL will have the right to terminate this Agreement in full or in part, with respect to
VIGIL, its Affiliates or Sublicensee’s Exploitation of MAB Products (the “MAB Program”) or Exploitation of Small Molecule Products (the “Small Molecule Program”): 

(a) In the time period prior to the initiation of clinical development for any MAB Product (with respect to the MAB Program) or Small Molecule
Product (with respect to the Small Molecule Program), upon thirty (30) day’s prior written notice to AMGEN 

  
 -46- 

 (b) In the time period after the initiation of clinical development for any MAB Product
(with respect to the MAB Program) or Small Molecule Product (with respect to the Small Molecule Program), upon one hundred twenty (120) day’s prior written notice to AMGEN 

if, in each case, VIGIL concludes due to scientific, technical, regulatory or commercial reasons, including (i) safety or efficacy concerns, including
adverse events of such Product, (ii) concerns relating to the present or future marketability or profitability of such Product, (iii) reasons related to patent coverage or (iv) existing and anticipated competition, renders the
Exploitation of the MAB Product or Small Molecule Product no longer commercially practicable for VIGIL. Following any such notice of termination, VIGIL shall have no further obligation pursuant to Section 5.2 (Diligence) to further Exploit any
MAB Product (with respect to the termination of the MAB Program) or any Small Molecule Product (with respect to the termination of the Small Molecule Program) (each such affected Licensed Product, a “Terminated Product” and the
terminated MAB Program and/or Small Molecule Program, a “Terminated Program”), however, VIGIL shall use its reasonable efforts to facilitate a smooth, orderly and prompt transition of all Terminated Products Controlled by VIGIL
prior to the effective date of termination of this Agreement from VIGIL to AMGEN. 
 Section 9.4 Termination Upon Bankruptcy. Either
Party may terminate this Agreement if, at any time, the other Party shall (a) file in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization
or for an arrangement or for the appointment of a receiver or trustee of that Party or of its assets, (b) propose a written agreement of composition or extension of its debts, (c) be served with an involuntary petition against it, filed in
any insolvency proceeding, and such petition has not been dismissed within [***] days after the filing thereof, (d) propose or be a party to any dissolution or liquidation, (e) make an assignment for the benefit of its creditors or
(f) admit in writing its inability generally to meet its obligations as they fall due in the general course. 
 Section 9.5 Effects of
Termination. Upon termination by either Party under Section 9.2 (Termination by AMGEN), Section 9.3 (Termination by VIGIL) or Section 9.4 (Termination Upon Bankruptcy): 

(a) VIGIL will responsibly wind-down, in accordance with accepted pharmaceutical industry norms and ethical practices and all legal and
regulatory requirements, any on-going clinical studies involving a Terminated Product for which it has responsibility hereunder in which patient dosing has commenced or, if reasonably practicable and not adverse to patient safety and requested by
AMGEN, VIGIL shall complete such trials and AMGEN shall reimburse VIGIL its reasonable, out-of-pocket costs and internal labor costs at the FTE Rate associated therewith. For the purpose of clarity, except as provided for above, VIGIL may wind-down
any ongoing clinical trials prior to the date of termination in accordance with accepted pharmaceutical industry norms and ethical practices and VIGIL will be responsible for any costs associated with such wind-down. 

  
 -47- 

 (b) A termination of this Agreement will automatically terminate any sublicense of Licensed
Know-How and Licensed Patents relating to the Terminated Program(s) (including all Products in such Terminated Program(s)) granted by VIGIL pursuant to Section 2.2 (Sublicenses) unless AMGEN has approved such sublicense in writing, in which
case all rights under such sublicense shall be deemed to survive termination as long as Sublicensee complies with its obligations thereunder, and provided that in no event will AMGEN be obligated to fulfill any of VIGIL’s obligations under such
sublicense. 
 (c) All rights and licenses granted by AMGEN to VIGIL in Article 2 (License Grant) and all restrictions on AMGEN under
Section 2.3 (Retained Rights and Limitations) will terminate, and VIGIL and its Affiliates, and (subject to Section 9.5(b)) Sublicensees will cease all use of Licensed Know-How relating to the Terminated Program(s) and Licensed Patents
relating to the Terminated Program(s) and all Exploitation of any Terminated Product, except to the extent required hereunder. For clarity, after termination, while VIGIL will retain rights in any Newly Added Product(s) (the “Retained
Products”), the licenses granted by AMGEN to VIGIL in Article 2 (License Grant) will terminate with respect to such Retained Products relating to the Terminated Program(s) and VIGIL and its Affiliates, and (subject to Section 9.5(b))
Sublicensees will cease all use of Licensed Know-How relating to such Retained Products. 
 (d) Upon AMGEN’s request, all Marketing
Approvals and other regulatory filings and communications owned (in whole or in part) or otherwise controlled by VIGIL and its Affiliates, and (subject to Section 9.5(b)) Sublicensees, and all other documents relating to or necessary to further
Exploit any Terminated Product, as such items exist as of the effective date of such termination (including all documents related to completed and ongoing clinical studies) will be assigned to AMGEN to the extent practicable (or, if not so assigned,
VIGIL shall make the benefit of the foregoing reasonably available to AMGEN), and VIGIL will provide to AMGEN one (1) copy of the foregoing and all documents contained in or referenced in any such items, together with the raw and summarized
data for any clinical studies (and where reasonably available, electronic copies thereof). All expenses in relation to such assignment will be borne by AMGEN. In the event of any failure to obtain assignment, VIGIL hereby consents and grants to
AMGEN the right to access and reference (without any further action required on the part of VIGIL, whose authorization to file this consent with any Regulatory Authority is hereby granted) any such item. 

(e) Upon AMGEN’s election, VIGIL shall and hereby does grant to AMGEN and its Affiliates effective upon such AMGEN election at the time of
termination (i) an automatic, worldwide, perpetual and irrevocable exclusive license, with the right to grant sublicenses through multiple tiers, solely for use in Exploiting such Terminated Product, under Know-How and Patent Rights that are
Controlled by VIGIL or any of its Affiliates and Sublicensees prior to termination and that Cover such Terminated Product and which are necessary for Exploiting such Terminated Product and any improvement of any of the foregoing, and (ii) an
automatic, 

  
 -48- 

 
worldwide, perpetual and irrevocable non-exclusive license, with the right to grant sublicenses through multiple tiers, solely for use in Exploiting such Terminated Product, under Know-How and
Patent Rights that are Controlled by VIGIL or any of its Affiliates and (subject to Section 9.5(b)) Sublicensees that are not solely related to such Terminated Product but that are necessary for Exploiting such Terminated Product and any
improvement to any of the foregoing. For the purpose of clarity, upon AMGEN’s election at the time of termination, (1) such license shall be effective only as of and after the effective date of such termination and (2) Amgen will be
obligated to pay royalties during the Royalty Term(s) as provided for in Section 3.3 (Royalties); provided, all deductions and reductions contemplated in Section 3.3 will apply to such payments and the definition of Net Sales and Sections
3.4 (Method of Payment) -3.9 (Taxes) (inclusive) will apply mutatis- mutandis to Amgen in connection with the payment of such royalties and provided further that the royalty rates shall be [***] the rates set forth in Section 3.3 with respect
to any Terminated Product. Notwithstanding the foregoing, in the event that any of the foregoing Know-How or Patent Rights are not Controlled by VIGIL (or any of its Affiliates and Sublicensees) due to the fact that such party would be obligated to
make any payments to a Third Party in connection with the grant of the foregoing licenses, then AMGEN shall have the right to assume such payment obligations and should it elect to do so, such Know-How and Patent Rights shall be included in such
license grant. 
 (f) Upon AMGEN’s request, VIGIL will assign (or, if applicable, will cause its Affiliates or (subject to
Section 9.5(b)) Sublicensees to assign) to AMGEN all of VIGIL’s (and such Affiliates’ and Sublicensees’) right, title and interest in and to any (1) registered or unregistered trademarks or internet domain names that are
specific to the Terminated Product(s), provided that such assignment is in accordance with VIGIL’s policy on trademarks (it being understood that the foregoing will not include any trademarks or internet domain names that contain the corporate
or business name(s) of VIGIL) and (2) Program Patents that claim any Licensed Know-How. 
 (g) VIGIL agrees (and shall cause its
Affiliates and Sublicensees as a condition of the grant of the applicable Sublicense to so agree) to fully cooperate with AMGEN and its designee(s) to facilitate a smooth, orderly and prompt transition of the Exploitation of the Terminated Products
in the Territory to AMGEN and/or its designee(s). Upon request by AMGEN, VIGIL shall transfer to AMGEN some or all quantities of the Terminated Product(s) in its possession. If VIGIL is, at the time of such termination of this Agreement, party to
any Third Party contracts with respect to such Terminated Product(s), then it shall provide AMGEN notice of and (to the extent permitted to do so), copies thereof. VIGIL shall assign to AMGEN any such contracts requested by AMGEN, to the extent
relating to such Terminated Product(s) and to the extent it has the right under such contract(s) to do so (and shall use commercially reasonable efforts to obtain any required consents, which efforts shall not require making any payments or
incurring any liabilities unless AMGEN agrees to reimburse VIGIL therefor (and VIGIL shall inform AMGEN of any such required payment or liability)). In addition, VIGIL shall, at AMGEN’s 

  
 -49- 

 
cost and expense, (i) provide any cooperation reasonably requested by AMGEN to ensure uninterrupted supply of such Terminated Product(s) (including VIGIL’s employees’ time at the
FTE Rate), and (ii) if VIGIL manufactured such Terminated Product(s) at the time of termination, continue to provide for manufacturing of such Terminated Product for AMGEN, at [***] of the fully-burdened manufacturing cost therefor, from the
date of notice of such termination until the sooner to occur of such time as AMGEN is able, using commercially reasonable efforts to do so, to secure an acceptable alternative commercial manufacturing source from which sufficient quantities of such
Terminated Product(s) may be procured and legally sold in the Territory or [***] months from the effective date of termination of this Agreement. 

(h) VIGIL shall duly execute and deliver, or cause to be duly executed and delivered, such instruments and shall do and cause to be done such
activities and things, including the filings of such assignments, agreements, documents and instruments, as may be necessary under, or as AMGEN may reasonably request in connection with, AMGEN’s rights under this Section 9.5 (Effects of
Termination). 
 (i) Notwithstanding a partial termination of this Agreement pursuant to Section 9.2.1 or 9.3.2 or a complete
termination of this Agreement pursuant to Section 9.2, Section 9.3.1 or Section 9.4, VIGIL’s obligations to pay royalties and milestone payments under Section 3.3.2 and Section 3.3 shall continue with respect to any
Retained Product , in each case on a Retained-Product-by-Retained-Product and country-by-country basis until the expiration of the Royalty Term with respect to such Retained Product. 

(j) VIGIL shall remain financially responsible for (and shall pay to AMGEN) (1) the Reservation Fee and Reservation Agreement Process
Consumables Fees and (2) all amounts due under the Order and the Reservation Agreement, as contemplated in Section 2.5.3(a). 
 (k)
VIGIL shall return to AMGEN (or cause to be returned to Amgen) all Licensed Materials 
 (l) In the event of a termination under
Section 9.3.2 (Discretionary Termination) or Section 9.3.1, in either case with respect to a Terminated Program only (and not with respect to this Agreement in its entirety), VIGIL’s obligations under Section 5.2 with respect to
Products in the Terminated Program shall cease and Amgen’s restrictions under Section 5.5 (Amgen Restrictions) shall cease with respect to (1) small molecules (if the Terminated Program is the Small Molecule Program) or
(2) antibodies (if the Terminated Program is the MAB Program). 
 Section 9.6 Survival. In addition to the termination consequences
set forth in Section 9.5 (Effects of Termination), the following provisions will survive termination or expiration of this Agreement: Articles 1 (Definitions), 7 (Indemnification), 8 (Confidentiality), and 10 (Miscellaneous) and Sections 2.5.3
(AMGEN Cell Line and Licensed Manufacturing Know-How) (with respect to VIGIL’s payment obligations in respect of the Order or as otherwise accrued 

  
 -50- 

 
before such expiration or termination), 2.7 (No Other Rights), 3.1 (Equity in Vigil), 3.2 (Upfront and Milestone Payments) (with respect to payment obligations accrued before such expiration or
termination and with respect to Retained Products), 3.3 (Royalties) (with respect to sales of Licensed Product made before such expiration or termination and with respect to all future sales of Retained Products), 3.4 (Method of Payment) through 3.9
(Taxes) (inclusive) (with respect to all payments due prior to the termination of the agreement and for all future payments due post-terminations), 4.3 (Enforcement) through 4.5 (Recovery) (inclusive) (with respect to any action initiated prior to
such expiration or termination), 6.3 (Disclaimer), and this Section 9.6 (Survival). Termination or expiration of this Agreement are neither Party’s exclusive remedy and will not relieve the Parties of any liability or obligation which
accrued hereunder prior to the effective date of such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement nor prejudice
either Party’s right to obtain performance of any obligation. All other rights and obligations will terminate upon expiration of this Agreement. 

ARTICLE 10. MISCELLANEOUS 

Section 10.1 Entire Agreement; Amendment. This Agreement and all Exhibits attached to this Agreement constitute the entire agreement
between the Parties as to the subject matter hereof. All prior and contemporaneous negotiations, representations, warranties, agreements, statements, promises and understandings with respect to the subject matter of this Agreement are hereby
superseded and merged into, extinguished by and completely expressed by this Agreement. None of the Parties shall be bound by or charged with any written or oral agreements, representations, warranties, statements, promises or understandings not
specifically set forth in this Agreement. No amendment, supplement or other modification to any provision of this Agreement shall be binding unless in writing and signed by all Parties. 

Section 10.2 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this Agreement
are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(35A) of the U.S. Bankruptcy Code to the extent
permitted thereunder. The Parties shall retain and may fully exercise all of their respective rights and elections under the U.S. Bankruptcy Code. Upon the bankruptcy of any Party, the non-bankrupt Party shall further be entitled to a complete
duplicate of (or complete access to, as appropriate) any such intellectual property, and such, if not already in its possession, shall be promptly delivered to the non-bankrupt Party, unless the bankrupt Party elects to continue, and continues, to
perform all of its obligations under this Agreement. 
 Section 10.3 Independent Contractors. The relationship between VIGIL and AMGEN
created by this Agreement is solely that of independent contractors. This Agreement does not create any agency, distributorship, employee-employer, partnership, joint venture or similar business relationship between the Parties. Neither Party is a
legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever. Each Party shall use its own
discretion and shall have complete and authoritative control over its employees and the details of performing its obligations under this Agreement. 

  
 -51- 

 Section 10.4 Dispute Resolution; Governing Law; Jurisdiction. The Parties recognize that
a dispute may arise relating to this Agreement (a “Dispute”). Any Dispute, including Disputes that may involve the Affiliates of any Party, shall be resolved in accordance with this Section 10.4. If there are any Disputes in
connection with this Agreement, including Disputes related to proposed termination of this Agreement under Article 9, all rights and obligations of the Parties shall continue until such time as the Dispute has been resolved in accordance with the
provisions of this Section 10.4. Any Dispute, including any claim, or controversy as to the breach, enforcement, interpretation or validity of this Agreement shall be referred to a member of each Party’s executive management team (the
“Executive Officers”) for attempted resolution. If the Executive Officers are unable to resolve such Dispute within [***] days of such Dispute being referred to them, the Parties hereby agree that either Party may initiate litigation in a
court of competent jurisdiction located in New York, New York to address such Dispute. This Agreement and its effect are subject to and shall be construed and enforced in accordance with the law of the State of New York, without regard to its
conflicts of laws, except as to any issue which depends upon the validity, scope or enforceability of any Licensed Patent, which issue shall be determined in accordance with the laws of the country in which such patent was issued. Each of the
Parties hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the courts of the State of New York for any matter arising out of or relating to this Agreement and the transactions contemplated hereby, and agrees
not to commence any litigation relating thereto except in such courts. Each of the Parties hereby irrevocably and unconditionally waives any objection to the laying of venue of any matter arising out of this Agreement or the transactions
contemplated hereby in the courts of the State of New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such matter brought in any such court has been brought in an
inconvenient forum. The Parties agree that a final judgment in any such matter shall be conclusive and may be enforced in other jurisdictions by suits on the judgment or in any other manner provided by law. Any proceeding brought by either Party
under this Agreement shall be exclusively conducted in the English language. 
 Section 10.5 Notice. All notices or communication
required or permitted to be given by either Party hereunder shall be deemed sufficiently given if mailed by registered mail or certified mail, return receipt requested, or sent by overnight courier, such as Federal Express, to the other Party at its
respective address set forth below or to such other address as one Party shall give notice of to the other from time to time hereunder. Mailed notices shall be deemed to be received on the third (3rd) business day following the date of mailing.
Notices sent by overnight courier shall be deemed received the following business day. 
  

			
	 If to VIGIL:
	  	VIGIL NEUROSCIENCE, INC.
		  	400 Technology Square, 10th Floor
		  	Cambridge, MA 02139
		  	Attn: CEO
		
		  	With a copy to:
		  	Cooley LLP
		  	500 Boylston Street, 14th Floor
		  	Boston, MA 02116-3736
		  	Attn: Marc Recht

  
 -52- 

			
	 If to AMGEN:
	  	Amgen Inc.
		  	One Amgen Center Drive
		  	Thousand Oaks, CA 91320
		  	Attn: [***]

 Section 10.6 Compliance With Law; Severability. Nothing in this Agreement shall be construed to require the
commission of any act contrary to Law. If any one or more provisions of this Agreement is held to be invalid, illegal or unenforceable, the affected provisions of this Agreement shall be curtailed and limited only to the extent necessary to bring it
within the applicable legal requirements and the validity, legality and enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby. 

Section 10.7 Non-Use of Names. AMGEN shall not use the name, trademark, logo, or physical likeness of VIGIL or any of its officers,
directors or employees, or any adaptation of any of them, in any advertising, promotional or sales literature, without such VIGIL’s prior written consent. AMGEN shall require its Affiliates to comply with the foregoing. VIGIL shall not use the
name, trademark, logo, or physical likeness of AMGEN or any of its officers, directors or employees, or any adaptation of any of them, in any advertising, promotional or sales literature, without AMGEN’s prior written consent. VIGIL shall
require its Affiliates and Sublicensees to comply with the foregoing in connection with each such Sublicensee’s sublicense. Notwithstanding the foregoing, VIGIL and its Affiliates and Sublicensees may identify the existence of their rights as
licensees of the Licensed Patents as necessary or appropriate to exercise rights under this Agreement. 
 Section 10.8 Successors and
Assigns. Neither this Agreement nor any of the rights or obligations created herein may be assigned by either Party, in whole or in part, without the prior written consent of the other Party, not to be unreasonably withheld or delayed except
that either Party shall be free to assign this Agreement (a) to an Affiliate of such Party (for so long as such Affiliate remains an Affiliate) provided that such Party shall remain liable and responsible to the other Party for the performance
and observance of all such duties and obligations by such Affiliate, or (b) in connection with any merger, consolidation or sale of such Party or sale of all or substantially all of the assets of the Party that relate to this Agreement (a
“Sale Transaction”), without the prior consent of the non-assigning Party. This Agreement shall bind and inure to the benefit of the successors and permitted assigns of the Parties hereto. Any assignment of this Agreement in contravention
of this Section 10.8 (Successors and Assigns) shall be null and void. 
 Section 10.9 Sale Transaction or AMGEN Acquisition. In the
event of (x) a Sale Transaction, or (y) the acquisition by AMGEN or VIGIL of all or substantially all of the business of a Third Party (together with any entities that were Affiliates of such Third Party immediately prior to such
acquisition, an “Acquiree”), whether by merger, sale of stock, sale of assets or otherwise (an “Acquisition”), intellectual property rights of the acquiring party in a Sale Transaction, if other than one of the Parties to this
Agreement (together with any entities that were affiliates of such Third Party immediately prior to such Sale Transaction, a “Third Party Acquirer”), or the Acquiree, as applicable, shall not be: (a) included (as the licensor or
licensee) in the technology licensed hereunder, (b) the subject (either granting or receiving) of any covenant not to sue hereunder except as provided for in Section 2.6 or (c) otherwise subject to this Agreement, except as specified
in Section 5.4 with respect to Distracting Products. 

  
 -53- 

 Section 10.10 Waivers. A Party’s consent to or waiver, express or implied, of any
other Party’s breach of its obligations hereunder shall not be deemed to be or construed as a consent to or waiver of any other breach of the same or any other obligations of such breaching Party. A Party’s failure to complain of any act,
or failure to act, by the other Party, to declare the other Party in default, to insist upon the strict performance of any obligation or condition of this Agreement or to exercise any right or remedy consequent upon a breach thereof, no matter how
long such failure continues, shall not constitute a waiver by such Party of its rights hereunder, of any such breach, or of any other obligation or condition. A Party’s consent in any one instance shall not limit or waive the necessity to
obtain such Party’s consent in any future instance and in any event no consent or waiver shall be effective for any purpose hereunder unless such consent or waiver is in writing and signed by the Party granting such consent or waiver. 

Section 10.11 No Third Party Beneficiaries. Except as expressly provided with respect to AMGEN Indemnified Parties and VIGIL Indemnified
Parties in Article 7 (Indemnification), nothing in this Agreement shall be construed as giving any Person, other than the Parties hereto and their successors and permitted assigns, any right, remedy or claim under or in respect of this Agreement or
any provision hereof. 
 Section 10.12 Headings; Exhibits. Article and Section headings used herein are for convenient reference only,
and are not a part of this Agreement. All Exhibits are incorporated herein by this reference. 
 Section 10.13 Interpretation. Except
where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). The
term “including” as used herein shall mean including, without limiting the generality of any description preceding such term. The term “will” as used herein means shall. All references to a “business day” or
“business days” in this Agreement means any day other than a day which is a Saturday, a Sunday or any day banks are authorized or required to be closed in the United States. The language in all parts of this Agreement shall be deemed to be
the language mutually chosen by the Parties. The Parties and their counsel have cooperated in the drafting and preparation of this Agreement, and this Agreement therefore shall not be construed against any Party by virtue of its role as the drafter
thereof. 
 Section 10.14 Equitable Relief. Each Party acknowledges that a breach by it of the provisions of this Agreement may not
reasonably or adequately be compensated in damages in an action at law and that such a breach may cause the other Party irreparable injury and damage. By reason thereof, each Party agrees that the other Party is entitled to seek, in addition to any
other remedies it may have under this Agreement or otherwise, preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of this Agreement by the other Party and is otherwise entitled to specific performance of
the terms hereof; provided, however, that no specification in this Agreement of a specific legal or equitable remedy will be construed as a waiver or prohibition against the pursuing of other legal or equitable remedies in the event of such a
breach. 

  
 -54- 

 Section 10.15 Force Majeure. Neither Party shall be held liable or responsible to the
other Party, nor be deemed to have defaulted under or breached this Agreement, for failure or delay in fulfilling or performing any term of this Agreement to the extent, and for so long as, such failure or delay is caused by or results from causes
beyond the reasonable control of the affected Party, including fire, floods, embargoes, power shortage or failure, acts of war (whether war be declared or not), insurrections, riots, terrorism, civil commotions, strikes, a pandemic (including
COVID19 related interruptions), lockouts or other labor disturbances, acts of God, or any acts, omissions, or delays in acting by any governmental authority or the other Party; provided, however, that the affected Party promptly notifies the other
Party in writing (and continues to provide monthly status updates to the other Party for the duration of the effect); and provided further, however, that the affected Party shall use its commercially reasonable efforts to avoid or remove such causes
of nonperformance and to mitigate the effect of such occurrence, and shall continue performance with reasonable dispatch whenever such causes are removed. The Parties acknowledge and agree that as of the Execution Date, the activities of both
Parties may be interrupted due to the COVID-19 pandemic and, as a result, each Party’s performance of some or all of the activities relating to the transfer of Licensed Material and Licensed Know-How may be delayed. Further, as COVID-19
pandemic circumstances evolve, there may be additional delays or other circumstances for either Party that were not initially foreseeable. In light of the foregoing, the Parties agree to discuss in good faith an extension to timelines contemplated
in this Agreement, as may be applicable. 
 Section 10.16 Further Assurances. Each Party shall execute, acknowledge, and deliver such
further instructions, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

Section 10.17 Counterparts. This Agreement may be executed in counterparts by a single Party, each of which when taken together shall
constitute one and the same agreement, and may be executed through the use of facsimiles or .pdf or other electronically transmitted documents. 

[signature page follows] 

  
 -55- 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above.

  

									
	VIGIL NEUROSCIENCE, INC	 	AMGEN INC.
					
	By:	 	 /s/ Ommer Chohan
	 		 	By: 	 	 /s/ Peter H. Griffith

	Name:	 	Ommer Chohan	 		 	Name:	 	Peter H. Griffith
	Title:	 	Chief Financial Officer	 		 	Title:	 	EVP & CFO
					
		 		 		 	By:	 	 /s/ David M. Reese

		 		 		 	Name:	 	David M. Reese
		 		 		 	Title:	 	EVP, Research & Development

  

			
		  	

 EXHIBIT A 

LICENSED KNOW-HOW 
 Access to documents
listed below in the fields of regulatory, research, pharmacology, toxicology, bioanalytical, pharmacokinetics, and their supporting information, including but not limited to, the final reports, study files, study samples/specimens, and individual
data files, will be made available to VIGIL within the timeframes shown below after the Effective Date. 
 [***] 

[***] 
  

	 	•	 	 [***] 

  

					
	 [***]
	  	 [***]

	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	1

					
	 [***]
	  	 [***]

	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	2

					
	 [***]
	  	 [***]

	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 [***] 
  

					
	 [***]
	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	3

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	4

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 [***] 
  

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	5

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 [***] 

[***] 
  

					
	 [***]
	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	6

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

					
	 [***]
	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	7

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

					
	 [***]
	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

					
	 [***]
	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
		  		  	
	[***]	  	[***]	  	[***]
		  		  	

  

			
		  	8

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

					
	[***]	  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]

  

			
		  	9

					
	 [***]
	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	10

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

					
	 [***]
	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 [***] 

[***] 
  

					
	 [***]
	  	 
		  		  	[***]
	[***]	  	[***]	  	[***]
			
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  		  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	11

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
		  	[***]	  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	12

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 [***] 
  

					
	 	  	 	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 [***] 
  

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	13

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	14

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	15

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	16

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	17

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	18

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	19

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	20

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	21

 EXHIBIT B 

LICENSED PATENTS 
  

							
	 Country
	  	 Application No.
	  	 Filing Date
	  	 Title

				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]

  

			
		  	

							
	 Country
	  	 Application No.
	  	 Filing Date
	  	 Title

				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]

  

			
		  	

 EXHIBIT C 

PERMITTED CMOS/CROs 
 [***] 

 EXHIBIT D 

LICENSED COMPOUNDS 
 [***] 

 EXHIBIT E 

SUPPLEMENTAL CONFIDENTIALITY AGREEMENT 

[***] 

 [***] 

[***] 
  

					
	[***]	  	[***]	  	[***]

 EXHIBIT F 

RESERVATION AGREEMENT 

[***] 

 [***] 
 [***]

 [***] 

 EXHIBIT G 

ONGOING STUDIES 
  

													
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 Exhibit H 

[***] Order Summary 
  

					
	[***]                                
                                
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]